

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 192

1 Q. When you have worked as a consultant for 03:17
2 Quantic Regulatory Services, have you done batch 03:17
3 record reviews for them or for other companies and 03:17
4 other products? 03:17

5 A. No. And if I could, please, when you 03:17
6 say Quantic Regulatory Services, there's -- if I'm 03:17
7 not mistaken there's like three entities of 03:17
8 Quantic. One is the regulatory services, one 03:17
9 Quantic, and there's another one, depending on 03:17
10 what the job is covered by. 03:17

11 So to answer that question accurately, I'm not 03:17
12 sure which one we're referring to, which one of 03:17
13 those business entities, just to be clear. 03:17

14 Q. How many companies -- how many other 03:18
15 companies that you worked for in the 03:18
16 pharmaceutical industry were at one point on 03:18
17 consent decree? 03:18

18 A. As a permanent employee worked for? 03:18

19 Q. Yeah. 03:18

20 A. At one point? 03:18

21 Q. Yeah. 03:18

22 A. To my knowledge, none of the companies. 03:18

23 Q. What about in your consulting 03:18
24 arrangements? How many of the companies have been 03:18
25 on consent decree at some point? 03:18

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 193

1 A. That I know of? 03:18

2 Q. Yeah. 03:18

3 A. Two. 03:18

4 Q. And Wyeth was one. Are you able to tell 03:18
5 me who the other one is? 03:18

6 A. Schering Plough. 03:18

7 Q. When you were working with those 03:18
8 companies regarding consent decrees, did you tell 03:18
9 them that a consent decree was because of a 03:19
10 repeated and persistent non-compliance with the 03:19
11 law? 03:19

12 A. That was not my function to tell the 03:19
13 companies that. So me personally, no. 03:19

14 Q. Did you believe when you were consulting 03:19
15 with them that they were on consent decree because 03:19
16 of repeated, persistent non-compliance with the 03:19
17 law? 03:19

18 MR. KERENSKY: Wait a minute. I want to 03:19
19 caution you there. 03:19

20 THE WITNESS: Yeah. 03:19

21 MR. KERENSKY: We're on the same page. 03:19
22 Because you're now asking him to say 03:19
23 something, a conclusion he drew based on stuff 03:19
24 he knew about while working there and working 03:19
25 with them, which may be covered by the 03:19

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 194

1 confidentiality agreements he has. 03:19

2 THE WITNESS: All I know, if I could, is 03:19

3 that these companies all post the consent 03:19

4 decree and the letter by quality assurance and 03:19

5 management on bulletin boards so everybody can 03:20

6 see what it's all about. That's part of the 03:20

7 function. 03:20

8 BY MR. MORIARTY: 03:20

9 Q. I understand that. But do you -- I mean 03:20

10 you have said that my client or pharmaceutical 03:20

11 companies in general go on consent decree for 03:20

12 repeated, persistent non-compliance with the law, 03:20

13 and I'm trying to find out whether that is a 03:20

14 phrase that you're applying only to Actavis or 03:20

15 whether you also apply it to companies that you 03:20

16 consult with in the non-litigation world. 03:20

17 A. Again, I'm not -- 03:20

18 THE VIDEOGRAPHER: Five minutes. 03:20

19 THE WITNESS: Again, I'm not sure I 03:20

20 really understand the gist of the question. I 03:20

21 apologize. 03:20

22 BY MR. MORIARTY: 03:21

23 Q. Okay. At page 8 of your report. 03:21

24 A. Okay. 03:21

25 Q. It says: 03:21

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 195

1 "It should be noted in my experience consent 03:21
2 decrees are not common and mostly occur when a 03:21
3 company has shown repeated and persistent 03:21
4 non-compliance with the law." 03:21

5 Do you see that? 03:21

6 A. Yes, I do. 03:21

7 Q. All right. What I'm trying to find out 03:21
8 about, Dr. Bliesner, is whether you are just 03:21
9 making a comment about my client or whether that 03:21
0 is your opinion about pharmaceutical companies and 03:21
1 the consent decree generally. 03:21

12 A. Yes. 03:21

13 Q. Yes which? 03:21

14 A. They -- that it takes an awful lot to 03:21
15 get a consent decree. It's a process of numerous 03:21
16 483s, warning letters in most circumstances. 03:21
17 Sometimes they go directly to it. There's 03:21
18 numerous 483s, warning letters, and then it gets 03:21
19 to the point where the agency says we don't have 03:21
20 enough resources anymore to manage this. Let's go 03:21
21 into an agreement. 03:22

22 Q. And have you ever consulted with a 03:22
23 pharmaceutical company about a product that was in 03:22
24 litigation, product liability litigation? 03:22

25 A. Consulted specifically about the product 03:22

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 196

1 liability? 03:22

2 Q. Yeah. 03:22

3 A. No. 03:22

4 Q. Does the ANDA for any product, including 03:22

5 Digitek, contain the formula for the active 03:22

6 ingredients and how they are to be blended? 03:22

7 A. The formula, yeah. The combination of 03:22

8 excipients and active. 03:22

9 Q. Yes. 03:22

10 A. In my experience they do contain that. 03:22

11 Q. And presumably they have to be mixed in 03:22

12 appropriate proportions in order to comply with 03:22

13 the formula; correct? 03:22

14 A. They need to follow their manufacturing 03:23

15 steps in order to -- to come up with a proper 03:23

16 dosage for them, whether it involved mixing or 03:23

17 whatever. 03:23

18 Q. And those steps are approved by the FDA; 03:23

19 correct? 03:23

20 A. Those steps are in the application. If 03:23

21 the application is approved and the FDA has found 03:23

22 the information in the application acceptable. 03:23

23 THE VIDEOGRAPHER: We should definitely 03:23

24 change tapes. 03:23

25 The time is 3:26 p.m. We're going off 03:23

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 197

1 the record. 03:23

2 THE VIDEOGRAPHER: The time is now 03:34

3 3:37 p.m. We are back on the record. This is 03:34

4 the beginning of tape six. 03:34

5 BY MR. MORIARTY: 03:34

6 Q. Okay. We were asking before the break 03:34

7 about formulas; okay? Have you seen any 483 or a 03:34

8 warning letter, any sort of citation or sanction 03:35

9 by the FDA on Actavis for any problem with the 03:35

10 actual mixing of the ingredients? In other words, 03:35

11 using inappropriate proportions of ingredients? 03:35

12 A. Proportions? 03:35

13 Q. Yes. 03:35

14 A. Not that I recall. 03:35

15 Q. So you don't have any evidence that any 03:35

16 Digitek batch started with too much active 03:35

17 pharmaceutical raw ingredient? 03:35

18 A. I don't have any evidence. 03:35

19 Q. You are aware that Actavis tests every 03:36

20 batch at the blend stage. 03:36

21 A. Every batch at the blend stage? 03:36

22 Q. Yeah. 03:36

23 A. I don't have information that I've seen 03:36

24 that confirms or denies that. 03:36

25 Q. Okay. 03:36

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 198

1 In your work in the pharmaceutical industry -- 03:36
2 not in your consulting work -- how much contact 03:36
3 did you have with blend uniformity sampling or 03:36
4 testing? 03:36

5 A. Testing. 03:36

6 Q. So not sampling? 03:36

7 A. No. 03:36

8 Q. Not the core sampling? 03:36

9 A. No. 03:36

10 Q. But you did have some with testing? 03:36

11 A. Yes. 03:36

12 Q. And typically when a company does blend 03:36
13 sampling from a dry blend batch, how many core 03:36
14 samples do they take and submit to a QC lab for 03:37
15 analysis? 03:37

16 A. That varies. It's not a set thing. 03:37

17 Q. From your reading -- 03:37

18 A. And it's always a battle. 03:37

19 Q. Why is it a battle? 03:37

20 A. Because the lab always wants less 03:37
21 samples and the validation people want more 03:37
22 samples, and they go back and forth to try to 03:37
23 determine number of samples to be sent to be 03:37
24 analyzed. It's a very big challenge. 03:37

25 Q. Why does the lab want less samples? 03:37

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 199

1 A. Because usually you're doing their 03:37
2 release testing on top of process validation, so 03:37
3 it's doubling their workload. 03:37

4 Q. From your reading in pharmaceutical 03:37
5 publications over time, have you found that blend 03:37
6 uniformity sampling and testing in general is a 03:37
7 controversial subject? 03:37

8 A. Controversial? 03:37

9 Q. Yes, sir. 03:37

10 A. I wouldn't use the word controversial. 03:38

11 Q. Have there been efforts by 03:38
12 pharmaceutical companies to have the FDA eliminate 03:38
13 the requirement of blend uniformity sampling 03:38
14 because it's notoriously difficult to do and 03:38
15 control well? 03:38

16 A. I know that Actavis in some of their 03:38
17 documentation make reference to try to stop blend 03:38
18 uniformity testing. 03:38

19 Q. Do you know about any other company? 03:38

20 A. Specifically that I've been involved 03:38
21 with? 03:38

22 Q. Actually I mean generally. 03:38

23 A. Generally. 03:38

24 Q. Your general knowledge of the industry. 03:38

25 A. Blend uniformity as I said is always a 03:38

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 200

1 challenge anyway, so... 03:38

2 Q. Okay. So can you point to me any 03:38
3 document where the FDA cited or warned the company 03:38
4 because an actual batch had out-of-specification 03:38
5 blend uniformity samples? 03:39

6 A. The FDA cited? 03:39

7 Q. Yeah, which then went on uncorrected or 03:39
8 the tests weren't repeated? 03:39

9 A. It would -- there are references to 03:39
10 blend -- if I'm not mistaken there are references 03:39
11 in 483s and/or potentially EIRs with respect to 03:39
12 blend if I recall. I'd have to go back and dig 03:39
13 through and look at it specifically. 03:39

14 Q. Yeah, but do you know whether that had 03:39
15 to do with the way they investigated and the 03:39
16 number of samples -- and the number of samples 03:39
17 they took or whether it was actual blend 03:39
18 uniformity failures that were not addressed? 03:39

19 A. As I said, I would have to go back and 03:39
20 look specifically as what those discussions were. 03:39
21 It's been a while. 03:40

22 Q. Is it important to your opinions in this 03:40
23 case? 03:40

24 A. I think so, yes. 03:40

25 Q. Is there a difference between an actual 03:40

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 201

1 blend uniformity failure that might require batch 03:40
2 rejection and some technical need to either 03:40
3 investigate differently or the way you did your 03:40
4 backup testing? 03:40

5 A. I don't understand that question. 03:40

6 Q. All right. It wasn't a very good 03:40
7 question. You'll find that late in the day with 03:40
8 this stuff, you can mess up the questions. 03:40

9 A. This is hard work. 03:40

10 Q. All right. So let's just assume that a 03:40
11 company takes ten core samples from various 03:40
12 sections of the blender for the blend uniformity 03:40
13 sampling; okay? 03:40

14 A. Yes. 03:40

15 Q. Now, let's assume that one of the ten is 03:40
16 out of specification. 03:40

17 A. Yes. 03:41

18 Q. Okay. 03:41

19 A. Uh-huh. 03:41

20 Q. A company is entitled to retest either a 03:41
21 portion of that sample or take a new sample from 03:41
22 that part of the blender, aren't they? 03:41

23 A. Retest, resample. You have to be very 03:41
24 careful on how you're defining those terms. 03:41

25 Q. Well, let's go back. Let's assume that 03:41

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 202

1 the core sampling device, the sample thief. 03:41
2 A. Yes. 03:41
3 Q. Let's just assume for the sake of 03:41
4 argument -- 03:41
5 A. Uh-huh. 03:41
6 Q. -- that it is the length and diameter of 03:41
7 my pen -- 03:41
8 A. Okay. 03:41
9 Q. -- that I'm holding in front of the 03:41
10 camera; okay? 03:41
11 A. Uh-huh. 03:41
12 Q. So you put that in and you fill it with 03:41
13 blend. Actually, I think the sampling techniques 03:41
14 require a lot less than the length and diameter of 03:41
15 my pen. But let's assume you have enough to test, 03:42
16 okay, and you have some left over; all right? 03:42
17 A. Yes. 03:42
18 Q. Is there any FDA reg -- GMP or 03:42
19 otherwise -- that if the first test on the sample 03:42
20 is out of spec, it says that you have to reject 03:42
21 the batch and that you cannot test the remaining 03:42
22 sample in this sample field? 03:42
23 A. Well, there's a whole process that gets 03:42
24 to that, the resampling stage. If you have a 03:42
25 failure of an analysis in the laboratory, it 03:42

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 203

1 requires a laboratory investigation to determine 03:42
2 whether that result is valid or not. 03:42

3 Q. Okay. But the question is, is there a 03:42
4 FDA reg that prevents you from testing more of the 03:42
5 sample that you took? 03:42

6 A. Not to my knowledge. 03:42

7 Q. Is there an FDA reg that prevents you 03:42
8 from resampling from that part of the blender and 03:43
9 then testing that material? 03:43

10 A. Not to my knowledge. 03:43

11 Q. Is there any FDA reg -- including GMP 03:43
12 regs -- that require companies to reject a batch 03:43
13 based on one out of say ten blend uniformity 03:43
14 tests? 03:43

15 A. Regulations? 03:43

16 Q. Yeah. 03:43

17 A. Not to my knowledge. 03:43

18 Q. So if we were to look at the Actavis 03:43
19 batch records and find that, for example, that on 03:43
20 initial testing, one sample was out of spec, and 03:43
21 the company did an investigation and retested and 03:43
22 it was not out of spec on retesting, you're not 03:44
23 saying that Actavis had to reject that batch for 03:44
24 blend uniformity failure, are you? Just answer my 03:44
25 question. 03:44

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 204

1 A. Yeah. Say it again, please. These are 03:44
2 very difficult issues. 03:44
3 Q. Sure. 03:44
4 A. Very difficult issues and they happened 03:44
5 frequently. 03:44
6 Q. All right. So if you go into the 03:44
7 records -- 03:44
8 A. Yes. 03:44
9 Q. -- you've had, all this paper, and you 03:44
10 find that there was a blend uniformity out of spec 03:44
11 result -- 03:44
12 A. Yes. 03:44
13 Q. -- for one out of ten samples for a 03:44
14 particular batch; okay? 03:44
15 A. Uh-huh. 03:44
16 Q. Are you with me so far? 03:44
17 A. I am. 03:44
18 Q. And they retested it and it was within 03:44
19 the specs and hence passed blend uniformity and 03:44
20 was sent on for packaging, is it your opinion that 03:44
21 that one out of spec result would have -- would 03:44
22 have required rejection of the batch? 03:45
23 A. Perhaps. If you have a failure like 03:45
24 this and you can't find a root cause for it and 03:45
25 your investigation doesn't lead to anything, then 03:45

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 205

1 there are some very serious discussions that need 03:45
2 to be made with respect to the disposition of that 03:45
3 batch. 03:45

4 Q. All right. But that doesn't 03:45
5 automatically require a batch -- 03:45

6 A. Automatically -- 03:45

7 Q. -- rejection. 03:45

8 A. Automatically, knee jerk, no. 03:45

9 Q. You're supposed to -- the regs require 03:45
10 that you do an investigation; correct? 03:45

11 A. Specifically I'd have to go back and 03:45
12 look at the GMPs to see where they say -- excuse 03:45
13 me -- say exactly that you must reject. It is 03:45
14 expected in the industry that manufacturing 03:45
15 investigations are investigated very thoroughly to 03:45
16 determine a root cause. 03:45

17 Q. Okay. And it could be a manufacturing 03:45
18 investigation or a lab investigation under these 03:46
19 circumstances we're talking about with blend 03:46
20 uniformity, couldn't it? 03:46

21 A. Yes, the lab in most cases is involved 03:46
22 even if it is a manufacturing investigation 03:46
23 because the laboratory people have a tendency to 03:46
24 be some of the more technically trained folks on 03:46
25 the staff and they usually are cross-functional 03:46

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 206

1 teams when these types of issues come up. So you 03:46
2 can solve the problem with the best information we 03:46
3 have. 03:46

4 Q. So if there is a circumstance in the 03:46
5 documents where this has occurred, FDA could go 03:46
6 back and say we don't like the way you conducted 03:46
7 the investigation and write up an observation and 03:46
8 a 483 just about the way the investigation was 03:46
9 done; correct? 03:46

10 A. That is correct. 03:46

11 Q. But not necessarily go the next step and 03:46
12 say you should have rejected the batch. 03:46

13 A. It could; it could not. 03:47

14 Q. Right. 03:47

15 A. Uh-huh. 03:47

16 Q. But it doesn't follow as night does day 03:47
17 that they would say you have to reject the batch. 03:47

18 A. Not to sound redundant, these are very 03:47
19 complex issues and each one is separate and 03:47
20 unique. 03:47

21 Q. And each one needs to be studied in this 03:47
22 much detail; correct? 03:47

23 A. Absolutely. 03:47

24 Q. Now sitting here off the top of your 03:47
25 head, without having to dive into these boxes, do 03:47

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 207

1 you know exactly what the blend uniformity issues 03:47
 2 were that FDA addressed in 483s regarding Digitek? 03:47

3 A. Without going back and diving into my 03:47
 4 boxes, I can't tell you exactly what happened. 03:47

5 Q. Do you know off of top of your head 03:47
 6 whether FDA ever cited, warned, sanctioned Actavis 03:47
 7 for passing a batch at the blend uniformity stage 03:47
 8 that FDA says should have been rejected? 03:47

9 A. There were discussions, if I recall, in 03:48
 10 EIRs and 483s with respect to blend uniformity. 03:48

11 Q. That wasn't my question. 03:48

12 A. Okay. What was your question? 03:48

13 MR. MORIARTY: Read it back, Phil, 03:48
 14 please. 03:48

15 (Whereupon, the testimony was read 03:48
 16 back by the court reporter, as recorded above) 03:48

17 THE WITNESS: I can't off top of my head 03:48
 18 answer that question. 03:48

19 BY MR. MORIARTY: 03:48

20 Q. If a pharmaceutical -- let me withdraw 03:48
 21 that because I talked with you about that before. 03:49

22 Have you been shown any information whatsoever 03:49
 23 to indicate that there was an outbreak of Digoxin 03:49
 24 toxicity in 2006, 2007, or 2008 at any hospital, 03:49
 25 nursing home, clinic, or outpatient facility in 03:49

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 208

1 the United States? 03:49

2 A. When you say "outbreak" you mean? 03:49

3 Q. Up-tick, increase. 03:49

4 A. I know there's a document in here that 03:49

5 looks at adverse events and the numbers of them, 03:49

6 but that's all -- I would have to look at that and 03:49

7 speak to it. 03:49

8 Q. And you're not a pharmacovigilance 03:49

9 expert? 03:49

10 A. I am not. 03:49

11 Q. And do you know even know whether 03:49

12 adverse event reporting is considered by FDA to be 03:49

13 a causal connection? 03:49

14 A. Causal connection? 03:50

15 Q. Whether adverse event reporting is 03:50

16 necessarily caused by adulterated or out of spec 03:50

17 product? 03:50

18 A. It can be a flag, obviously. 03:50

19 Q. I understand that. 03:50

20 A. Yeah. 03:50

21 Q. For them to look that? 03:50

22 A. Yes. 03:50

23 Q. But if it did, it's not somebody makes 03:50

24 an adverse event report and you automatically 03:50

25 conclude that you have a problem with your 03:50

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 209

1 manufacturing; right? Am I right about that? 03:50

2 A. Say that again, please. And it's late 03:50

3 in the day for me, too, so... 03:50

4 Q. Okay. Let's take a step back. These 03:50

5 lawyers hired a pharmacovigilance expert. 03:50

6 A. Okay. 03:50

7 Q. From Philadelphia, Karen Frank. 03:50

8 A. Okay. 03:50

9 Q. Would you defer to her on these 03:50
10 pharmacovigilance issues? 03:50

11 A. Yes. 03:50

12 Q. So, what I was trying to -- oh, never 03:51
13 mind. Other than what you said, about AERs, which 03:51
14 you would defer to somebody else, you haven't seen 03:51
15 evidence in medical literature or scientific 03:51
16 publications that there was some increase in 03:51
17 Digoxin toxicity in two or three years before this 03:51
18 recall, have you? 03:51

19 A. I have not specifically gone out and 03:51
20 looked for that in the literature. 03:51

21 Q. Have you talked to any cardiologists 03:51
22 about this case, informally or otherwise? 03:51

23 A. In doctor-client privilege, I had 03:51
24 discussion. 03:51

25 MR. KERENSKY: That's interesting, isn't 03:51

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 210

1 it? 03:51

2 MR. MORIARTY: Yeah, this will be fun. 03:51

3 BY MR. MORIARTY: 03:51

4 Q. Do you take Digoxin? 03:51

5 A. I do not. 03:51

6 Q. And presumably you were not consulting a 03:51

7 doctor about a prescription for yourself -- 03:51

8 A. No. 03:51

9 Q. -- when you were talking about Digoxin; 03:51

10 correct? 03:51

11 A. That's correct. 03:51

12 Q. And was the party to this conversation 03:52

13 your primary care physician? 03:52

14 A. Yes. 03:52

15 Q. Is he or she a cardiologist? 03:52

16 A. Yes. 03:52

17 Q. Okay. But the discussion had to do with 03:52

18 Digitek or Digoxin? 03:52

19 A. Where do we really fall on this? I'm 03:52

20 not really comfortable talking about what I talked 03:52

21 about with my doctor regarding this. 03:52

22 Q. Well, if you were talking about your own 03:52

23 medical care, then it's privileged and I'm going 03:52

24 somewhere else. If you were talking hey, buddy, 03:52

25 I'm consulting on this Digitek litigation. What 03:52

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 211

1 do you know about it, what do you think about it, 03:52
2 that's not privileged because you weren't talking 03:52
3 to him about your own medical -- 03:52
4 A. I was not specifically asking him about 03:52
5 that. 03:52

6 MR. KERENSKY: Yeah, we don't 03:52
7 necessarily -- I don't necessary agree with 03:52
8 your characterization of where the line is on 03:53
9 what's privileged. And so there's an argument 03:53
10 just like he made and I made that the line is 03:53
11 here. There's an argument that everything you 03:53
12 talk to your doctor about in your doctor's 03:53
13 office is privileged; okay? I'm sure that's 03:53
14 what the doctor would say under HIPAA. 03:53

15 So it's your call whether or not you want 03:53
16 to share this with him. 03:53

17 THE WITNESS: I prefer not to talk about 03:53
18 it. 03:53

19 MR. KERENSKY: And if you guys want to 03:53
20 press it, just take it up with the Judge; 03:53
21 okay. 03:53

22 BY MR. MORIARTY: 03:53

23 Q. Did you show this doctor any documents 03:53
24 from the Digitek litigation? 03:53

25 A. I didn't think we were going to talk 03:53

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 212

1 about this anymore. 03:53

2 Q. That's a different question. 03:53

3 A. No. 03:53

4 Q. Dr. Bliesner, you are aware that Digitek 03:54

5 has a theoretical batch yield, are you not? 03:54

6 A. Yes. 03:54

7 Q. So if you put the ingredients in 03:54

8 appropriately, if you're making .125 Digitek, you 03:54

9 should get 4.8 million Digitek tablets or 03:54

10 thereabouts; right? 03:54

11 A. Say that again. 03:54

12 Q. If you put the appropriate ingredients 03:54

13 into according to the formula, you should get 4.8 03:54

14 million tablets before waste, sampling, retained 03:54

15 samples, things of nature? 03:54

16 A. Without having gone back to look at it, 03:54

17 I'll trust you have the number and that's 03:54

18 accurate. 03:54

19 Q. Is there always at least some loss or 03:54

20 waste in the manufacturing process? 03:54

21 A. Invariably, yes. 03:55

22 Q. If a company consistently made 03:55

23 double-sized tablets, would the actual batch 03:55

24 production outcomes come close to the theoretical 03:55

25 yield numbers? 03:55

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 213

1 A. I'm sorry. Say that again. 03:55
2 Q. If the company consistently made 03:55
3 double-sized the tablets -- 03:55
4 A. Uh-huh 03:55
5 Q. -- would the actual batch production 03:55
6 numbers come close to the theoretical yield 03:55
7 numbers? 03:55
8 A. I don't know. I would have to think 03:55
9 about that a little more. I don't think there's a 03:55
10 one-to-one correlation between theoretical yield 03:55
11 and this potential double-thick tablet. I 03:55
12 don't -- I would not speak definitively on that. 03:55
13 I have to really think about it. 03:55
14 Q. Well, if you made an entire batch 03:55
15 somehow of double-thick tablets -- 03:55
16 A. Uh-huh. 03:55
17 Q. -- are you going to get 4.8 million? 03:55
18 A. An entire batch? 03:55
19 Q. Yes, sir. 03:56
20 A. I would say that's probably not going to 03:56
21 get 4.8 million. 03:56
22 Q. If you made one quarter of the tablets 03:56
23 double thick, you wouldn't get close to 4.8 03:56
24 million either, would you? 03:56
25 A. No, I think you have to be very careful 03:56

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 214

1 in trying to make those kinds of assessments 03:56
2 because we don't know double-thick tablet again 03:56
3 was ever testified. So we don't know what the 03:56
4 weight is, we don't know what the total 03:56
5 excipients, we don't know what the active is. We 03:56
6 have no idea of being able to just off the top of 03:56
7 your head, back of envelope calculation say how 03:56
8 much it would be up short. I just don't think 03:56
9 it's possible. 03:56

10 Q. Did you ever see any evidence in any 03:56
11 company documents to indicate that there was some 03:56
12 adverse trend in Digitek yield production? 03:56

13 A. If I recall, early on there was some 03:57
14 discussions -- and it may have been with the 03:57
15 FDA -- with respect to yield difficulties. 03:57

16 Q. What years are you talking about? 03:57

17 A. I don't know. Again, I'd have to go 03:57
18 back and dig through the documents and look at 03:57
19 them. 03:57

20 Q. Did any of that occur in 2005, 6, 7 or 03:57
21 8? 03:57

22 A. I can't tell that you without going back 03:57
23 and looking through them. 03:57

24 Q. Why, in general, do you think some 03:57
25 problem that occurred in 1995, for example, is 03:57

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 215

1 evidence that defective Digitek got into the hands 03:57
2 of consumers in 2007 or 2008? 03:57

3 A. It's actually fairly straightforward. 03:57
4 As I said in the report, primary difficulties in 03:57
5 situations like this, in my experience and my 03:57
6 opinion is lack of leadership. It's the number 03:57
7 one. The people who were running the company back 03:58
8 then when they had problems with first consent 03:58
9 decree up until just before the second consent 03:58
10 decree are same people who are running people the 03:58
11 same people on regulatory force, the same people 03:58
12 in quality, the same people that caused all the 03:58
13 initial problems were still there. 03:58

14 Q. Is that some scientific theory? 03:58

15 A. It's a -- it's a statement of fact. 03:58

16 Q. So, in other words essentially what 03:58
17 you're saying is because they were sloppy in '95 03:58
18 means they must have been sloppy in '06 and '07? 03:58

19 A. I think the information that I've 03:58
20 reviewed pretty consistently shows they got out 03:58
21 from underneath the consent decree, they became 03:58
22 recidivistic, and they moved right back into 03:58
23 another situation with many of these same 03:58
24 problems. That reflects on leadership. 03:58

25 Q. But not one thing that you just told me 03:58

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 216

1 is scientific evidence of defective tablets 03:58
2 getting into the hands of consumers. Are you 03:59
3 talking about FDA documents? 03:59
4 A. It's a failure of quality which impacts 03:59
5 the quality of the product going out the door. 03:59
6 Q. Well, if the quality was so bad from '95 03:59
7 through 2008 -- let's just pick that period of 03:59
8 time, those 13 years -- shouldn't there be some 03:59
9 evidence of defective Digitek getting into the 03:59
10 hands of consumers? 03:59
11 A. There are evidence. The pharmacy 03:59
12 individuals. 03:59
13 Q. One tablet out of a billion. Got 03:59
14 anything else? 03:59
15 A. As far as scientific data specifically 03:59
16 showing that it was in the hands of the 03:59
17 individual? 03:59
18 Q. Yes. 03:59
19 A. There was nothing in the record. 03:59
20 However, you know, you have a billion tablets 03:59
21 let's say. It's the number everybody's throwing 03:59
22 around. Start doing the math, say it's .00001 03:59
23 percent, you know, how many tablets is that? 03:59
24 There's a lot of tablets in the market and you may 03:59
25 never seen it. They could hurt the people. 04:00

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 217

1 Q. You may never see it; right? 04:00
2 A. That exists. 04:00
3 Q. Okay. So the one tablet that was found 04:00
4 in 2003 or 4 was found by a pharmacist, wasn't it? 04:00
5 A. I believe that's what we said earlier. 04:00
6 Q. Have you ever worked in a pharmacy? 04:00
7 A. I have not. 04:00
8 Q. Do you have any expertise in pharmacy? 04:00
9 A. A pharmacist? No, sir. 04:00
10 Q. Well, if the one tablet we know about in 04:00
11 2004 could be detected by a pharmacist, isn't it 04:00
12 reasonable to conclude that other extra-thick 04:00
13 tablets, if they existed, would be detected by 04:00
14 pharmacists? 04:00
15 A. Could be. 04:00
16 Q. But that is the only one you know 04:00
17 about. 04:00
18 A. Those two specific instances and the 04:00
19 documents I've reviewed. 04:00
20 Q. Let's talk about sampling rates. Are 04:01
21 you an expert in the design and implementation of 04:01
22 sampling plans for in-process pharmaceutical 04:01
23 testing? 04:01
24 A. I am not. 04:01
25 Q. Do you at least know that in-process 04:01

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 218

1 sampling plans are FDA approved? 04:01

2 A. In the application? Is that what you're 04:01

3 asking? 04:01

4 Q. Initially in the AMDA; correct. 04:01

5 A. I'm not sure whether that specific 04:02

6 sample plan exists in the AMDA. I would have to 04:02

7 take a look. I know procedures, internal guidance 04:02

8 and SOPs companies have with respect to sampling, 04:02

9 and they are pretty unique. 04:02

10 Q. Are you aware of any 483 or warning 04:02

11 letter comment at any point from 2005 to 2008, 04:02

12 which observed problems with Digitek in-process 04:02

13 sampling, meaning weight, thickness? 04:02

14 A. Specific physical testing? 04:02

15 Q. Hardness. 04:02

16 A. I have not seen any that I recall. 04:02

17 Q. And I assume that this sort of 04:02

18 in-process testing in general is supposed to tell 04:02

19 you something about the consistency of the tablets 04:02

20 that are coming off the presses; is that right? 04:02

21 A. At various stages within the process. 04:03

22 It's not like you just grab a hold and spot. 04:03

23 In-process testing involves -- as you said, you've 04:03

24 already said -- blend uniformity at certain steps 04:03

25 along the way. 04:03

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 219

1 Q. Well, right now I'm just talking about 04:03
2 the thickness, hardness, the color, weight. 04:03

3 A. That's kind of -- as far as in-process 04:03
4 goes? 04:03

5 Q. Yeah. 04:03

6 A. I'm not -- okay, I don't recall what 04:03
7 their in-process tests were for this particular 04:03
8 product. 04:03

9 Q. But you've not seen any FDA citations or 04:03
10 warning implicating those processes? 04:03

11 A. Not that I recall. 04:03

12 Q. But I am correct that what you do in 04:03
13 there when QA comes in and the actual press 04:03
14 operator is checking, is to see at least visually 04:03
15 and by measurement whether the tablets are 04:03
16 consistent in size, weight, hardness, things of 04:03
17 that nature; correct? 04:03

18 A. It's a limited testing in process to see 04:03
19 where you are, how it's progressing. 04:04

20 Q. But that's what it's designed to tell 04:04
21 you, limited as it may be? 04:04

22 A. Yes. 04:04

23 Q. So let's talk about finished product 04:04
24 testing, which is within your bailiwick. Did the 04:04
25 AMDA have description of the methods that would be 04:04

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 220

1 used to assay content uniformity and dissolution 04:04

2 tests Digitek at the finished product stage? 04:04

3 A. Not specifically looking at the ANDA. I 04:04

4 remember -- I'm pretty sure the methods would be 04:04

5 in there. They should be. 04:04

6 Q. Are they also -- 04:05

7 A. I need to interject here that I'm not 04:05

8 sure that I had an opportunity to review all of 04:05

9 the sections of the ANDA when they were up on the 04:05

10 website for me. So I got to be careful here. I'm 04:05

11 not sure if I had the whole package 04:05

12 Q. Have you looked at the method operating 04:05

13 instructions or anything else regarding the 04:05

14 testing methods? 04:05

15 A. I have looked at some methods. I would 04:05

16 have to go back and look and see what specific 04:05

17 methods there were. 04:05

18 Q. I didn't see any criticism in your 04:05

19 report of Actavis's method for finished process 04:05

20 testing Digitek. Am I correct about that? 04:05

21 A. There is nothing in the report. 04:05

22 However, I was not pointed specifically to look at 04:05

23 methods in particular. I did not do a wholesale, 04:05

24 soup to nuts -- as I normally do -- review of the 04:05

25 laboratory control system. 04:05

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 221

1 Q. When you say as you normally do in a lab 04:05
2 control system, you mean for a consulting 04:05
3 non-litigation project; right? 04:06

4 A. Yes. 04:06

5 Q. Well, certainly if the Plaintiffs' 04:06
6 lawyers were concerned about the finished product 04:06
7 methods, they would have probably pointed you in 04:06
8 that direction; correct? 04:06

9 A. I wouldn't make that conclusion. We ran 04:06
10 out of time as much as anything else. 04:06

11 Q. And excuse me if I asked you this 04:06
12 before, but you have not seen in any 483 or 04:06
13 warning letter any sort of statement by FDA that 04:06
14 Actavis's finished product testing of Digitek was 04:06
15 in some way deficient; correct? 04:06

16 A. No, we did not talk about that. And I 04:06
17 vaguely recall that there are discussions with 04:06
18 respect to analytical methods not being sufficient 04:06
19 for their intended use and/or validated in some of 04:06
20 these documents that the FDA has generated. I 04:06
21 have to go back and look at them. 04:07

22 Q. For Digitek? 04:07

23 A. I can't say for certain, but I know that 04:07
24 there are discussions through 483s and warnings 04:07
25 letters with respect to the laboratory records and 04:07

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 222

1 methods. 04:07

2 Q. Did FDA ever say that there was a batch 04:07
3 that had out-of-spec results that should have been 04:07
4 rejected because the methods or even the 04:07
5 investigations were inadequate? 04:07

6 A. Methods? 04:07

7 Q. Or investigations? 04:07

8 A. Or investigations. Again, I'd have to 04:07
9 go back and look at it because there are 04:07
10 discussions with respect to methods, methods 04:07
11 validation and testing that come up throughout 04:07
12 these FDA documents. 04:07

13 Q. But my question is very specific. 04:07

14 A. Okay. 04:08

15 Q. Do you remember any statements in any 04:08
16 FDA documents to the effect that Digitek batches 04:08
17 should have been rejected because analytical 04:08
18 methods were inadequate or investigations were 04:08
19 inadequate? 04:0820 A. I can't say that off the top of my 04:08
21 head. I really can't. Analytical methodology is 04:08
22 invariably one of the observations the FDA makes 04:08
23 for companies in trouble. 04:08

24 Q. Let's go to page 7 of your report. 04:08

25 MR. KERENSKY: Can we take a stretch 04:09

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 223

1 break after you finish this thing, this little 04:09
2 subject? 04:10
3 MR. MORIARTY: How long on the tape? 04:10
4 THE VIDEOGRAPHER: 25 minutes. 04:10
5 MR. MORIARTY: Yeah. 04:10
6 BY MR. MORIARTY: 04:10
7 Q. Okay. Page 7. 04:10
8 A. Yes. 04:10
9 Q. It says product recalls. 04:10
10 A. Yes. 04:10
11 Q. The first one is in 1990. Was that 04:10
12 Digitek? 04:10
13 A. I don't know. 04:10
14 Q. What would you have to look at to figure 04:10
15 it out? 04:10
16 A. It was just a -- if I recall, it was a 04:10
17 business summary that was presented by one of the 04:10
18 CEOs and it just said there was a product recall. 04:10
19 If I -- I'm pulling this off my memory, which I 04:10
20 hesitate to do that. 04:10
21 Q. In 1995, Class III? 04:10
22 A. Uh-huh. 04:10
23 Q. That's not recalled at the consumer 04:10
24 level; correct? 04:10
25 A. Uh-huh. 04:10

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 224

1 Q. Is that right? 04:10
2 A. That's correct. 04:10
3 Q. Because of incorrect package insert. 04:10
4 Which is, in your words, a failure of packaging 04:11
5 and labeling portions of the cGMPs; correct? 04:11
6 A. Correct. 04:11
7 Q. Was it Digitek? 04:11
8 A. I'd have to look. That may be one of 04:11
9 those things as well that was just stated as. 04:11
10 Q. And certainly FDA or Amide at the time 04:11
11 didn't consider this as a patient safety issue 04:11
12 because it was a Class III recall; correct? 04:11
13 A. Correct. An immediate threat. 04:11
14 Q. And the 2008 August total product 04:11
15 recall, which is the last one that you list -- 04:11
16 A. Yes. 04:11
17 Q. -- that was a Class III recall, wasn't 04:11
18 it? 04:11
19 A. I don't recall. 04:11
20 Q. Well, that's important to know, isn't 04:11
21 it? 04:11
22 A. Let's take a look. 04:11
23 MR. MORIARTY: Let me make sure we're on 04:12
24 the same page. 04:12
25 THE WITNESS: Okay. 04:12

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 225

1 BY MR. MORIARTY: 04:12

2 Q. Was the 2008 August recall to the 04:12

3 consumer level? 04:12

4 A. What page were we on again back in the 04:12

5 document? 04:12

6 Q. Seven. 04:12

7 A. Seven? 04:12

8 Q. But you don't have a reference? 04:12

9 A. Seven, the August recall? 04:12

10 Q. Yeah, I guess you would be looking at 04:12

11 A49, A55, 63. That's what your table says 04:12

12 A. 25 April, 2008? 04:13

13 Q. No, sir. August 2008. It would be your 04:13

14 reference A63. 04:13

15 A. 63. 04:13

16 Q. And on page 61 of your report you say 04:13

17 that it was recalled at the retail level. 04:13

18 A. Where in the report? 04:13

19 Q. Page 61. 04:13

20 A. Yeah. 61, reference A63? 04:13

21 Q. Yes, sir. 04:14

22 A. Recall from press release, FDA website 04:14

23 "Actavis auto announces voluntary recall at retail 04:14

24 level of all drugs manufactured." Then that's 04:14

25 what that was. 04:14

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 226

1 Q. All right. So even though FDA may have 04:14
2 been concerned about good manufacturing practice 04:14
3 violations in 2008 or 2007, there was not a recall 04:14
4 of these other products to the consumer level; 04:14
5 correct? 04:14

6 A. According to that. 04:14

7 MR. MORIARTY: Okay. You want to take a 04:14
8 stretch break? Let's go off the record for -- 04:14

9 MR. KERENSKY: Thank you for remembering. 04:15

10 MR. MORIARTY: For five minutes. 04:15

11 THE VIDEOGRAPHER: The time is 4:17 p.m. 04:15

12 We're going off the record. 04:15

13 THE VIDEOGRAPHER: The time is now 04:25
14 4:28 p.m. We are back on the record. 04:25

15 (Whereupon, Exhibit 106 was marked 04:26
16 for identification) 04:26

17 BY MR. MORIARTY: 04:26

18 Q. Okay. I'm going to show you what has 04:26
19 been marked as Exhibit 106; okay? This is a 04:26
20 notice of your deposition for today; all right? 04:26

21 A. Okay. 04:26

22 Q. Have you seen that before? 04:26

23 A. I have. 04:26

24 Q. All right. And it tells you to bring a 04:26
25 lot of stuff; right? 04:26

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 227

1 A. Yes. 04:26

2 Q. So when this is going to be restarted on 04:26

3 the 18th, there will be a new notice that goes 04:26

4 out. You will have to bring your stuff and 04:26

5 somehow the lawyers will figure out a way to get 04:26

6 this hard drive duplicated so we can find these 04:26

7 other things; okay? 04:26

8 A. Okay. 04:26

9 Q. So it's possible you'll have to be in 04:26

10 communication with people between now and then -- 04:26

11 A. Yes. 04:26

12 Q. -- to facilitate that; all right. 04:26

13 Okay. Fair enough. 04:27

14 MR. ANDERTON: We should plan to start 04:27

15 perhaps as early at 8 o'clock on the 18th? 04:27

16 THE WITNESS: That's fine. 04:27

17 BY MR. MORIARTY: 04:27

18 Q. Let's go to page 8 of your report. Do 04:27

19 you see in the middle of the page where you have 04:27

20 the three bullet points? 04:27

21 A. Yes. 04:27

22 Q. Does it gives the three addresses? 04:27

23 A. Yes. 04:27

24 Q. All right. Do you know that Taft Road 04:27

25 was only a packaging facility for Digitek? 04:27

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 228

1 A. I knew that it was in limited 04:27
2 operations. Specifically packaging, I don't know 04:27
3 if I could -- I could say that definitively 04:27
4 without going back and looking at the EIR. 04:27

5 Q. Do you remember anything in a 483 or a 04:27
6 warning letter or an EIR to the effect that there 04:28
7 was a problem in any facility of Taft Road that 04:28
8 affected the potency of Digitek that made it to 04:28
9 consumers? 04:28

10 A. I can't say without going back. It gets 04:28
11 pretty complex on what the facilities are and how 04:28
12 they are, what's going on at them. It's kind of a 04:28
13 mess just breaking out what the three were. So 04:28
14 I -- I can't definitively answer that, sorry. 04:28

15 Q. And do you know what was going on at 990 04:28
16 Riverview Drive? 04:28

17 A. Again, it's the same thing. Very 04:28
18 confusing reviewing documents what specific 04:28
19 operations were going on at these individual 04:28
20 facilities. 04:28

21 Q. Well -- 04:28

22 A. And how they impacted or didn't. 04:28

23 Q. Hypothetically I want to you assume that 04:28
24 all that was going on at Riverview was -- from a 04:29
25 production standpoint was the attempt to validate, 04:29

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 229

1 process validate a new location with different 04:29
2 equipment to manufacture Digitek; okay? 04:29
3 A. Theoretically; okay. 04:29
4 Q. No. 04:29
5 A. That's what you're saying. 04:29
6 Q. No, I'm asking you to assume that. 04:29
7 A. Hypothetically. 04:29
8 Q. And that no product from Riverview was 04:29
9 ever released to market at all; okay. 04:29
10 A. If that's what you say hypothetically, 04:29
11 yeah. 04:29
12 Q. So if, for example, they had a problem 04:29
13 some day with an oil leak on a tableting machine 04:29
14 and tablets got oily but were, you know, rejected 04:29
15 because they were not going to market anyway, that 04:29
16 wouldn't affect the potency of Digitek that 04:29
17 actually was made at Little Falls and shipped to 04:29
18 consumers, would it? 04:30
19 A. What facility are we talking about? 04:30
20 Q. Riverview. 04:30
21 A. Riverview. Okay. And you're saying 04:30
22 that hypothetically if there was problem at 04:30
23 Riverview where they're only doing process 04:30
24 validation; is that correct? 04:30
25 Q. Yeah. 04:30

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 230

1 A. That that action would not influence 04:30
2 what was going on at the Little Falls facility. 04:30

3 Is that what you're saying? 04:30

4 Q. Yes. 04:30

5 A. Yes, hypothetically, yes. 04:30

6 Q. Okay. Well, do you have any evidence 04:30
7 that any Digitek that was made at Riverview was 04:30
8 released to consumers? 04:30

9 A. Other than going back and digging 04:30
10 through documents, I can't say that explicitly. 04:30
11 I -- it's just -- it's too much to go back and 04:30
12 piece together. 04:30

13 Q. Okay. Miss Donahue represents Mylan. 04:31
14 Do you know who Mylan is? 04:31

15 A. I do. 04:31

16 Q. Do you know that they were only a 04:31
17 distributor not a manufacturer of Digitek? 04:31

18 A. Is that a totally accurate statement 04:31
19 because I don't know if I understand the 04:31
20 relationship, UDL, Bertek, how they fall into 04:31
21 that. 04:31

22 Q. Do you know whether Digitek was ever 04:31
23 manufactured by anyone other than Amide or 04:31
24 Actavis? 04:31

25 A. I don't know that definitively because I 04:31

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 231

1 know there was discussion that Mylan was going to 04:31
2 take it over via UDL or Bertek, so I don't know. 04:31

3 Q. Well, have you seen any documents to 04:31
4 indicate that Mylan or UDL ever manufactured 04:31
5 tablets of Digitek? 04:32

6 A. I don't believe that they did. 04:32

7 MR. MORIARTY: Okay. The bottom line is 04:32
8 she has a couple of questions that she wants 04:32
9 to get out of the way during session one. So 04:32
10 I'm going to let her ask those questions and 04:32
11 then if there's time left on my tape, I'll get 04:32
12 back to you; okay? 04:32

13 THE WITNESS: Okay. 04:32

14 DIRECT EXAMINATION 04:32

15 BY MS. DONAHUE: 04:32

16 Q. Good afternoon, Dr. Bliesner. 04:32

17 A. Hello. 04:32

18 Q. I have reviewed your -- first, let me 04:32
19 start by asking you this. 04:32

20 A. Yes. 04:32

21 Q. You are not an expert in pharmaceutical 04:32
22 distribution, are you? 04:33

23 A. Distribution, no. 04:33

24 Q. And you're not an expert on the industry 04:33
25 practices related to pharmaceutical distribution? 04:33

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 232

1 A. Distribution, no. 04:33

2 Q. You're not expert on the FDA regulations 04:33

3 applicable to pharmaceutical distribution? 04:33

4 A. I have not -- I mean don't even know 04:33

5 what specifically the regulations would relate to 04:33

6 distribution, so, no. 04:33

7 Q. So you're not expert? 04:33

8 A. No. 04:33

9 Q. And you've never published any articles, 04:33

10 textbooks, treatises on pharmaceutical 04:33

11 distribution practices? 04:33

12 A. I have not. 04:33

13 Q. Now, I reviewed your 21-plus attachment 04:33

14 page report before coming here today. 04:33

15 A. Yes. 04:33

16 Q. And the purpose of that report is set 04:33

17 forth on page 1 of your report; correct? 04:33

18 A. Correct. 04:33

19 Q. And can you read that purpose out loud, 04:33

20 please, for the record? 04:34

21 A. Sure. Purpose: "This report is a 04:34

22 thorough, detailed, independent review of the 04:34

23 facts related to Digitek product litigation. In 04:34

24 particular, this review is specifically conducted 04:34

25 to determine if Amide Pharmaceutical, Inc. which 04:34

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 233

1 later became Actavis Totowa, LLC and referred to 04:34
 2 as Amide/Actavis within this report, demonstrated 04:34
 3 a systematic failure to implement quality systems 04:34
 4 which in turn created a high likelihood that 04:34
 5 adulterated product made it to the marketplace." 04:34

6 Q. Thank you. And is that an accurate 04:34
 7 statement of the purpose of your report? 04:34

8 A. Yes. 04:34

9 Q. And I think you told me -- you told us 04:34
 10 earlier in response to Mr. Moriarty's questions, 04:34
 11 that -- let's see. When you first were contacted 04:34
 12 by Plaintiffs' counsel in these cases, your task 04:34
 13 or the guidance they gave you was to evaluate the 04:34
 14 status of Actavis's or Amide's compliance with 04:34
 15 GMPs; is that correct? 04:34

16 A. Yes, that's correct. 04:34

17 Q. If we turn to page -- the bottom of page 04:35
 18 20 of your report under the heading root causes 04:35
 19 for Amide Pharmaceutical and Actavis's failure to 04:35
 20 comply with GMPs which led to release of 04:35
 21 adulterated product to market. 04:35

22 A. Yes. 04:35

23 Q. You see that there? 04:35

24 A. I do. 04:35

25 Q. And then you have list of the root 04:35

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 234

1 causes; right? 04:35

2 A. Yes. 04:35

3 Q. And nowhere among the one, two, three, 04:35
4 four, five root causes that you've identified in 04:35
5 your report is there mention of any conduct on 04:35
6 behalf of -- or on the part of Mylan or UDL as a 04:35
7 root cause; is that correct? 04:358 A. Specifically, "yes, but." Mylan was 04:36
9 contracted to have amide then or Actavis 04:36
10 manufacture the tablets, and there was no quality 04:36
11 agreement that was in place that I saw in the 04:36
12 record. 04:3613 So lack of quality assurance oversight 04:36
14 overlaps into that because the innovator, as I 04:36
15 understand, or the head of the contract -- Mylan 04:36
16 in this case as I understand as I read it -- is 04:36
17 responsible for the product as well and making 04:36
18 sure that their contractors, contract 04:36
19 manufacturers, whatever, follow the GMPs. 04:3620 Q. Have you been asked in this case by 04:36
21 Plaintiffs' counsel to provide an opinion as to 04:36
22 Mylan's alleged liability? 04:36

23 A. Formally, prior to this? 04:36

24 Q. Yes. 04:36

25 A. Prior to this session? 04:37

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 235

1	Q.	Yes.	04:37
2	A.	No.	04:37
3	Q.	Prior to authoring your report, were you	04:37
4		asked by Plaintiffs' counsel to render a report as	04:37
5		to Mylan's liability in these cases?	04:37
6	A.	I recall the discussion with the Miller	04:37
7		law firm regarding Mylan and asked for guidance.	04:37
8		This is from memory, so it's not written down.	04:37
9		It's a bit vague. And they -- their guidance was,	04:37
10		you know, however they fit into this, put it in	04:37
11		your report as you see fit.	04:37
12	Q.	And you saw fit not to mention Mylan	04:37
13		specifically or any specific Mylan conduct in the	04:37
14		report that you've stated was -- was written for	04:37
15		the purpose of advising counsel as to what your	04:37
16		opinions are in this case.	04:37
17	A.	There are references in the attachment	04:37
18		section to discussions with Mylan that talk about	04:38
19		quality issues they were concerned with for some	04:38
20		time.	04:38
21	Q.	Okay. Can you please point to me --	04:38
22	A.	Sure.	04:38
23	Q.	-- in your attachments every reference	04:38
24		to Mylan.	04:38
25	A.	Okay.	04:38

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 236

1	MR. MORIARTY: I think this is going to	04:38
2	take a couple of minutes. You might want to	04:38
3	go off the video record.	04:38
4	THE VIDEOGRAPHER: The time is 4:41 p.m.	04:38
5	We're going off the record briefly.	04:38
6	(Short break)	04:39
7	THE VIDEOGRAPHER: The time is now	04:39
8	4:49 p.m. We are back on the record.	04:46
9	BY MS. DONAHUE:	04:46
10	Q. All right. Dr. Bliesner, off the record	04:46
11	you were reviewing your report --	04:46
12	A. Yes.	04:46
13	Q. -- in order to answer my question which	04:46
14	was where -- will you please point out every	04:46
15	reference in your report to a Mylan document.	04:46
16	A. Yes. The other question I have, are you	04:46
17	considering UDL Bertek to be part of the Mylan	04:47
18	umbrella?	04:47
19	Q. Sure.	04:47
20	A. Okay. Page 15, number 33.	04:47
21	Q. Uh-huh. Yes. Thank you. We have	04:47
22	number page 15, number 33?	04:47
23	A. Yes.	04:47
24	Q. Yes.	04:47
25	A. Page 18, number 46.	04:47

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 237

1 Q. Yes. 04:47

2 A. And number 49. Page 19, number 54. 04:47

3 Q. Any others? 04:47

4 A. Yes. Page 41, number A24; page 43, A28; 04:47

5 page 46, A33; page 47, A36; page 54, A44; page 56 04:48

6 A 49; page 57 A52; page 58, A53. 04:49

7 There is a reference to Bertek UDL in A55 on 04:50

8 page 59, embedded in the press release, and on 04:50

9 page 60, A59. And I believe with that quick 04:50

10 review of the report, that should be most all of 04:50

11 them. 04:50

12 Q. Thank you. 04:50

13 A. Uh-huh. 04:50

14 Q. Now each of those references that you've 04:50

15 just given us to Mylan documents, are just that; 04:50

16 correct? They are references to Mylan documents 04:50

17 and in some instances quotations from the 04:50

18 documents; is that correct? 04:50

19 A. For e-mails, yes. 04:50

20 Q. And nowhere in the course of those 04:50

21 references have you rendered an opinion in regard 04:50

22 to Mylan or UDL's conduct in distributing Digitek? 04:50

23 A. In this report? 04:51

24 Q. Yes. 04:51

25 A. I have not written it in the report. I 04:51

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 238

1 do have an opinion, but I have not written it in 04:51
2 the report. 04:51

3 Q. Did you have an understanding as you 04:51
4 came here today that your report was to contain 04:51
5 the totality of your opinions that you intend to 04:51
6 render at trial in this case? 04:51

7 A. With respect to the guidance that I got, 04:51
8 thought and think and do believe that I put the 04:51
9 information that was desired specifically related 04:51
10 to Digitek, Actavis Totowa. That was my guidance. 04:51

11 MR. MORIARTY: You have 60 seconds. 04:51

12 BY MS. DONAHUE: 04:51

13 Q. As you sit here today, what is your 04:52
14 opinion with regard to Mylan's conduct in the 04:52
15 distributing Digitek in the case, Mylan and UDL? 04:52

16 A. Just based upon the documents that I 04:52
17 reviewed and, again, not concentrating on Mylan's 04:52
18 position in this thing, I found it odd and not 04:52
19 customary that no quality agreement was in place. 04:52

20 Q. You would agree, would you not, that 04:52
21 quality agreements are not required by the FDA 04:52
22 regulations? 04:52

23 A. By regulations? Specifically in 21 CFR 04:52
24 210 and 211, not to my knowledge is there a 04:52
25 requirement for a quality agreement. It is 04:52

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 239

1 standard industry practice. 04:52

2 Q. That's a relatively new standard 04:52

3 industry practice, would you agree with that? 04:52

4 A. Relatively new? I'm not sure how you 04:52

5 define relatively new. 04:52

6 Q. In your opinion, when did it become 04:53

7 standard industry practice? 04:53

8 A. Well, let's see. For the last -- at 04:53

9 least the last three to five years in my 04:53

10 consulting endeavors I've expected and seen 04:53

11 quality agreement with contractors. 04:53

12 Q. Do you understand that as you sit here 04:53

13 today, Dr. Bliesner, that Mylan or -- neither 04:53

14 Mylan or UDL was the innovator in regard to 04:53

15 Digitek? In other words, neither one of them held 04:53

16 the ANDA? 04:53

17 A. That is correct. I understand that. 04:53

18 MS. DONAHUE: Since we're almost out of 04:53

19 tape, I'm going to stop questioning now, but I 04:53

20 reserve the right to come back. 04:53

21 Oh, yeah. Before we go off the record, 04:53

22 let me finish my sentence. I reserve the 04:53

23 right to come back and continue my 04:53

24 questioning. And you've been, I think, taking 04:53

25 some notes during the deposition and we would 04:53

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 240

1 like to get those marked as an exhibit, 04:54
2 please. 04:54

3 THE WITNESS: Okay. 04:54

4 MS. DONAHUE: Let's wait. Before we go 04:54
5 off the record, let's mark them. 04:54

6 MR. KERENSKY: You didn't write anything 04:54
7 down about Mr. Anderton's tie, did you? 04:54

8 THE WITNESS: No, it was noted though. 04:54

9 MR. KERENSKY: Okay. 04:54

10 MR. ANDERTON: I will accept the 04:54
11 compliment. 04:54

12 (Whereupon, Exhibit 109 was marked 04:54
13 for identification) 04:54

14 THE VIDEOGRAPHER: The time is now 04:54
15 4:57 p.m. We're going off the record. 04:54

16

17 (THEREUPON, the taking of the deposition
18 was concluded at 4:57 p.m.)

19

20

21

22

23

24

25

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 241

1 CERTIFICATE OF OATH

2

3 STATE OF FLORIDA

4 COUNTY OF HILLSBOROUGH

5

6 I, the undersigned authority,

7 certify that David Bliesner, Ph.D., personally

8 appeared before me and was duly sworn by me.

9 WITNESS my hand and official

10 seal, this 3rd day of February, 2011.

11

12

13

14 PHILIP RYAN, RPR
15 NOTARY PUBLIC - STATE OF FLORIDA
16 COMMISSION # DD 988415
17 MY COMMISSION EXPIRES: JUNE 28, 2014

18

19

20

21

22

23

24

25

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 242

1 CERTIFICATE OF REPORTER

2 STATE OF FLORIDA

3 COUNTY OF HILLSBOROUGH

4 I, PHILIP RYAN, RPR, certify that I
5 was authorized to and did stenographically
6 report the foregoing deposition; and that the
7 foregoing transcript is a true record of the
8 testimony given by the witness.

9 I further certify that I am not a
10 relative, employee, attorney, or counsel of any
11 of the parties, nor am I a relative or employee
12 of any of the parties' attorneys or counsel
13 connected with the action, nor am I financially
14 interested in the action.

15

16 DATED this 3rd day of February,
17 2011.

18

19

20

21

22

PHILIP RYAN, RPR

23

24

25

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 1

A AAPS 178:13,14 ABI 69:24 able 193:4 214:6 above-listed 176:21 absolutely 15:16 72:18 76:21 91:15 95:15 168:16 206:23 academic 11:19 12:5 accept 240:10 acceptable 196:22 acceptance 171:12 accepted 168:6,12 188:10 access 21:10 43:20 189:9,11 191:7 accommodate 60:3 60:16 accurate 48:22 212:18 230:18 233:6 accurately 36:4 94:14 192:11 achieved 19:14 achieving 150:1 acknowledge 131:2 ACS 166:16,18 Act 25:1 30:8 Actavis 2:16,16 2:17 4:21,24 37:9 48:14 58:21 59:4,8 67:14 75:24 92:14 93:17 94:6,18 95:11 96:12 98:14 116:4 117:15 118:4 128:2,8 137:11 137:16,20,21 138:23 139:15,16 141:10 154:12 157:19 175:15 180:13 185:6 186:7 194:14	197:9,19 199:16 203:18,23 207:6 225:23 230:24 233:1 234:9 238:10 Actavis's 128:11 141:8 142:18 180:5 220:19 221:14 233:14,19 action 30:10,14 30:15,20,21,25 74:24 148:8,11 148:17 149:17,18 151:8,11,14,15 151:17 176:23 230:1 242:13,14 actions 57:5,6,9 144:24 147:7 active 40:5 66:18 66:25 67:9 68:25 69:8,24 70:20 72:21 73:1,20 89:2 90:3 91:2 91:25 92:3 93:1 93:8,16 104:18 104:24 105:17 159:10,17 165:8 165:14 196:5,8 197:16 214:5 actives 105:24 actual 19:21 82:3 82:10 92:10 141:21 171:21 197:10 200:4,17 200:25 212:23 213:5 219:13 addition 153:22 159:25 189:5 additional 57:1 102:14 119:11 130:5 154:6,9 175:4 176:11 181:11 address 45:8 147:11 addressed 148:3 200:18 207:2 addresses 173:11 227:22	addressing 179:21 adhere 18:24 adherence 15:15 17:2,15 18:2 adjunct 156:19 Administration's 135:3 administrator 153:12 admit 78:21 adulterated 23:5 24:12,15 27:24 28:21 30:7 49:24 50:5 52:22 53:1 80:7 81:4 83:7 83:20 84:20 85:19,23 101:14 103:10,19 188:2 188:8,19 208:16 233:5,21 adulteration 22:17 24:6,20,24 26:17,23 85:2 advance 48:16 advantage 158:20 adverse 76:14 187:3 208:5,12 208:15,24 214:12 advertising 115:12 advised 63:21 advising 235:15 advisory 146:19 146:22 147:21 148:3 AERs 209:13 affairs 163:7 affect 229:16 afford 149:15 afternoon 231:16 agencies 101:21 agency 147:16,16 148:1,8,11,17 149:11,25 151:8 151:11,13,15,17 152:10 183:8 195:19 aggressive 74:24 ago 8:1 41:24
--	--	---

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 2

181:19	117:23 118:12	196:12 212:12	109:7 110:21
AmSel 10:6	119:10 124:22	appropriately	126:5,15 127:22
analysis 21:15	136:25 137:2	212:8	128:20,24 130:11
58:22 77:14	143:9 144:15	approval 48:17	130:14,17 131:2
108:4 126:20	147:4 181:8	approved 46:24	131:2,5,25 135:1
127:24 128:1,4	182:20 192:11	71:13 72:14,21	135:2,24 140:11
128:16,23 130:5	203:24 207:18	78:18 133:11	140:25 168:17,20
130:19 132:17	228:14 236:13	135:4 136:6,20	171:9 220:1
165:16,19 168:11	answered 147:13	196:18,21 218:1	assays 108:21
198:15 202:25	answers 52:2	approximately 4:4	assembling 161:7
analytical 46:9	anybody 61:2,4,13	77:4 170:5,7	assess 38:11,14
110:20 125:18	89:4 102:20	April 104:22	39:4 77:17
160:13 161:13	115:8 132:6	121:20 129:13,20	103:16 180:23
162:1 164:3	anymore 31:13	225:12	assessment 46:23
171:2 221:18	156:12 195:20	arbitration 5:25	181:24 182:1
222:17,21	212:1	6:3,5,17,18	assessments 214:1
analyze 103:19	anyway 200:1	area 101:17,18	assistance 37:10
analyzed 109:8	229:15	argument 202:4	associated 41:21
198:24	API 71:1,6 105:21	211:9,11	42:5 47:4 77:1
analyzing 19:11	165:17	arrangement	92:23 175:16
171:23	apologize 70:3	100:11 181:21	Association
ANDA 19:1 42:2	129:10 166:15	arrangements 6:10	166:21 178:15
46:20,24 48:10	194:21	192:24	assume 11:12
86:9 87:2 131:6	apparently 63:11	article 20:2,8,18	39:25 68:23 80:6
132:5 133:10,11	167:20 188:6	21:14,20	95:20,23 100:10
137:3 161:18	appear 28:23 29:7	articles 20:23	110:15 119:10
181:3 188:25	33:8,11 43:20	21:11 178:3,5,8	128:12 131:12,15
196:4 220:3,9	130:4,10	232:9	134:17 157:25
239:16	APPEARANCES 2:1	aside 111:14	169:9 186:12
ANDAs 179:7	appeared 241:8	asked 38:9 39:4	188:23 201:10,15
Anderton 2:12	appears 36:1	80:4 125:9	201:25 202:3,15
4:23,23 10:17	75:21 108:21	133:20,24 168:3	218:17 228:23
143:11,15,19	132:25 140:7	189:16,17,19	229:6
174:1,3,6 227:14	176:24 186:11	190:9,13 221:11	assumed 37:9
240:10	appendices 153:19	234:20 235:4,7	142:15
Anderton's 240:7	applicable 232:3	asking 16:9 18:15	assuming 34:3
and/or 200:11	application 47:3	28:13 30:18	132:19 133:5
221:19	47:4 161:17	51:11,13 69:17	187:21 188:16
Anita 162:15	179:2 196:20,21	69:18 79:14	assumption 141:17
announcement	196:22 218:2	95:18 100:25	assurance 122:14
147:22	applies 28:9	123:8 132:14	131:2 163:10
announces 225:23	apply 194:15	144:6 160:5	184:11,14 185:1
annual 39:2,2	applying 194:14	171:1 174:12	194:4 234:13
40:1,2	approach 19:17	180:22 189:6	assure 46:19 49:3
answer 16:16	35:16 36:6	193:22 197:6	76:2
18:11,17 37:3	appropriate 71:22	211:4 218:3	ate 115:16,19
61:10,21,25	72:22 133:5	229:6 231:19	attachment 232:13
62:11 73:9 77:10	149:16 184:13,16	assay 67:2 94:23	235:17
87:13 94:13	185:25 186:2	95:12 108:18	attachments

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 3

235:23	A52 237:6	bailiwick 219:24	133:23,25 140:3
attempt 228:25	A53 237:6	balance 105:17,19	140:5 186:16
attempted 75:24	A55 225:11 237:7	105:19	187:5,14,16,19
attention 79:1	A59 237:9	based 67:13,23	188:2,18 222:16
attorney 2:16,21	A63 225:14,20	80:7,16,18 81:3	Bates 126:2 175:8
242:10	<hr/> B	116:8 130:6	184:3
attorneys 2:11	back 12:13,15	141:19 143:9	battle 198:18,19
4:15 242:12	15:19,22 17:18	176:24 186:24	Bauman 20:2
audit 37:14,18	17:21 21:13	193:23 203:13	bear 129:10
40:18 183:8	24:19 26:8 28:25	238:16	137:19 170:23
184:12 185:24	29:2 40:14,17	basic 137:24	bears 175:8
August 174:23	43:8 48:20 49:5	basics 68:18	beginning 40:15
175:1 224:14	50:3 51:7 58:14	basing 141:22	52:22 80:1 120:5
225:2,9,13	62:19,24 67:11	basis 76:22 158:4	156:3 197:4
authored 16:5	68:18 72:6 75:16	164:9	behalf 1:17 4:24
authoring 235:3	77:2,4 78:19	batch 38:16,19,22	5:1 234:6
authority 62:8	79:8,25 81:19	40:1 41:18 42:10	believe 9:8 42:7
241:6	113:14,16 120:4	42:17 43:24 47:8	42:15 51:5 52:19
authorized 242:5	121:22 123:5,18	47:11,13 48:5,20	74:8 101:24
auto 225:23	124:23 125:15	54:8 75:13,16	105:3 116:16
automatically	129:21 137:24	86:5,8,15,17,19	135:19 174:9
205:5,6,8 208:24	140:21 142:25	86:23 87:3,15	180:9 190:1
available 39:8,22	143:5 144:10,14	93:12 95:12,24	191:21 193:14
41:1,4 52:9 55:5	144:21 151:19	98:14,16 107:16	217:5 231:6
158:21 167:23	156:2 158:5	126:14 127:21	237:9 238:8
184:1 187:7	167:5 170:4	128:23 132:17	bell 155:5
Avenue 2:14	172:17 175:7	134:5 135:11	Bellingham 51:8
aware 33:17	178:10 180:16	141:7 186:16,20	54:3
197:19 212:4	181:15 182:7	186:25 187:9,10	Bennett 10:6
218:10	188:21 197:3	187:14,24 188:5	Bertek 2:22
awful 195:14	198:22 200:12,19	188:16,17,23	230:20 231:2
A(2) (b) 30:8	201:25 205:11	189:2,14,17	236:17 237:7
A-11 120:22,24	206:6 207:3,13	190:12 192:2	best 10:9 19:14
121:2 122:3	207:16 209:4	197:16,20,21	29:6 34:16 46:19
123:8,23	212:16 214:7,18	198:13 200:4	76:12 171:3
a.m 1:11 4:4 26:4	214:22 215:7,22	201:1 202:21	191:21 206:2
26:7 40:10,14	220:16 221:21	203:12,19,23	better 13:19 19:4
43:4,8 79:25	222:9 225:4	204:14,22 205:3	127:24
81:16,19	226:14 228:4,10	205:5 206:12,17	beyond 176:22
A2 (b) 26:25 27:1	230:9,11 231:12	207:7 212:5,23	big 198:24
27:8,10 28:3,17	236:8 239:20,23	213:5,14,18	bigger 145:21
28:20	background 77:16	222:2	billed 181:19
A24 237:4	152:19	batches 47:21	billing 181:8,9
A25 174:1	backup 201:4	86:2 87:8,12,14	billings 182:3
A28 237:4	Bacon 2:18 4:6	88:18 91:21	billion 116:17
A33 237:5	5:1	92:14,19 95:13	117:2 216:13,20
A36 237:5	bad 112:10,11	95:21,24 96:14	binary 103:6
A44 237:5	216:6	97:12 98:6,9,11	bit 82:6 108:14
A49 225:11		99:19 125:19	126:25 127:10

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 4

152:20 184:4 235:9 black 99:4 177:14 blacked 177:1,2 177:13 blanks 170:11 blend 46:17 67:20 67:25 92:7 93:3 93:4 94:22 95:4 105:14 109:17 141:24 197:20,21 198:3,12,13 199:5,13,17,25 200:5,10,12,17 201:1,12 202:13 203:13,24 204:10 204:19 205:19 207:1,7,10 218:24 blended 196:6 blender 201:12,22 203:8 blending 161:8 Bless 21:21 Bliesner 1:14 4:14 5:9,16 16:3 25:22 70:6 74:5 80:3,3 123:8 141:18 195:8 212:4 231:16 236:10 239:13 241:7 blister 59:12,14 59:17,20,20,24 60:2,8,17,21,24 65:11,12,18 116:24 139:2,5 162:12 block 13:18 boards 194:5 bold 55:21 84:14 book 167:19,23 170:5 bookkeeper 158:7 181:7 books 179:1 Boston 154:23 bottles 107:14 bottom 21:14	231:7 233:17 Boulevard 2:3,9 box 152:11 boxes 41:23 44:14 206:25 207:4 Branch 56:8 branches 77:22 brand 75:1 break 26:6 40:8 40:12 43:6 79:23 81:17 100:2 119:23 120:2,8 123:2 140:19 142:23 155:25 172:10,15 197:6 223:1 226:8 236:6 breaking 228:13 Bridgeside 2:9 briefest 153:11 briefly 26:5 40:11 43:5 45:11 45:12 79:22 120:1 123:1 140:18 142:22 172:14 236:5 bring 125:2 189:22 226:24 227:4 bringing 90:8 106:8 broad 68:17 85:16 broader 138:7,22 138:22 brought 35:22,25 153:22 buddy 210:24 Building 2:13 built 160:11 bulk 143:4,7 144:4,8 164:22 164:25 165:3 172:20 173:22 175:5,22 176:2 176:20,25 bullet 37:8 75:4 75:7,8,11,22 76:11 227:20 bulletin 194:5	Bush 2:19 business 15:8 37:22 47:7 48:24 81:24 90:22 157:25 158:10,13 158:20 160:10,12 164:23 168:13 192:13 223:17 businesses 164:12 buy 21:10 91:17 114:12 <hr/> C C 128:12 133:7 CA 2:6,20 cabinet 114:21 118:3 calculate 91:16 calculation 214:7 calibration 159:23 call 46:7 120:11 211:15 called 64:13 74:13,19 100:11 159:16 163:2 calling 91:8 camera 202:10 cap 31:10 55:22 capacity 191:24 caption 4:8 49:16 car 158:16 card 58:1,21 59:3 59:13,17,21,24 60:8 63:20,22 cardiologist 154:22 210:15 cardiologists 209:21 cards 91:6,7,8,9 care 122:15 210:13,23 career 11:15,19 12:5 21:8 careful 20:12 201:24 213:25 220:10 carefully 32:13 50:9 111:10	Carolina 157:1,5 Carter 2:8 5:5 case 4:8 6:13,24 7:2,7 16:6 18:14 20:1 25:20 33:21 36:11,15 43:13 47:10,16 48:21 74:24 80:6 102:25,25 114:1 114:16 116:1 132:2,4 141:19 153:3,8,10 155:9 200:23 209:22 234:16,20 235:16 238:6,15 cases 53:8 108:5 153:16 164:16 167:1 171:15 205:21 233:12 235:5 cash 158:16 categories 18:23 102:19 causal 208:13,14 cause 1:21 56:18 67:7,8 106:1 165:22 204:24 205:16 234:7 caused 68:25 69:3 208:16 215:12 causes 68:12 233:18 234:1,4 caution 193:19 cavity 139:2 Cedar 90:18 Celsis 125:18 127:5,12 128:15 133:22 139:23 140:3,24 154:3 CEN 178:13 centered 55:22 CEO 147:18 CEOs 223:18 certain 95:13 112:9,9 148:21 160:22 218:24 221:23 certainly 56:7 64:6 191:6 221:5
---	---	---	--

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 5

224:10	chem 164:3	clients 39:16	comment 174:6
certainty 17:3	chemical 58:24	40:20 90:25	195:9 218:11
72:2 79:10	59:1 166:20	91:12 97:6	commenting 146:25
190:14	169:17,18 178:19	158:22 159:4	commercially
certificate	178:20	client's 36:12	71:22 72:15
126:19 128:1,4	chemically 110:17	119:12 128:13	COMMISSION 241:15
130:18 241:1	chemist 162:1	clinic 207:25	241:15
242:1	171:2	close 116:17	commit 25:5
certificates	chemistry 169:20	117:2 121:18,24	committee 156:12
127:23	children 14:23	129:8 212:24	committees 156:11
certification	chose 110:17	213:6,23	common 90:15
47:8,11 48:5,20	chromatographic	clue 120:23	169:18 195:2
certify 241:7	167:20	coach 13:1,3,6,9	commonly 20:21,22
242:4,9	chromatography	13:22,24 14:4,23	communicating
certifying 47:21	108:15 126:24	coaches 13:15	34:12
CFR 16:17,24 23:9	127:5,10,11,17	coaching 14:13,15	communication
24:3 30:1 238:23	170:19	14:22	140:2 227:10
cGMP 84:19 85:4	chronic 116:8	code 22:16,25	communications
184:13 185:25	182:18	23:6,17 24:4,4,5	81:7 189:24
186:2	Cincinnati 155:1	25:14,14,22	companies 8:18
cGMPs 35:16 36:5	circumstance	26:12,22 29:7,16	39:4,17 81:23
84:15 224:5	206:4	cognizant 179:10	91:13 98:6
chain 57:24	circumstances	coincidence	101:22 141:10
101:12 102:10	27:25 116:11	115:17 116:2	147:9 148:1
chair 124:24	195:16 205:19	collected 107:5,8	192:3,14,15,22
challenge 198:24	citation 99:22	107:14	192:24 193:8,13
200:1	197:8	collecting 19:10	194:3,11,15
chance 62:10	citations 219:9	19:18	195:10 199:12
106:24	cite 73:19 92:13	collection 177:25	203:12 218:8
chances 17:15	92:17	college 11:13	222:23
18:3,25 134:21	cited 200:3,6	13:13	company 38:2
change 146:5	207:6	colloquialism	45:17 56:12 70:8
155:22 196:24	cites 180:13	102:8	77:6,8 78:17
chapter 30:5	citing 23:7	color 99:4 219:2	79:2 81:8 84:19
149:6	Class 104:14	column 160:11	91:1,24 92:4,25
characterization	123:6 223:21	combination 196:7	93:6 102:2
211:8	224:12,17	come 65:24 70:6	122:18 123:18
charge 36:10,15	classes 13:5	129:8 171:12	141:25 147:13
charging 181:5	classroom 156:21	178:9 182:7	154:12 158:3
Charleston 1:2	claycoachonlin...	196:15 206:1	159:22 160:19
4:12	14:2	212:24 213:6	162:25 181:20
check 22:12 25:25	clear 27:12 125:7	222:11 239:20,23	182:10,13,16
41:20 42:20	145:3 192:13	comes 83:14 123:5	195:3,23 198:12
86:12 89:19,23	Cleveland 2:14	128:1 150:11	199:19 200:3
124:22,22 137:6	client 37:10	178:24 219:13	201:11,20 203:21
155:6	38:10,14 47:20	comfortable	212:22 213:2
checked 40:19	81:4 116:2	210:20	214:11 215:7
checking 99:3	117:12 159:5	coming 218:20	company's 144:24
219:14	194:10 195:9	232:14	compare 155:16

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 6

compendium 44:12	concluded 240:17	84:20 85:19	223:23 225:3
competencies 167:4,16	conclusion 50:4	151:8 180:18	226:4
competitively 12:22	52:21 60:23	185:20 186:1	consumers 28:8,14
complaint 57:10	64:10 187:21	208:12	36:17 50:14 51:1
complaints 57:2	193:23 221:9	considering 145:1	51:21 64:15 78:9
complete 166:15	conclusions 10:14	236:17	82:12 83:3 84:1
completed 56:10	19:12,20 34:4	consistency 76:3	97:25 101:9
completely 68:3	141:19,22	consistent 91:20	116:3,5 117:6,13
completeness 43:23	conditions 85:3	103:1 149:10,19	117:17 122:5,20
complex 101:20	conduct 98:23	150:5 219:16	123:14,22 124:3
206:19 228:11	234:5 235:13	consistently 45:23	215:2 216:2,10
compliance 35:16	237:22 238:14	46:19	228:9 229:18
36:5,12,20 37:11	conducted 173:9	230:8	contact 198:2
37:16 38:11 39:5	188:17 206:6	contacted 21:22	233:11
40:19 56:8 77:24	232:24	contain 10:14	21:15 72:21
90:24 111:25	conducting 65:8	consult 70:7	181:3 187:1
112:19,22 150:2	102:3 143:4,7	constitute 149:13	196:5,10 238:4
150:8,10,14	conference 9:7	consult 70:7	contains 21:15
152:11 159:25	confidentiality 159:2	149:13 159:18	59:7
175:15 178:23	confirm 20:7	163:2,3 194:16	content 32:23
182:19 183:6,13	171:15	consultant 15:9	67:2 70:21 93:20
233:14	confirmed 187:22	64:13 145:18	93:22 94:4,7,21
complied 28:1	confirms 197:24	159:12 164:22	95:12 168:17,21
85:4	conflict 77:23	192:1	220:1
compliment 240:11	conform 128:18	consultations 158:25	context 15:4,5
comply 30:3,10	conformed 126:17	consulted 81:25	16:12 66:6 72:10
182:11 183:1,2	127:22	155:7 157:19,21	continue 183:9
196:12 233:20	Conforms 128:20	157:22 160:4	239:23
complying 84:19	confuse 114:8	163:16 195:22,25	continues 183:8
components 45:14	confusing 228:18	consulting 6:10	contract 160:13
65:6	connected 242:13	37:10,22 38:10	234:15,18
composed 105:24	connection 208:13	90:22 100:11	contracted 234:9
compression 69:2	208:14	101:12 102:2,10	contractors 234:18
69:3	consent 77:8	117:24 147:7	239:11
concentrating 238:17	78:18,23 80:17	157:6 163:21	contributed 158:9
concept 101:19	80:18,24 145:2	164:4,7,10 181:6	contribution 158:15
102:18	149:21 182:10,13	181:21 185:9,10	control 48:25
concern 23:21	182:15,17,25	191:17,24 192:23	49:3 69:14 91:23
concerned 29:13	183:3,5,7,12,16	193:14 198:2	130:23 161:14
221:6 226:2	191:20,20 192:17	210:6,25 221:2	199:15 220:25
235:19	192:25 193:8,9	239:10	221:2
concerns 159:25	193:15 194:3,11	consumed 115:20	controls 145:17
conclude 64:23	195:1,11,15	115:21	controversial 199:7,8,10
109:9,20 187:8	215:8,9,21	consumer 57:19	conversation
208:25 217:12	consider 64:19	64:7 82:10,23	
	148:7,10 151:10	83:21 100:17	
	179:19 224:11	113:12 116:14	
	considered 57:4		

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 7

104:6 113:3 210:12 coordinations 101:21 copy 23:2 25:18 49:7 55:11 58:7 58:13 74:3 155:16 173:7 190:25 cord 20:13 core 103:17,18 160:10 167:4,15 198:8,13 201:11 202:1 corner 35:12 corporate 175:15 corporation 158:18 160:8 Corps 81:20 correct 7:15 8:10 8:11 11:16 14:5 14:6 20:3 21:17 25:9 26:15,19 29:22 31:1 32:11 33:15 34:19,20 34:24 35:3 36:17 37:17,20 46:21 47:2,14 49:3,4 50:15 52:23 54:22 55:3 56:10 56:19 57:12 58:18 59:9 62:1 64:3,7,24,25 65:4,5 66:3,25 67:3 68:22 69:4 69:21,25 70:15 70:22 71:2 72:2 72:22 75:1,2,14 76:4,10 80:8,14 80:15,23 81:11 82:20,24 83:21 84:12,16 86:1 91:17,22 96:2,4 97:15 98:8,16 99:15 105:2,2 110:1,10 112:13 112:23 121:5,18 122:5,12 125:20 126:15 129:14	130:11 131:14 133:11,12 134:7 134:22 140:9 144:1 145:6,7,10 147:23 150:19 151:1,18 152:6 153:20,21,25 154:1 158:13,14 160:3,15,16 165:20,21 167:22 175:23 180:8 183:14 186:7 187:11,22 188:3 188:4,15,16 196:13,19 205:10 206:9,10,22 210:10,11 218:4 219:12,17 220:20 221:8,15 223:24 224:2,5,6,12,13 226:5 229:24 232:17,18 233:15 233:16 234:7 237:16,18 239:17 corrections 175:11,13,17 176:19 corrective 57:4,6 57:9 149:16 176:23 correctly 30:11 36:7 57:8 73:10 74:21 76:17 78:22 84:22 85:5 85:12 139:8 150:3 165:16 correlate 12:10 173:21 correlates 174:13 correlation 213:10 corresponded 190:2 correspondence 139:22 189:22 Cosmetic 25:1 counsel 233:12 234:21 235:4,15 242:10,12	count 107:14 country 114:12 COUNTY 241:4 242:3 couple 8:4 116:11 141:2 156:11 231:8 236:2 course 77:3 89:9 97:21 113:10 237:20 court 1:1,18 4:11 4:17 5:6,18,20 5:22,23 12:15 15:22 17:21 23:22 29:2 34:25 62:24 67:12 113:17 123:4 125:14 167:1 207:16 covered 121:16 192:10 193:25 created 233:4 creation 139:2,5 criteria 171:13 critical 45:14 65:6,7 criticism 220:18 cross-functional 46:3 205:25 CSC 63:22,24 116:23 Curiously 166:9 current 37:15 76:3 84:11 155:15,16 176:11 178:9 currently 16:21 customary 238:19 customer 100:10 cut 113:23 184:4 CV 156:6 C11719 127:21 <hr/> D daily 90:14 164:9 danger 28:14 84:3 149:12 dangerous 28:8 31:4,18,21,23,24	36:22,24 51:20 51:22 82:4,11,23 83:2,25 data 19:10,11,15 19:16,18,21,22 21:15,16,16 39:3 40:2 61:9 64:16 64:22 65:2 67:14 78:11,13,14 79:15,18 95:25 96:16 100:22 103:9 115:10 117:7 128:11 141:11,13,14,15 141:21 142:17 175:22 176:2 179:6 187:7 216:15 date 4:2 53:25 129:15 132:19 173:3 181:20 182:4 dated 183:19 186:6 242:16 dates 123:16 David 1:14 4:13 5:9,16 241:7 day 106:19 111:19 111:21 112:16 117:25 118:17,22 118:25 119:1,4,7 129:3 182:8 201:7 206:16 209:3 229:13 241:10 242:16 days 129:9 134:3 day-to-day 90:21 DD 241:15 deal 177:4 Dean 10:17 December 10:4 56:4 75:12 186:7 decent 108:25 109:2 decree 77:8 78:18 78:23 80:24 145:2 149:21 182:11,14,17 183:1,3,7,12,16
---	--	--	--

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 8

192:25 193:9,15	depending 192:9	169:25	36:22 40:24
194:4,11 195:11	depends 38:20	developed 168:20	41:17 42:9 44:3
195:15 215:9,10	99:8 169:20	169:1	44:9 46:25 47:16
215:21	179:14	developing 19:10	50:12,25 51:20
decrees 80:17	Deponent 5:8	development	52:10,17,24 53:4
182:15 193:8	deposition 1:14	160:20	54:6,9 73:19
195:2	1:21 3:7,9,12	developments	74:19 75:25 79:1
defective 28:18	4:5 6:19 7:3	161:17	81:4 86:2,7 87:3
28:19,22 31:4,19	10:20 11:2 23:12	device 202:1	87:7,21 88:16,25
31:21,25 52:17	23:14 62:5 66:5	diameter 202:6,14	89:6 90:2 92:14
52:20 76:13 78:7	89:13 154:11,21	Didomenico 20:2	92:19,20 93:14
215:1 216:1,9	154:25 189:19	died 153:13	93:15,21,24 94:1
Defendant 2:16	226:20 239:25	difference 14:24	94:2,7,20 96:13
153:15	240:17 242:6	15:2,13 18:9,13	97:10 98:15
defendants 1:17	described 53:11	49:11 71:10 72:8	103:3 104:25
4:22,24 5:2	107:19	92:12 200:25	106:15 107:4,14
Defendant's 1:20	describes 55:24	different 25:13	107:20 111:23
defer 209:9,14	describing 75:10	25:14 34:10	112:5,19 115:13
deficiencies	description 111:1	42:18 46:11	116:3,18 117:5
187:2	111:2 153:11	50:19 67:7 68:12	117:13 125:19,21
deficient 221:15	219:25	69:9,19 71:2,3	125:21,22,25
define 14:15	design 162:12	72:1 78:1 85:24	128:18 129:13,23
20:22 38:20	217:21	100:2 101:16,18	132:18,24 134:5
239:5	designed 18:19	101:20 125:24	135:10 138:3
defines 22:16	160:11 219:20	129:5 137:22	139:23 140:3,6
23:5 24:6	desire 65:23	139:20 149:6	140:13 141:12
defining 201:24	desired 238:9	156:8 165:18	142:2,5,19
definitely 196:23	detail 9:11 41:11	175:2 179:15	144:13,20 145:6
definition 16:12	80:5 206:22	182:15 212:2	145:13 162:9
24:20,24 26:23	detailed 232:22	229:1	176:18 177:11,14
27:24 29:9 53:1	detected 93:3,10	differently 44:25	177:15,17 186:16
69:20 72:6 84:25	116:4 117:14	201:3	187:13,14,15,19
85:8	122:11 217:11,13	difficult 64:4	196:5 197:16
definitively	detecting 122:7	67:17 70:1 73:8	207:2 210:18,25
213:12 228:3,14	detection 117:16	130:22 134:15	211:24 212:4,8,9
230:25	detects 179:11	146:5 175:25	214:12 215:1
deflect 79:1	determination	177:22 180:23	216:9 218:12
degree 11:13	83:24 152:10	199:14 204:2,4	220:2,20 221:14
87:18 88:15	determine 36:16	difficulties	221:22 222:16
99:10 157:13,16	37:15 67:3 83:1	67:25 93:19	223:12 224:7
delete 191:10	83:19 89:4 103:2	106:2 214:15	227:25 228:8
delineating 45:13	130:21 171:22	215:4	229:2,16 230:7
Delphi 156:25	188:18,21 189:16	difficulty 23:19	230:17,22 231:5
157:8,24	198:23 203:1	34:9	232:23 237:22
demonstrated 63:3	205:16 232:25	dig 200:12 214:18	238:10,15 239:15
183:15 233:2	determined 76:1	digging 230:9	Digoxin 20:3,24
demonstrates	determining 37:11	Digitek 1:5 4:9	23:20 43:25 44:3
74:24	detract 19:12	7:15 8:13,24	63:22 71:11
denies 197:24	develop 169:10,14	9:23 16:6 36:16	73:16 74:19

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 9

104:14 168:18 207:23 209:17 210:4,9,18 direct 3:4 5:13 79:18 180:2 231:14 direction 221:8 directly 163:9 164:1 167:8 174:9 195:17 director 175:14 disagree 57:14 76:19 97:16 107:25 112:1 147:2,21 148:9 148:15 187:8 disagreement 76:22,24 discovered 164:18 164:19 discrete 154:8 discuss 159:3 discussion 89:22 174:12 209:24 210:17 231:1 235:6 discussions 77:21 163:20 181:11 200:20 205:1 207:9 214:14 221:17,24 222:10 235:18 disposed 115:23 disposition 205:2 dispute 6:9,11 disputing 147:24 dissolution 95:13 108:17 126:5,15 127:22 128:21,24 130:11 141:2,3 220:1 Distance 156:22 distinct 68:11 114:6 distinction 15:10 distracted 82:6 distributed 47:22 117:3 distributing	237:22 238:15 distribution 160:24 231:22,23 231:25 232:1,3,6 232:11 distributor 100:16 230:17 District 1:1,1 4:11,11 56:8 dive 206:25 diving 207:3 Division 1:2 4:12 doctor 16:2 210:7 210:21 211:12,14 211:23 doctor's 211:12 doctor-client 209:23 document 20:16,18 22:24 24:22 25:10 29:13 42:5 42:14 43:15,25 44:10 58:3 72:24 73:2,3,4,5,11 94:5 112:2 122:18 124:17,24 125:1 126:8 130:6 134:12 136:19 142:3 143:14 144:18,21 152:12 179:11,15 180:12 184:3 200:3 208:4 225:5 236:15 documentation 58:23 60:5 78:15 91:14 92:2 105:1 105:4 123:24 124:1 141:23 150:7 179:16,21 180:14,19 189:4 199:17 documentations 111:21 documenting 180:17 documents 31:12 32:17 39:19 41:5 41:20 42:20	43:12 44:12,22 45:3 47:9 48:22 53:11 59:2 60:6 80:14,22 81:2,3 94:3,17 99:19 104:22 106:7,18 118:1 119:19 124:5 128:14 129:5,7 130:23 132:9,17 133:22 133:24 141:20 146:21 147:1 151:2 154:4,6,9 179:25 180:6 189:10,12 190:6 190:9 206:5 211:23 214:11,18 216:3 217:19 221:20 222:12,16 228:18 230:10 231:3 237:15,16 237:18 238:16 doing 19:11 33:18 70:21 111:5 145:15 155:21 157:4 160:20 171:3 191:3 199:1 216:22 229:23 Donahue 2:18 3:5 4:25,25 118:7 127:2 230:13 231:15 236:9 238:12 239:18 240:4 door 216:5 dosage 105:23 106:1 109:6 110:23 111:5 114:6 196:16 dose 42:10 87:12 160:3,14,24 162:3 163:11,17 168:22 169:3 doses 139:17 169:6 dots 99:5 double 60:23 63:20,23 69:2	71:21 95:17 213:23 double-sized 212:23 213:3 double-thick 51:9 53:10,13,17 54:21 58:1 60:9 63:5 64:14,24 66:2,8,11 68:21 69:20 70:10,18 72:15 75:13 86:15 97:17,23 100:13 101:1 104:14 108:25 109:10,16 113:11 114:10 115:3,5 116:3 117:1,5 119:17 124:8 141:15 213:11,15 214:2 doubling 199:3 doubt 117:22 142:10 145:2 179:14 dozens 115:11,11 Dr 4:13 16:1,3 80:3 123:8 141:18 154:22 195:8 212:4 231:16 236:10 239:13 drafted 22:15 33:14 drafting 33:18 drafts 105:7 draw 60:22 64:11 drawing 19:12 drew 193:23 drive 189:24,25 190:16,21,22,23 190:24,25 191:1 191:2,5,7 227:6 228:16 drug 15:16 17:3 18:3 19:1 23:5 24:25 27:15 30:6 30:7,8 45:22 47:1 49:24 74:17 77:23 82:17
---	---	---	---

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 10

84:16,20 85:11
 85:15,19,23,25
 91:2,25 135:3
 145:19 159:16
 161:16 184:14
drugs 18:20 28:4
 28:7 47:17 74:14
 74:20,25 85:3
 225:24
dry 198:13
duces 3:8
due 71:20 123:6
duly 5:10 241:8
duplicated 227:6

E

earlier 18:8
 121:17 149:21
 170:18 172:19
 173:11 217:5
 233:10
early 21:22 67:17
 142:9 214:13
 227:15
edition 168:4
editorial 21:16
 21:18 22:1,3,6
education 156:20
effect 45:16 83:6
 83:23 132:11
 147:1 180:10
 222:16 228:6
effective 18:21
efforts 199:11
eight 180:3
EIR 54:18 55:14
 55:17 79:19
 92:18 99:24
 100:3 144:10
 172:25 173:18
 174:12 228:4,6
EIRs 99:22 118:1
 200:11 207:10
either 8:14,22
 26:11 79:9 89:15
 105:13 164:22
 201:2,20 213:24
Eldepryl 161:3
elderly 114:7,10

Elders 13:17
electronic 129:19
elements 102:21
eliminate 199:12
Elizabeth 2:17
Ellis 2:13
else's 130:22
embedded 237:8
employee 163:13
 164:11 192:18
 242:10,11
employees 157:8
employment 6:9,11
enclosing 173:7
 186:9
encompass 102:19
encouraging 14:16
endeavors 239:10
ended 78:19
ends 78:1 164:17
enforcement 90:24
 149:17
Eng 175:14
engaged 38:1
 157:6
engagement 113:10
Engineering
 178:19
enhancements
 56:24 57:10
entire 21:8 86:23
 213:14,18
entities 192:7,13
entitled 84:11
 201:20
entity 169:17,18
envelope 214:7
equation 103:20
equipment 46:16
 158:17 164:13
 171:14 229:2
Ernst 2:5
escaped 117:16
especially 118:1
ESQUIRE 2:2,5,8
 2:12,12,18
essence 45:21
essentially 48:18
 215:16

established
 171:17
establishing
 171:13
establishment
 54:14 78:15
 80:12 173:8
estate 153:13
estimate 65:21,23
 88:23
et 173:10
ethical 166:25
Euclid 2:14
evaluate 36:4,11
 36:19 233:13
event 57:3,15
 208:12,15,24
events 69:15
 76:14 208:5
everybody 106:9
 194:5
everybody's
 115:13 216:21
evidence 57:17
 58:20 116:7
 117:4 123:13,21
 142:8 188:10
 197:15,18 209:15
 214:10 215:1
 216:1,9,11 230:6
exact 9:6 87:9
 164:7
exactly 19:23
 99:21 205:13
 207:1,4
EXAMINATION 3:4
 5:13 231:14
examinations
 11:15
examined 5:12
example 47:18
 82:13,16 107:4
 203:19 214:25
 229:12
examples 90:25
exceed 170:21
exceeds 172:1,3
Excellent 58:2
excerpts 11:5

exchange 62:17
recipient 69:1
recipients 105:11
 105:24 196:8
 214:5
exclusively 69:12
 71:8
excuse 118:22
 155:19 174:21
 205:12 221:11
exempting 48:4
exhibit 3:5,7,7,9
 3:10,12 22:10
 25:23 26:22
 29:19,25 30:24
 32:2,20 33:4
 41:16 42:8,15
 43:22 44:2,6,16
 44:23 45:2 47:19
 47:25 48:1 55:10
 55:15 58:3,10
 71:16 74:2,7
 84:5 87:25 88:2
 104:8 106:13
 107:4,20 111:18
 112:15 118:16,22
 118:24 119:3,6
 124:14 129:1
 130:7 132:16
 134:2 135:10
 137:5 139:22
 140:14 145:25
 149:5 152:5,5
 155:13 158:23
 172:24 175:7
 183:17 185:7
 186:4,6 226:15
 226:19 240:1,12
exhibits 3:9,11
 31:5 45:4,5
 153:23
existed 217:13
exists 217:2
 218:6
expand 165:24
expanded 122:16
expect 11:10 21:5
 108:25 109:2
expected 95:16

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 11

205:14 239:10	159:1,7 165:5	230:2	147:2,19,22
expects 147:17	217:12	falsified 179:6	148:7,10,14
experience 13:17	e-mail 45:8 57:24	179:25 180:6,13	151:1,9,10 163:7
77:17,20,20 78:2	58:18 59:10 61:4	falsifying 180:20	172:25 175:13
82:3,8 91:12	61:6,16 63:17	180:21,21,23	177:7 178:7
99:2 106:4 114:4	64:4,10,16,20	familiar 27:25	179:5,11,21
143:5 144:5	81:7 181:10,15	47:15 53:7 129:3	180:11,25 183:4
147:4,5 149:19	189:24 190:1	168:10	184:10 185:23
150:5 164:20	e-mails 141:23	fan 12:19	186:7 188:9,10
170:14 179:5,17	237:19	far 42:6 43:10	196:18,21 197:9
179:25 180:2	F	47:17 110:19	199:12 200:3,6
182:19 195:1	facilitate 227:12	132:11 133:2,24	202:18 203:4,7
196:10 215:5	facilities 162:18	178:4 191:17	203:11 206:5
experiment 65:6	228:11,20	204:16 216:15	207:2,6,8 208:12
experiments 19:11	facility 37:15	219:3	214:15 216:3
expert 7:6 16:6	111:16 161:19	Farley 9:16 10:19	218:1 219:9
46:1 83:18 84:4	180:24,25 207:25	farm 102:7	221:13,20 222:2
101:11,13 107:9	227:25 228:7	Farrell 63:22	222:12,16,22
155:10 179:19	229:19 230:2	fashion 34:18	224:10 225:22
208:9 209:5	fact 44:5 46:14	148:3	226:1 232:2
217:21 231:21,24	51:12 64:23	father's 153:12	238:21
232:2,7	72:14 74:23	favorite 106:6	FDA's 74:8,23
expertise 77:13	80:16 82:21 83:4	FDA 23:21 39:7,13	76:20 77:3 79:19
77:16 101:16	85:18 101:21	46:24,25 47:13	84:9 90:13
102:14,16 103:1	107:10 132:10	47:19 48:4,14	107:10 136:5,20
103:18 162:22	145:13 215:15	54:11 55:3 56:12	149:14 179:2
163:7 184:13	facts 74:13 84:11	57:15 63:4 71:9	FDA-approved
185:25 186:2	232:23	71:13 72:13,24	131:6 132:5
217:8	fail 136:9	73:5,12,18 74:1	133:16 134:14
experts 10:5,23	failed 136:1,9	75:25 76:23,24	135:23 138:2
103:2 107:11	failure 30:3,9	77:2,5,14,22	139:16
155:8	69:15 145:16	78:25 80:14,21	FDA-related
expiration 56:3	201:1 202:25	80:22 81:3,11	141:23
142:11 184:15	fair 46:22 110:2	83:6,19,23 90:21	February 107:5,13
expires 39:25	145:11 181:24	92:13,19 93:13	132:18,20 143:2
241:15	182:1 227:13	93:17,18 94:5,18	143:24 241:10
explain 77:12,15	fairly 36:18	97:10 104:21	242:16
158:11	215:3	105:1,4 106:14	federal 17:23
explicitly 230:10	fall 54:18 102:22	107:5,14,19	24:5,25 26:12
exposed 110:5	132:1 135:8	108:5 110:15	29:7,16 30:22,25
exposure 107:12	210:19 230:20	111:23 112:5,18	fee 14:19,21
external 190:20	falls 18:22 143:8	117:17 119:12,16	feel 184:11,25
190:22	174:24 229:17	121:3 122:18	field 55:3,4,8,22
extra 57:18 60:3		127:5,7,12,13,15	56:17 160:4
66:14 67:7 68:20		133:10,21 134:16	185:21 202:22
99:18 106:8		135:2 141:19,20	Fifteen 24:8
120:9		142:4,17 143:3	figure 64:13
extra-thick 69:20		144:21,23 145:10	100:14,19 101:6
71:10 124:11		146:3,20,25	102:4 191:12

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 12

223:14 227:5 file 58:4 136:24 filed 135:25 136:12 files 57:10 filings 158:5 fill 202:12 final 148:8,11,17 151:8,11,13,15 151:17 152:10 financially 242:13 find 26:11 27:10 31:9 63:8 64:14 98:15 100:3,12 120:8,9 145:4 146:4,5 151:22 182:2 194:13 195:7 201:7 203:19 204:10,24 227:6 finding 63:22 112:19,21 119:13 145:5 findings 63:4 76:20 143:3 183:8 fine 68:7 227:16 finish 61:21,24 62:10,13,21,25 182:6 223:1 239:22 finished 40:3 46:12 93:10,14 94:19,23,25 95:2 95:24 96:3,6,10 96:12 99:12 100:21 117:14 141:8 161:16 162:2 168:14 176:5 219:23 220:2,19 221:6 221:14 firm 21:22 184:12 185:1,21,24 235:7 firms 149:15 185:9,10 first 5:10 8:1,5	22:14 23:14 27:11 35:13 49:20 53:23 54:8 54:20 55:16 63:18 66:10 70:23 74:13 75:8 75:11 76:17,24 78:18,22 83:13 84:18 103:20 106:21 107:12,24 108:12 118:2 121:16 126:3 129:14 144:12 146:2,18 148:20 150:7,11 161:25 164:19 188:13 191:2 202:19 215:8 223:11 231:18 233:11 fit 60:10,23 132:2 235:10,11 235:12 Fitzpatrick 5:4 8:6 55:9 57:20 64:18 120:19,25 173:2 five 38:12,13,15 39:3,10 118:10 156:3 194:18 226:10 234:4 239:9 FL 1:10 flag 208:18 flagrant 149:14 flavors 179:16 Florida 1:19 4:7 162:19 241:3,14 242:2 fluffy 69:2 flushed 118:4 focus 71:5 focusing 115:13 folder 189:13 folders 154:7 folding 30:6 folks 205:24 follow 17:8 18:21 19:3 196:14 206:16 234:19	following 17:6 36:6 45:13 84:15 123:3 150:19 176:4 follows 5:12 follow-up 123:22 Food 24:25 135:3 force 147:1 215:11 foregoing 242:6,7 foreign 157:15 forensic 168:7,8 168:10 forget 65:17 110:24 forgetting 104:5 forgot 40:18 form 57:21 64:18 105:23 106:1,14 109:13 111:5 114:6 121:3 129:18 158:5 160:3,14 formal 65:1 150:18 151:9 formally 234:23 format 132:20 formatting 36:1 formed 158:18 forms 110:23 161:5 formula 196:5,7 196:13 212:13 formulas 197:7 formulate 43:12 formulation 162:12 forth 17:4 30:4 186:25 198:22 232:17 forward 67:19 found 51:9 53:8 58:1 64:2 77:6 95:16 97:22 111:24 112:5 113:4 120:10,12 131:20 183:5 186:19 196:21 199:5 217:3,4	238:18 four 35:13 59:13 63:20 120:5 136:9 169:8 234:4 fourth 84:14 146:16 frame 142:6 Francisco 2:20 Frank 9:18 10:19 209:7 frankly 94:6 Fred 34:21 190:2 free 14:21 freestyle 13:18 frequently 114:2 146:5 204:5 front 25:11 130:7 131:10 202:9 fulfilled 183:15 full 146:16 fun 210:2 function 193:12 194:7 functional 158:4 158:7 funnel 178:10 further 242:9
G			
Galanter 20:3 GC 160:10 general 10:13 36:19 38:13 45:10,25 46:22 53:9 68:13 81:4 81:5 82:14 93:22 145:16 156:24 194:11 199:6,24 214:24 218:18 generally 12:1 39:15 195:11 199:22,23 generated 221:20 generic 74:14,17 74:18,19 75:1 114:4 getting 32:18 36:22 40:17			

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 13

150:10 216:2,9 gist 194:20 give 31:14 74:3 83:12 120:13 153:10 164:6 169:22 given 5:17 6:19 76:12 106:9 114:2 124:6,18 152:4 237:15 242:8 gives 227:22 giving 79:16 126:9 glasses 114:18 GL-Gloucester 63:23 GMP 38:15 40:19 85:4 164:12 202:18 203:11 GMPs 15:15,23 16:6,10,12,19,23 17:2,6,8,15,22 18:2,18 28:1 29:12,15 36:12 36:20 37:12 38:11 77:7 78:16 102:18 164:24 182:12,16,19 183:1,2,6,14 205:12 233:15,20 234:19 go 16:1 20:9,12 21:13 26:1 35:4 42:21 43:1 44:19 50:3 52:6 60:5 62:13,15,19 71:16 74:11 75:3 75:6,16 77:2,4 77:21 79:8 81:14 89:23 100:1 101:25 103:16 106:24 113:22 121:8 122:22 128:22 129:21 135:5 137:24 139:12 140:14 142:20 144:10,14 146:12 149:7,22	151:19 152:1 158:5 167:5 168:14 170:4 174:19 175:7,10 180:15 181:15 182:15 184:2 186:15 188:21 191:5,17 194:11 195:17,20 198:22 200:12,19 201:25 204:6 205:11 206:5,11 214:17 220:16 221:21 222:9,24 226:8 227:18 230:11 236:3 239:21 240:4 goes 51:7 110:20 132:12 141:1 143:22 147:18 182:16 219:4 227:3 going 19:4 22:21 26:4,25 38:20 40:10 43:4 44:16 44:24 45:2 46:17 46:18 61:19 62:10 63:10 79:22 81:16 83:1 83:1 93:5 98:6 100:23 106:6 115:17,25,25 116:6 117:11,19 119:25 120:7,17 121:22 122:25 131:15 140:17 142:22 143:13 144:21 145:23 155:23 169:9 170:12 172:14 181:12 182:6 191:6 196:25 207:3 210:23 211:25 213:17,20 214:22 216:5 226:12,18 227:2 228:4,10,12,15 228:19,24 229:15 230:2,9 231:1,10	236:1,5 239:19 240:15 golf 12:19 good 8:15 76:3 84:12 132:13 133:3,8 201:6 226:2 231:16 government 17:24 25:16 30:16,22 30:25 grab 20:10 218:22 graduate 157:16 great 147:6 148:2 174:5 gross 78:16 118:5 149:13 ground 147:25 guarantee 15:16 17:2,9,13,13 18:22 89:21 guess 21:21 225:10 guessing 162:7 guidance 36:18 218:7 233:13 235:7,9 238:7,10 guidelines 166:25 guns 88:8 guys 211:19	190:3 204:4 207:4 hard 11:19,23 78:20 189:23,24 190:16,24,25 191:1,2,5,7 201:9 227:6 hardness 98:24 218:15 219:2,16 Hardy 2:18 4:6 5:1 harm 76:15 116:3 117:13 hauling 181:16 HCL 159:16 head 24:14 86:4 97:13 110:25 181:22 206:25 207:5,17 214:7 222:21 234:15 heading 233:18 health 149:13 hear 123:15 heard 4:10 19:5 48:23 66:10 91:11 179:4 heart 114:2 Heck 114:15 held 4:5 75:1 239:15 Hello 231:17 help 31:9 36:15 39:17 helping 14:16 101:25 hesitate 223:20 hesitating 137:17 hey 210:24 high 13:10 49:24 57:3 74:25 233:4 higher 108:18 higher-level 29:12 high-volume 111:3 111:8 HILLSBOROUGH 241:4 242:3 HIPAA 211:14 hire 101:22,23
---	--	---	--

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 14

hired 9:20 10:23 10:24 39:17,17 156:18 209:5 history 78:17 hold 143:4 172:21 173:22 174:20 175:5 176:3,20 176:25 218:22 holding 143:7 144:4,9 202:9 home 207:25 honest 181:12 honestly 102:22 181:8 hospital 207:24 hours 7:24 8:4,9 170:13 house 114:21 Houston 2:3 HPLC 160:10 HR 6:5 huh-uh 37:5 Hum 154:15 human 6:6 Huntington 2:13 hurry 110:22 hurt 116:14 216:25 hydrochloride 161:4 hypothesis 19:10 19:13 hypothetically 91:24 228:23 229:7,10,22 230:5	I idea 22:6 34:7 96:22,25 142:10 214:6 identification 45:6 226:16 240:13 identified 97:21 234:4 identify 4:16 53:2 144:16 identity 28:11	184:16 187:3,23 II 123:6 141:1 III 223:21 224:12 224:17 imagination 148:18 150:25 immediate 84:3 176:22 224:13 impact 102:12 145:24 187:3 impacted 228:22 impacting 145:22 impacts 145:20 216:4 implement 233:3 implementation 217:21 implicating 219:10 implied 134:22 imply 66:23 105:9 109:5 important 105:25 178:11 200:22 224:20 impression 148:13 improve 14:17 inadequate 69:1 76:2 222:5,18,19 inappropriate 197:11 incident 54:4,12 54:21 56:13 57:4 57:15 75:11 include 150:18 included 36:19 37:19 175:17 includes 46:16 including 34:13 46:3 196:4 203:11 inconsistent 170:13 incorrect 224:3 increase 18:25 208:3 209:16 increases 17:15 18:3 independent 39:21	96:21 158:8 232:22 index 3:2,5 42:23 121:3 indicate 59:3 73:14 93:13 94:6 94:18 122:18 141:11 142:17 176:19 207:23 214:11 231:4 indicated 67:15 indicates 61:14 157:24 indication 134:12 135:22 136:19 individual 53:5 99:8 216:17 228:19 individuals 10:22 53:7 149:15 216:12 industry 16:7,20 16:21 29:11 37:23 66:7,11,15 72:10 114:4 117:24 147:10,11 148:24 159:24 163:3 171:8 177:20 192:16 198:1 199:24 205:14 231:24 239:1,3,7 influence 230:1 informal 146:19 146:22 147:10,21 148:3 150:24 151:6 informally 209:22 information 21:16 34:4 60:25 67:13 67:23 89:4 90:20 94:13 117:22 174:9 196:22 197:23 206:2 207:22 215:19 238:9 ingredient 66:18 66:22,25 67:9 69:1,8,25 72:22
--	---	--	---

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 15

intentional 149:13	103:8 163:19 164:1,17 169:4	judge 68:5 211:20 judgment 76:12 July 48:4 74:9 174:23,25	43:14 44:2 47:7 47:15 49:8 50:18 51:23 53:9,20,21 54:14,20 55:2
interacting 163:25 164:8	185:9 196:16 199:20 205:21	June 10:16 135:11 135:16 157:5 241:15	59:23 60:1,2 61:13 62:17 63:9 63:11,25 64:1
interested 100:14 242:14	involves 99:14 101:20 218:23	jury 115:18,25 116:1,6 117:11 117:19	66:2,8,13,17,20 66:22 67:5 69:12 72:8,14 74:4
interesting 61:7 131:4 145:14 209:25	in-process 98:23 99:6,13 117:14 161:9 217:22,25		75:15 77:3 79:11 82:25 83:3 86:2
interject 220:7	218:12,18,23 219:3,7		87:6,8,11 88:21
internal 81:12 218:7	IQ 159:23	K	91:9 93:24 94:10
interpose 57:20	isolated 57:4,15	Karen 9:18 10:19 209:7	94:16 95:6,7,8
interpret 31:2	issue 60:7 70:20 76:7 82:18 105:10 173:22 180:19 224:11	keep 91:13 104:5 120:17 178:9	96:11,19,23 97:9
interpretation 19:16,22	issued 143:2 174:22	Kenny 9:14 10:18	98:1 99:24 101:4
interrupted 62:3 62:20	issues 94:4 95:4 105:14 163:4 164:13,14,17	Kerensky 2:2 5:3 5:4 7:25 20:14 23:13 27:10 31:8 32:4 51:25 52:4 61:11,17,21,24	102:17,20 105:23 107:10 109:4
Interruption 81:13		62:2,5,9,19,25 68:4,7 72:3 88:4 106:11 109:13 113:24 120:11,14	110:2,24 111:1,7 111:10 113:6
invariably 166:2 212:21 222:22		120:17 131:16,19 132:13 143:18 184:20,23 193:18 193:21 209:25	114:11,19 115:6
inventory 91:6,7 91:8,9,14 92:2		211:6,19 222:25 226:9 240:6,9	115:7 116:10,18
investigate 201:3		key 133:12	119:1 121:16
investigated 54:21,23 200:15 205:15		kicked 81:20	131:8,9 132:3,6
investigating 101:13	item 148:22 150:19	Kilpatrick 2:5 97:4	132:8,12 133:2,3
investigation 41:21 42:4 54:24 56:9 65:1 70:22 71:2 86:16,19,21 98:2 102:24 172:8 203:1,21 204:25 205:10,18 205:18,22 206:7 206:8		kind 6:3 11:9 85:2 88:8 90:19 126:24 145:15 219:3 228:12	133:13,17,22 134:1,16,24
investigations 65:8 81:10,12 97:18 141:25 205:15 222:5,7,8 222:18	job 36:11 158:3 192:10	kinds 101:20 146:6 214:1	135:24,25 136:2 136:4,13,25
invoice 181:12	jobs 6:9 191:17	knee 205:8	137:2 142:11,16
involve 160:2	Johnson 2:8 5:5 106:18	knew 193:24 228:1	144:22 145:5,8
involved 46:6 86:3,15 87:7 97:2 101:25	178:1,4	know 7:11 9:6,12 13:2,8 14:22,24	145:19 154:9,14
	journals 21:2,9 21:10 177:20,22	15:2 18:8 19:23 22:3 24:17 26:18	159:6 162:16
		34:22 35:1 39:13	166:24 167:2
			177:2,3 178:5
			179:2 181:11,19
			183:11,18,22
			185:6,8,10,15,18
			186:15 187:13,18
			193:1 194:2
			199:16,19 200:14
			207:1,5 208:4,11
			208:11 211:1
			213:8 214:2,3,4
			214:5,17 216:20
			216:23 217:10,16
			217:25 218:7
			221:23 223:13

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 16

224:20 227:24	larger 138:10	141:20 147:25	124:25 153:19
228:2,15 229:14	Largo 162:18	148:7,10 149:24	158:22 183:24
230:14,16,19,22	late 201:7 209:2	184:1 195:16,18	189:15,18 190:11
230:25 231:1,2	law 19:3 84:21	221:25	224:15 233:25
232:4 235:10	193:11,17 194:12	let's 23:13,15	listed 154:2,16
knowing 87:15	195:4 235:7	24:9,19 35:4,7	154:17,18 166:9
knowledge 9:25	lawsuit 30:14,18	35:21 40:7 49:5	listen 100:25
10:9 29:6 41:15	30:19 90:8	62:19 68:18 75:3	lists 153:24
68:10 77:7	lawsuits 115:11	75:6 93:18 95:20	literature 20:19
162:19,20 191:22	153:17	98:21 100:10	20:21 52:9 61:3
192:22 199:24	lawyers 7:14 8:12	119:22 120:17	209:15,20
203:6,10,17	8:23 9:21 10:1	128:5,11,20,22	litigation 1:6
238:24	10:10 11:4,7	133:7 137:24	4:9 7:15 8:13,24
known 23:20 97:17	29:13 32:10	138:24 146:12	36:10 40:23
knows 71:9	33:13,19 34:21	149:22 152:19	49:10 53:3,14
L			
lab 46:8 133:22	36:9 41:3 115:12	174:20 176:13	89:6,17 90:2
141:4 161:15,18	115:14 129:2	177:4 188:23	96:20 142:8
164:13,13,23	155:15 190:2	191:19 195:20	177:15 195:24,24
165:1,3,19 166:3	209:5 221:6	201:10,15,25,25	210:25 211:24
198:14,20,25	227:5	202:3,15 209:4	232:23
205:18,21 221:1	lead 83:8 204:25	216:7,21 217:20	little 126:25
label 82:18 118:4	leadership 215:6	219:23 222:24	127:10 158:11
174:10	215:24	224:22 226:8	174:23 184:4
labeling 224:5	leak 229:13	227:18 233:11	190:23 213:9
Laboratories 5:2	learning 156:22	239:8 240:4,5	223:1 229:17
laboratory 46:2	leave 103:1	level 29:14 37:11	230:2
111:4 159:20	led 158:15 233:20	72:21 78:9 82:10	LLC 2:8,16,17
160:13 161:13,13	left 39:11 120:10	83:21 87:12	128:8 233:1
161:14 164:16,16	202:16 231:11	100:17 223:24	LLP 2:13,18
164:19 188:6	legal 8:15 15:1	225:3,17,24	LMSI 160:5
202:25 203:1	lend 108:16	226:4	loans 158:20
205:23 220:25	length 202:6,14	liability 1:5 4:9	located 4:6
221:25	lengthy 16:5	7:2,7 195:24	location 173:10
labs 2:22 96:21	Leo 156:19	196:1 234:22	229:1
97:6 128:13	letter 47:19,23	235:5	logically 12:8
lack 76:14 79:2	48:3 73:13 92:18	liberty 159:3	logistically
150:7,14 215:6	130:20 143:2,6	likelihood 49:24	191:13
234:13	143:10,24 144:7	233:4	long 7:22 8:3,8
ladder 150:13	146:19 147:5,9	limit 131:25	23:11 37:21 47:7
laid 17:23	147:17,20 150:10	137:21	162:6 165:17
landlord 153:8	151:7,9 173:4	limited 219:18,21	166:19 169:13
landlord-tenant	174:14,22,25	228:1	223:3
152:23 153:8	180:12 183:19,19	line 21:14 66:1	look 19:15,20
languages 157:15	185:12 186:6	174:21 211:8,10	21:13 24:19 30:2
laptop 190:19	188:12 194:4	231:7	35:9,12,21 38:16
large 1:19 109:5	197:8 218:11	link 109:4	38:18,22,25 39:2
157:6	221:13 228:6	links 146:4	39:7,19,21 40:21
	letters 39:18	list 37:18 41:22	40:25 41:7 42:21
	79:20 80:10 81:8	43:14 45:2 55:7	42:23 48:1,19

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 17

49:6,19 51:6	130:18,20,25	manual 146:2,3	82:5 95:21
52:8 53:25 54:10	131:1 137:12	147:20 149:7	101:14 102:12
55:21 60:5 61:8	143:20 147:12,15	151:2	103:4,5,15,22
63:4 66:21 71:7	183:24 214:23	manufacture 23:20	112:11 116:10
73:22 74:2 75:8	220:3 225:10	30:5 142:18	216:24 229:9,15
75:16 77:2,5	228:4	160:2,6,7,14,23	233:21
86:5,14,16 90:1	lookout 179:6	161:7 229:2	marketed 184:14
90:12 100:21	looks 114:16	234:10	marketplace 49:25
104:7 108:20	174:18 208:5	manufactured	50:5 51:1,20
110:22 111:2	loss 212:19	52:24 54:9 85:3	52:12,18 73:21
112:7 124:20	lost 168:23	99:9 225:24	119:18 233:5
126:9 128:15	lot 38:19,21 56:3	230:23 231:4	Martha 10:6
129:3 130:16,22	67:18 85:24	manufacturer	Massachusetts
135:12 136:15	110:7 161:5	33:20 46:15	57:25
137:8 138:24	164:15 165:2	59:24 60:14,19	match 32:23 33:4
141:7 143:1	195:14 202:14	84:15 230:17	material 25:19
144:10,14 151:19	216:24 226:25	manufacturers	32:11 33:13
156:5 158:5	lots 112:9 119:14	98:23 234:19	91:17 94:17
165:17 170:4	184:14	manufacturer's	161:8 187:3
173:15 180:16	Lou 10:5	139:3	203:9
181:15 183:17	loud 37:3 232:19	manufacturing	materials 26:11
186:22 189:16	low 135:1	45:14,18 54:23	60:15 91:14,20
190:10 200:13,20	Lower 35:12	56:21 67:6,16,22	91:23 92:11
203:18 205:12	Luis 2:6	68:9,11 69:10,13	129:1 134:3
208:6,21 212:16	lunch 100:2	70:7 74:18 76:4	181:6
214:18 218:7	119:22 120:2,8	84:12 91:2 93:1	math 137:24
220:16,22 221:21	Lynne 63:21	93:7 97:22 101:1	216:22
222:9 223:14	M	142:2 145:17	Matt 4:20
224:8,22	machine 229:13	160:21 163:10,17	matter 33:7
looked 25:13 40:1	mad 113:22	164:2,14,24	MATTHEW 2:12
42:3 67:23 86:8	magazine 178:13	166:4 167:17	Mattison 2:5
86:18,18,21,23	178:24	196:14 205:14,17	maximum 139:4
87:3 94:12 96:8	magazines 21:7	205:22 209:1	MD 113:25
106:20 108:12	178:8	212:20 226:2	MDL 1:3 4:9 49:10
111:11 118:3	main 102:21,23	manufacturing- ...	49:19
129:6,7 173:24	maintenance	164:17	mean 13:3,9 16:9
186:16 209:20	159:23	MAR 3:6	18:10,15,16
220:12,15	major 77:22	March 132:20	21:18 25:12
looking 23:10	102:19 147:7	152:6 159:15	30:24 34:11
24:13 26:10 40:3	making 48:15 50:5	margin 148:21	41:23 45:21
46:4 57:23,24	69:2 74:1 83:24	Marine 81:20	59:14 82:22
58:4 65:18 87:10	92:8,14 123:19	mark 240:5	85:10,20 104:19
89:25 99:10,13	130:16 195:9	marked 22:9 25:23	105:19,20 107:7
99:25 102:11	212:8 234:17	45:5 88:2 137:4	108:23 125:9
110:13 111:4	manage 195:20	139:22 226:15,19	128:10 142:7
116:24 124:24	management 159:20	240:1,12	149:20 158:12
126:8,18 127:9	194:5	market 36:22	170:20 171:24
127:23 128:6	manner 111:24	47:14 48:17	177:23 179:24
129:5,17 130:12		52:25 76:14 78:8	188:1 191:6

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 18

194:9 199:22	76:1 108:17	mirrors 29:8	132:16,22 140:22
208:2 221:2	110:20,21 134:19	misquoting 14:1	143:23 152:3,14
232:4	168:21 169:2,10	missed 184:19	152:17,18 156:4
meaning 218:13	169:14,25 220:12	mission 78:22	172:12,18 173:4
means 19:9 22:7	220:19	missions 78:1	173:14 174:11
22:13 24:17	methodology	misspeaking 43:16	182:22,24 185:3
26:19 34:10	171:14 222:21	misspoke 99:21	194:8,22 197:5
59:16 85:2	methods 27:17	mistaken 44:23	207:13,19 210:2
149:24 150:10	110:18 111:15	93:23 180:15	210:3 211:22
215:18	167:21 168:6,13	192:7 200:10	223:3,5,6 224:23
measure 61:5	219:25 220:4,14	misunderstood	225:1 226:7,10
65:25 132:23	220:15,17,23	95:3	226:17 227:17
134:9 135:20	221:7,18 222:1,4	mixed 196:11	231:7 236:1
188:20	222:6,10,10,18	mixing 196:16	238:11
measured 61:14	Michael 2:12 4:23	modern 157:15	Moriarty's 233:10
116:22 129:23	microgram 137:20	molecule 169:21	Motion 68:2
130:3	138:3	moment 20:7	motivated 77:25
measurement 65:3	micrometer 61:5	monitoring 107:10	78:12
219:15	61:15	month 161:25	motivation 78:6
measuring 134:17	microphone 20:13	178:25	motivations 77:18
136:11	middle 62:3	months 66:14	Motley 2:8
medical 20:19,21	186:23 227:19	129:8 170:7	mouth 64:7 114:14
21:1,9,10 209:15	Mike 2:2 5:4	176:22 180:3	move 63:1 118:7
210:23 211:3	27:11 34:22	Moriarty 2:12 3:4	118:14 127:2
medication 114:1	61:13 106:5	4:20,21 5:14	moved 67:19
114:8	113:22	12:13,18 15:19	215:22
medicine 114:16	Miller 7:12,18,23	15:25 17:18,25	Mt 2:9
114:21 118:2	21:22 235:6	20:17 23:16,24	mutually 71:8
meet 8:1,5 17:4	milligram 44:9	26:1,9 27:11,14	Mylan 2:21,22,22
18:4,25 109:11	milligrams 44:4	28:25 29:5 31:10	3:9 5:1 44:22
Meghan 2:8 5:5	millimeter 65:10	31:13,16 32:5	45:3 58:22 59:4
8:10 34:22 106:5	65:14	39:12 40:7,16	59:9 116:5
120:10,19 190:3	millimeters 138:3	43:2,9 52:2,6,13	117:16 125:17
member 166:5,13	million 42:10,17	55:11,13 57:22	131:1 157:20
166:14,15,18,19	43:24 212:9,14	61:12,19,22 62:1	230:13,14 231:1
memory 25:6	213:17,21,24	62:7,12 63:14	231:4 234:6,8,15
166:14 171:3	mind 22:12 55:12	64:21 68:2,8	235:7,12,13,18
223:19 235:8	83:14 209:13	72:4 80:2 81:14	235:24 236:15,17
mention 234:5	mine 31:13,14	81:22 88:8,10	237:15,16,22
235:12	minimum 17:22	106:5,12 109:22	238:15 239:13,14
mentioned 172:20	18:18	113:14,19 114:24	Mylan's 234:22
176:18 177:11,17	minute 41:24	118:9,11,14,15	235:5 238:14,17
mere 82:21	61:17,18,20	119:20,22 120:6	Myth 74:16
mess 201:8 228:13	99:17 193:18	120:12,16,23	Myths 74:14
met 7:17 8:10,14	minutes 39:10	121:1 122:22	MOORIARTY 123:7
8:22 11:7 107:22	118:10 119:20	125:9,13,16	<hr/>
107:23 108:21	152:16 194:18	127:3 131:23	N
method 19:6,9,14	223:4 226:10	<hr/>	N 1:9
19:17 64:12,16	236:2	<hr/>	nag 113:9

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 19

nagged 113:8	91:17 169:17	34:10 49:13	122:10,14 144:22
name 4:1,13,20	201:21 227:3	72:18 90:18	173:15,20 174:13
5:15 14:1 75:1	229:1 239:2,4,5	105:7 149:25	174:16 175:4,21
116:24 128:13	news 178:13,19	189:19 226:20	176:1,11,14,16
155:1	newsletter 90:18	227:3	177:12 206:7
named 8:22	newspaper 21:24	notices 178:7,23	observations 65:7
names 10:25 155:5	22:4	notified 56:9	152:9 175:16
narrower 137:21	nice 144:6	notoriously 199:14	222:22
138:10	night 206:16	November 75:12	observe 65:9
nationwide 115:12	nine 170:7	121:4 172:24	73:19 92:13,17
nature 212:15	NMS 97:6	173:5,5 174:17	observed 121:10
219:17	nobody's 113:2,7	number 4:10 9:6	218:12
NDA 19:1 46:20	nods 37:6	22:24 37:8 63:3	observing 45:15
NDAs 179:7	non-compliance 193:10,16 194:12	69:3 76:13 78:7	obtained 176:3
necessarily 12:10	195:4	86:9 87:9 88:19	obvious 52:10
83:25 84:3 85:10	non-conformances 187:1	91:20 97:11	obviously 67:21
85:20 92:5 102:3	non-litigation 194:16 221:3	99:20 112:8	146:22 179:15
110:22 112:10	non-responsive 68:3 118:8	126:9 133:20	208:18
115:21 128:10	non-trivial 94:15	134:1 148:22	occasion 11:18,22
206:11 208:16	normal 66:17 67:8	164:6,7 173:15	Occasionally 21:25
211:7	71:11 73:19 90:3	173:24 198:23	occasions 181:1
necessary 160:21	104:17,23 165:8	200:16,16 212:17	occur 180:18
211:7	165:13	215:6 216:21	195:2 214:20
need 20:10 31:7	normally 167:11	236:20,22,22,25	occurred 206:5
45:15 48:16	183:10 220:24	237:2,2,4	214:25
55:11 65:23	221:1	numbers 25:5	October 121:4
89:19 135:12	normal-sized 66:24 69:7,19,23	32:22 33:6,9	odd 108:14 238:18
143:16 159:6	71:1 72:25 73:15	126:3 141:3	office 4:6 10:18
191:7 196:14	159:10	184:3 208:5	25:17 158:17
201:2 205:1	North 4:7 156:25	212:25 213:6,7	211:13
220:7	157:5	numerous 38:7,17	offices 115:14
needed 60:16,20	Notary 1:18	83:11 147:9	156:25
91:17	241:14	195:15,18	official 241:9
needing 37:10	notations 180:17	nursing 207:25	oh 2:14 22:13
needs 206:21	note 100:8	nuts 220:24	23:13,23 53:22
negotiated 80:22	notebooks 96:8	o	88:1 91:15 98:21
181:9	111:16	OATH 241:1	99:17 108:12
neither 239:13,15	noted 56:18 139:1	Obispo 2:6	174:20 181:18
Nelson 155:1	195:1 240:8	Object 64:18	191:11 209:12
never 7:1 15:9	notes 3:9,10,12	109:13	239:21
18:12 53:12 55:4	22:12 73:25 88:3	objection 57:21	oil 229:13
72:18 91:11	239:25	72:3 118:7	oily 229:14
92:10 98:1	notice 1:20 3:7	obligations 183:16	okay 5:17 10:19
118:20 146:23	33:20 34:1,3,6	obscured 45:8	13:21,25 14:24
169:11,19 179:4		observation 65:5	15:15 16:3,15,16
191:3 209:12		99:15 121:3	17:1,14 18:24
216:25 217:1			19:5,19 20:10
232:9			23:16 24:11,16
new 37:9 56:8			

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 20

24:19,20 25:2,7	155:19 156:5,13	156:19 177:24	outbreak 207:23
25:18 26:24 27:1	156:25 157:16	189:9	208:2
27:6,18 29:19	164:10,21 166:1	operating 18:19	outcome 12:10
30:23 33:8,12	167:9 169:13	220:12	outcomes 212:24
35:9 36:3 37:6	170:18 171:11	operational 29:14	outpatient 207:25
38:18 39:16	172:7,21,25	operations 228:2	outside 28:4
43:22 44:21,24	173:1,6,12,13,17	228:19	85:20 87:22
45:4,7,9 46:6,10	173:19 175:9,18	operator 219:14	88:16,25 89:7,17
46:14 47:6 49:12	176:8,14,17,17	opinion 18:2	101:21 102:1,23
49:17 51:11	177:5,15,16,16	36:19 51:14,19	131:3,5,6 134:13
52:15 54:6 57:17	178:17 182:4,5,8	52:17 78:3 79:15	135:2,23 136:20
58:2,10,12,14,15	182:9 183:21,25	79:17 87:17	141:10,12 182:16
61:4,20 62:19	184:24 185:4	88:14,24 89:3	183:9
66:13 68:16,19	186:4,12 187:6	142:2 143:5	out-of-spec 96:12
71:19 75:9,19	187:24 188:22	148:5 151:13	96:23 222:3
77:12 78:5,19	191:6,8,14	180:5 186:24	out-of-specifi...
80:21 81:2 82:8	194:23,24 197:6	195:10 204:20	53:3 94:19 103:3
82:16 83:6,15,19	197:7,25 200:2	215:6 234:21	117:13 200:4
84:5 87:24 88:9	201:13,18 202:8	237:21 238:1,14	overall 111:11
90:4,12 91:3,4	202:10,16 203:3	239:6	overlap 165:2
92:25 93:6,19	204:14 205:17	opinions 9:22	overlaps 234:14
94:16 95:4,9,19	207:12 209:4,6,8	20:1 25:20 33:21	oversight 79:2
95:21 96:17 98:4	210:17 211:13,21	34:1,14,19,22	234:13
99:13 100:9,10	217:3 219:6	35:1 43:12 50:21	oversized 66:3,7
100:17,18 102:2	222:14 223:7	51:11,18 80:6,19	overtones 76:25
102:15 103:7,17	224:25 226:7,18	81:3 102:25	77:18
104:15 106:3,7	226:19,21 227:7	200:22 235:16	overweight 105:8
106:10 107:21	227:8,13 229:2,3	238:5	105:10,11,16,21
108:2 109:9	229:9,21 230:6	opportunity	109:5
112:4 114:25	230:13 231:7,12	109:25 149:15	ownership 158:16
115:10,15,24	231:13 235:21,25	220:8	owns 158:12
117:9,10 120:16	236:20 240:3,9	opposed 19:16,21	o'clock 227:15
121:21 124:14	old 114:15	141:21 164:2,13	P
125:6,17 126:13	older 114:3	164:24	P 2:12
127:18,20 128:17	once 31:14 45:17	OQ 159:23	pack 59:12,14,18
129:19 130:9	112:5,18 146:11	oral 160:24 162:3	59:20,21,25 60:2
132:15,15,19	178:25	163:11,17 168:22	60:8,17,21,24
133:18 134:25	ones 106:7 110:17	169:2,6	65:11,12,18
135:19 136:7	111:14 122:13	order 19:19 36:3	116:24
137:5,10,24	125:24 154:14	100:19 102:25	package 46:17
138:19,24 139:11	166:8 178:17	137:19 158:5,19	48:10 60:20
139:12,13,15,19	188:25 189:6	196:12,15 236:13	220:11 224:3
139:21 141:6,10	One's 44:22	organizations	packaged 176:4
145:3,25 146:10	one-on-one 14:13	166:5,6,25	packaging 65:4
146:17,25 148:4	one-to-one 213:10	organize 33:25	82:17 121:10,13
148:19 149:8,22	online 13:5,22,24	organized 34:18	204:20 224:4
150:9 151:4,23	21:10 25:3,9,11	44:25	227:25 228:2
152:14,17 153:5	41:4 43:15,18	original 105:7	packing 30:6
153:14 154:21	44:13 153:24	ought 171:6	

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 21

packs 162:12	91:22 98:2,15	215:11,12 216:25	160:15,19,25
page 3:3 14:9	102:15,24 109:1	227:10	162:3,25 163:3
23:19 24:7 27:11	109:3 112:17	percent 17:3,9,13	163:11,18 164:11
32:22 33:6,9	124:17,21 144:4	131:13,24 135:7	164:23 165:9,14
35:4,10,11,14	188:6,11 194:6	158:13,19 216:23	166:22 168:13,22
36:2 50:4,12	201:22 203:8	perform 99:4	169:3 171:8
55:14,21 58:7	234:6 236:17	performed 37:14	177:20 178:16
74:11,16 104:7	partially 45:8	63:6	185:21 192:16
126:3,9,21,22	80:9,11,13,20	period 121:18,25	194:10 195:10,23
128:6,7,22	particular 29:25	216:7	197:17 198:1
129:15,21 130:25	64:8 110:22	periodically	199:4,12 207:20
132:23 134:5,9	119:14,15 126:14	178:22	217:22 231:21,25
135:19 136:14,16	163:24 204:14	permanent 21:3,6	232:3,10,25
137:8 143:11,15	219:7 220:23	157:12 163:13	233:19
143:18,19 146:12	232:24	192:18	Pharmaceuticals
146:12,14 148:20	particularly	persistant 193:10	2:21,22 160:17
149:7,22 157:24	64:17 108:16	193:16 194:12	pharmacist 51:8
158:23 167:6	parties 4:16	195:3	53:23 55:25
174:3,7,20 175:7	242:11,12	person 7:18 8:1	57:19,25 217:4,9
175:8,9 176:1	parts 30:4 98:9	8:14,22 30:9	217:11
184:3 186:20,21	98:11	64:2 114:10	pharmacists 116:5
186:23 193:21	party 210:12	personally 53:12	116:12 117:6,17
194:23 222:24	pass 55:9 128:24	65:18 102:20	122:20 123:13
223:7 224:24	140:14,23	193:13 241:7	124:2 217:14
225:4,16,19	passed 107:20	personnel 121:10	pharmacopeia 17:5
227:18,19 232:14	108:10,13 109:19	163:20	89:1 131:7
232:17 233:17,17	126:1 136:8	perspective 46:8	pharmacovigilance
236:20,22,25	204:19	147:13,16	162:22,24 163:4
237:2,4,4,5,5,5	passing 133:15	pertinent 178:4,6	208:8 209:5,10
237:5,6,6,8,9	207:7	Pete 7:11,17,22	pharmacy 216:11
pages 94:13	Passport 190:24	pharmaceutical	217:6,8
127:25	patient 224:11	7:2,6 8:18 15:8	Phil 4:18 37:5
Palm 2:6	patients 74:20	15:9 16:7,20	207:13
paper 25:8 37:14	76:15	33:20 37:22 38:1	Philadelphia 49:9
40:18 73:12 88:9	Peer-reviewed	38:14 39:4,16	49:16 97:7 209:7
174:22 204:9	178:1	40:5,20 45:17,19	PHILIP 1:18
paperwork 158:6	pen 31:7,8 88:5,9	46:16 47:7 48:24	241:14 242:4,22
paragraph 35:13	202:7,15	66:6,15,18,25	phone 8:23,25
49:20 146:16	people 8:17,21	67:9 68:25 69:8	phrase 28:23 29:7
148:6,20 150:16	9:4,20 10:6,24	69:9,25 70:7,20	48:24 194:14
184:8,21,23,24	14:14 16:12,22	73:1,20 81:24	physical 218:14
parameter 131:3	21:6 34:1,13	82:9 89:2 90:4	physician 210:13
parameters 131:5	90:7 94:1,2	91:3 92:1,3 93:2	Ph.D 1:14 5:9
Parkinson 161:4	101:22 103:15	93:7,8,16 98:5	11:14 154:25
part 24:3 30:4,15	107:11 110:21	98:23 99:14	241:7
42:2,4,5 47:16	111:4,6 114:2,7	104:18,24 105:17	pick 35:7 62:20
48:9 49:2 54:23	132:3 142:8	105:18 114:13	216:7
55:17 58:13	198:21 205:23	155:8 159:11,17	picked 93:5
86:20 90:21	215:7,10,10,11	159:24 160:3,6	108:15

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 22

picture 145:21	183:18 192:5	214:9 227:9	pretty 50:8 86:18
piece 25:8 65:2	204:1 207:14	possibly 18:5,6	86:20 128:3
230:12	209:2 232:20	18:11,15,16	147:17 215:20
place 51:24 57:5	235:21 236:14	25:15 28:21 33:7	218:9 220:4
78:20 145:23	240:2	47:24 82:15	228:11
154:8 234:11	plenty 125:4	103:25	prevent 57:5
238:19	Plough 191:20	post 194:3	prevents 203:4,7
placed 26:21	193:6	posted 74:8	previous 126:21
182:13	point 12:4 32:9	Post-It 20:5	128:7 174:16
places 101:24	34:8 37:8 46:25	potency 85:25	175:13,16
Plaintiff 8:16	61:7 70:19 75:4	169:2,10 228:8	Previously 18:12
53:2 89:6,16	75:7,22 76:11	229:16	pre-approved
90:2,7 97:3	101:10 113:1	potent 148:25	98:12
153:16	117:8 133:3,8	potential 213:11	Primarily 161:3
Plaintiffs 2:11	136:1 150:12	potentially 36:21	primary 83:16
3:10 5:3 7:14	180:11 185:9	36:24 78:21	210:13 215:4
8:13,23 9:21	189:20 191:7	103:14,22,25	principal 149:24
10:1,10 11:4	192:16,20,25	164:18 175:5	print 43:17 44:13
32:10 41:3 44:23	195:19 200:2	188:21 200:11	printed 25:19
45:4 96:19,24	218:11 235:21	pour 115:13	printing 25:16
129:2 152:5	236:14	power 99:14	33:7
155:14 190:2	pointed 149:21	PQ 159:23	printout 74:7
221:5 233:12	220:22 221:7	practice 76:4	84:8 129:19
234:21 235:4	points 63:10 75:8	147:11 226:2	153:25
plan 160:12 218:6	75:11 176:22	239:1,3,7	prior 111:21
227:14	227:20	practices 16:21	149:17,25 234:23
planning 157:4	Pokotilow 2:24	84:12 231:25	234:25 235:3
plans 217:22	4:2	232:11	privilege 209:23
218:1	policy 149:14	preapproval 55:19	privileged 210:23
plant 100:15	179:3	precisely 94:14	211:2,9,13
122:4	political 76:25	prefer 211:17	probability 14:25
plastic 60:15,20	77:13,17 78:5	premises 173:9	15:3,11 18:9
play 13:10	79:17	prepare 9:11 20:1	72:2 79:4,7,9
Pleasant 2:9	politically 77:25	23:11 89:11	87:18,20 88:15
please 4:15 5:7	78:12 79:3	prescription	88:24
8:16,20 12:12	politics 78:4	74:25 114:13	probable 56:18
15:18,20 17:1,17	79:11,13	210:7	72:7 114:9,23,25
17:19 23:1 26:2	poorly 11:20	present 2:23	115:7
27:12,21 28:24	portion 201:21	149:12	probably 12:4
31:5 33:22 42:20	portions 224:5	presented 223:17	21:22 64:11
47:25 58:7 63:21	position 238:18	press 42:18 46:17	154:20 213:20
68:15 74:2,11	possibility 14:25	71:13 77:2	221:7
77:13,15 82:7	15:3,10 18:9,10	211:20 219:13	probate 6:25
83:12 89:8 92:16	18:14,14 71:21	225:22 237:8	153:2,3,7,10
100:25 104:7	72:1 79:3,9	pressed 78:20	problem 56:19,21
113:15 116:20	109:15	presses 218:20	69:9,24 70:14,14
122:23 137:19	possible 48:9	presumably 26:18	70:25 71:3 88:9
151:12 165:10	67:23 68:1 69:14	34:25 196:11	93:14 100:23
170:23 172:11	72:7 114:7 129:7	210:6	101:1 102:6

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 23

111:3 113:5,7 127:4 142:19 165:22 179:15 197:9 206:2 208:25 214:25 228:7 229:12,22 problematic 108:18 110:13 142:1 problems 67:16,20 67:20,25 68:11 74:17 92:7 93:4 94:7 108:16 109:17 111:5 114:3 175:5 179:12,16 182:18 215:8,13,24 218:12 procedural 56:23 57:9 procedure 122:7 146:2 procedures 143:3 143:6 147:19 149:6,23 218:7 proceduring 146:3 proceed 4:19 proceeding 6:1,3 6:17 process 12:9 33:12,17,23 40:21,24 41:12 41:17 42:6,16,21 43:20,23 44:8 45:10,12,13,14 45:18,24 46:1,2 46:7,15 47:5 48:5,20,24 49:2 49:3 67:6 69:10 69:13,14,16 71:2 99:9 117:15 122:7 141:24 142:4,18 143:8 144:3,5,7 172:19 199:2 202:23 212:20 218:21 219:18 220:19 229:1,23 processes 47:1	219:10 processing 30:6 produce 18:20 46:20 produced 10:4 49:9,10 63:6 112:8 116:13 producing 91:21 91:25 product 1:5 4:9 15:16 17:3 18:3 19:3 23:5 36:21 39:22 40:3 45:16 46:12,20 47:12 48:15,17 49:24 50:5 55:20 57:3 67:16 76:2 80:7 82:4,9,12,17,22 83:7,20,24 84:16 93:8,10,14 94:19 94:24,25 95:2,25 96:3,6,10,12 99:12 100:22 103:10,19 104:12 108:6,6 109:18 110:7 112:11,11 116:9 119:12 135:4 136:21 141:8,21 142:12 144:25 159:6 161:16 162:2 163:12 168:14,22 169:3 195:23,24 195:25 196:4 208:17 216:5 219:8,23 220:2 221:6,14 223:9 223:18 224:14 229:8 232:23 233:5,21 234:17 production 163:11 163:18 212:24 213:5 214:12 228:25 products 7:2,6 17:10 28:21 40:4 44:3 101:13 108:24 145:19 160:15,22,25	161:2 162:3,5 176:5,21 177:8 177:10 184:15 192:4 226:4 product's 188:7 professional 148:5 166:6 professionally 14:19 Professor 156:19 program 47:8 97:10 107:12 110:5 111:8 119:9 184:12 185:24 progress 195:15 progressing 219:19 project 38:2,3,3 38:4 147:8 157:7 159:18 186:13 221:3 promise 157:14 prompt 149:16 promptly 184:12 185:1 promulgated 73:12 proof 82:3,10 Propafenone 159:16 proper 106:1 196:15 properly 122:15 proportions 196:12 197:11,12 protection 149:11 protocol 45:13 98:12 protocols 46:4 proved 113:5 provide 18:19 184:11,14,25 234:21 provided 159:23 189:5,12,15 190:11 provides 149:25 provision 23:18 25:14	prudent 60:14,19 PTL 62:8 public 1:18 78:21 149:10 241:14 publication 147:23 165:15 178:20 publications 165:4,7,11 177:25 178:9,12 199:5 209:16 published 156:16 167:25 232:9 pull 135:13 143:16 167:5 178:3 pulling 223:19 purity 184:17 187:4,23 purpose 33:24 45:24 49:21 77:25 232:16,19 232:21 233:7 235:15 purposely 111:2 purposes 25:20 pursuant 1:20 purview 143:8 put 12:9 31:10 33:25 34:6 44:13 44:16 45:2 57:5 74:20 88:4 114:13 128:13 152:13 190:21 202:12 212:7,12 235:10 238:8 puts 178:23 putting 33:19 p.m 119:25 120:4 122:25 140:17,21 142:21,25 155:23 156:2 172:13,17 196:25 197:3 226:11,14 236:4 236:8 240:15,17
			Q QA 163:16,20,25 164:1,8 219:13

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 24

QC 46:7,11 161:15 161:18 164:2 198:14 QRS 187:9 188:18 191:23 QRS's 186:24 187:21 qualified 160:12 quality 74:17 76:2 102:18,21 102:23 116:9 131:1 145:16 161:13 163:10 166:4,23 178:22 184:16 187:4,23 194:4 215:12 216:4,5,6 233:3 234:10,13 235:19 238:19,21,25 239:11 Quantic 185:15 186:1,9,13,16,19 191:16 192:2,6,8 192:9 quantification 22:22 quarter 74:9 78:6 213:22 question 8:19 16:16 17:1,7 18:1,1 19:24 23:17 24:9,10 31:17 34:7 43:11 61:10 62:17 66:21 68:3 70:2 73:9 88:11,12 94:14 95:6 117:9 117:23 123:12,20 126:25 131:17 132:6,8 133:15 136:12,18 137:1 137:2 140:1 141:5 144:15 145:14 147:14 156:5 164:21 168:25 177:4 181:9 182:7,22 182:25 192:11 194:20 201:5,7	203:3,25 207:11 207:12,18 212:2 222:13 236:13,16 questionable 180:6 questioned 154:23 155:2 questioning 239:19,24 questions 11:9 52:3 58:16 61:23 66:1 123:3 125:10 142:4 201:8 231:8,10 233:10 quibble 22:22 quick 73:22 237:9 quickly 155:18 quite 94:5 102:22 quotations 237:17 quote 55:25 56:18 quoted 167:8 quotes 167:7	11:1,4 12:13,14 15:19,21 17:18 17:20 20:1,8,21 20:23 21:19,24 23:25 27:8,21,22 28:25 29:1 30:11 34:25 36:7 57:8 61:3 62:23 67:11 74:21 76:17,18 84:22 85:5,12 96:2 113:14,16 114:1 125:23,25 139:8 146:2,23 150:3 154:21,25 179:1 207:13,15 232:19 234:16 readers 34:13 reading 19:25 90:18 150:16 178:4 198:17 199:4 readings 102:17 109:1 reads 84:18 ready 11:8 real 11:19 73:22 158:6 164:6 reality 147:25 151:5 realize 33:24 110:20 really 31:7 38:7 61:7 63:8 103:17 107:11 108:23 113:8 169:20 194:20 210:19,20 213:13 222:21 reason 57:14 76:19 105:22 107:24 112:1 137:17 147:2 177:1 188:22 189:2 reasonable 87:17 88:14 95:23 142:15 217:12 reasons 83:11 85:24 recall 9:2 10:8	10:12 11:3,21,25 12:1 15:12 20:25 21:21 41:2,24 42:3,12,14 44:5 48:7 51:17 54:7 55:6 71:14,20 72:18,25 73:2,14 73:17 74:10,18 76:15 78:6 79:1 82:17,21 83:4,8 83:21 84:2 86:3 86:9 87:7,12 90:18 92:22 96:9 101:11,19 102:3 102:7 104:12,23 105:7 115:12 121:18,19,20,24 123:5,17 124:3 127:6 129:14 154:24 155:3 156:10 159:15 162:7 165:16 167:18 173:23 197:14 200:12 207:9 209:18 214:13 218:16 219:6,11 221:17 223:16,18 224:12 224:15,17,19 225:2,9,22,23 226:3 235:6 recalled 54:6,8 83:25 87:22 88:15,18,25 95:20 96:14 133:25 187:15,19 223:23 225:17 recalls 66:13 81:25 82:2,9 83:18 84:4 101:15,22 223:9 receipts 182:3 received 53:3 57:3 129:13,15 132:18 134:6 135:11 181:20 receiving 129:17 recidivistic 215:22
--	--	--	--

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 25

recognize 10:25	92:21 93:19	146:1,3 147:19	remediation 39:19
recollection 12:3	120:8 121:2	149:6 163:7	147:6 188:11
73:18	122:3 123:9	180:12 185:16	remember 24:13
recommendation	124:7 174:19,24	186:1 191:16	34:18 54:11
191:4	199:17 225:8,14	192:2,6,8 215:11	55:17 60:12,13
reconciliation	225:20 235:23	reject 98:6,16	87:14 88:11,12
92:10	236:15 237:7	202:20 203:12,23	88:13 105:8
record 26:1,4,8	references 51:7	205:13 206:17	132:9 189:1
38:23 40:10,14	90:17 178:8,25	rejected 121:11	190:8,12 220:4
43:4,8 63:7 74:1	200:9,10 235:17	122:11 188:11	222:15 228:5
77:3 79:22,25	237:14,16,21	206:12 207:8	remembering 226:9
81:14,16,19	referred 105:8	222:4,17 229:14	removal 65:3 76:1
86:17,20,23	123:23 233:1	rejection 123:9	remove 61:4 75:24
93:13,13 119:25	referring 66:4	201:2 204:22	removed 59:17
120:4 122:22,25	76:6 87:15 122:3	205:7	61:14
123:4 125:8,15	133:14 143:12	relate 144:13	render 30:7 51:19
127:18,19 140:15	170:19 175:22	232:5	52:17 180:5
140:17,21 142:20	192:12	related 47:9	235:4 238:6
142:22,25 152:1	refers 63:19	96:10 119:8	rendered 237:21
155:24 156:2	100:3,5 144:8	231:25 232:23	reoccurrence 57:6
172:14,17 188:5	reflect 92:10	238:9	repeated 176:21
188:17 192:3	reflected 91:5	relates 145:13	193:10,16 194:12
197:1,3 216:19	92:2	relation 32:17	195:3 200:8
226:8,12,14	reflects 215:24	relationship 230:20	repeatedly 22:15
232:20 234:12	reg 202:18 203:4	relative 242:10	22:18 77:5
236:3,5,8,10	203:7,11	242:11	report 16:5 20:6
239:21 240:5,15	regard 76:20	relatively 239:2	22:14,20,23 23:1
242:7	144:24 147:3	239:4,5	23:18 24:1,7,13
recorded 12:15	237:21 238:14	release 71:14	24:15 26:18
15:22 17:21 29:2	239:14	161:18,22 199:2	32:16,20,25 33:9
62:24 67:12	regarding 75:12	225:22 233:20	33:11,14,18,24
113:17 123:4	152:10 161:7	237:8	34:17 35:1 41:17
176:2 207:16	164:12 166:25	released 71:23	49:5,20 50:8,12
records 38:16,19	172:23 193:8	72:15 96:15	50:16,21 51:12
40:1 86:5,8 87:4	207:2 210:21	229:9 230:8	51:19 52:16
95:24 141:7	220:13 235:7	reliability 64:2	54:15 55:24
186:16,25 187:9	regards 4:8	reliable 64:17,22	56:17 63:12
187:10,15,24	regs 203:12 205:9	185:20	64:17,20 73:13
188:17,23 189:2	regularly 177:19	reliably 187:22	73:23,25 89:5,11
189:14,17 190:13	179:6	relied 25:19	89:16,19,22 90:1
203:19 204:7	regulation 29:10	rely 51:13 90:20	90:11 103:18
221:25	regulations 24:5	90:23	104:7 116:16,21
redundant 206:18	26:12 29:8,16	remain 184:15	116:22 119:16
refer 22:15,21,23	30:3 76:4 84:19	remaining 59:19	120:20 121:6
23:4,17 24:1,6	203:15 232:2,5	202:21	122:17 128:15,22
26:25 29:11 31:3	238:22,23	remediate 39:18	139:25 143:11,18
reference 20:6	regulatory 30:10	remediated 144:23	143:19 144:14
58:9 59:5 66:11	30:14,15,20,21	145:9 177:6	153:19 154:2,18
68:21 90:10,16	30:25 102:22		173:8 174:4

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 26

180:4,10 194:23 208:24 215:4 220:19,21 222:24 225:16,18 227:18 232:14,16,17,21 233:2,7,18 234:5 235:3,4,11,14 236:11,15 237:10 237:23,25 238:2 238:4 242:6 reported 55:2 76:14 reporter 1:18 4:17 5:7 12:15 15:22 17:21 23:22 29:2 62:24 67:12 113:17 123:4 125:14 207:16 242:1 reporting 34:3 55:22 77:1 179:8 208:12,15 reports 9:21,24 10:2,5,7,11,14 39:2 40:2 57:2 63:4,22 78:16 80:12 116:12 141:25 186:9 repository 41:4 189:10 represent 4:17,21 33:19 94:2 106:14 107:13 152:9 represented 16:4 represents 188:6 230:13 reputable 11:13 requested 189:5 require 55:7 201:1 202:14 203:12 205:5,9 required 95:11 182:11 183:1,2 204:22 238:21 requirement 199:13 238:25 requires 172:8 203:1	resample 201:23 resampling 202:24 203:8 research 160:20 162:1 reserve 239:20,22 resolved 177:6 resources 6:6 158:8 195:20 respect 59:6 60:7 90:24 94:4,21 95:4 99:23 106:19 116:11 118:1 126:19 142:1 150:14 161:5 165:15 171:9 174:24 175:5 178:23 180:17 182:14,18 185:11 191:5 200:11 205:2 207:10 214:15 218:8 221:18,25 222:10 238:7 respond 147:17 responding 147:8 response 179:12 185:6 233:10 responses 81:8 105:7 responsibilities 149:11 responsible 30:9 234:17 rest 22:4 restarted 227:2 Restek 160:8 Restek's 160:10 result 131:2,3 172:5 203:2 204:11,21 results 40:3 96:6 96:13 109:1,3 126:18,25 141:8 141:24 170:20 171:6,18,21 222:3 resume 16:4 155:13 168:2	retail 225:17,23 retained 7:5 33:13 36:9 38:14 53:16 212:14 retest 201:20,23 retested 203:21 204:18 retesting 203:22 returned 58:21 59:4,8,11 review 20:15 32:11,13 35:15 47:3 55:18 57:10 129:11 154:11 177:19 181:6 186:20,24 188:23 189:2,5,14 220:8 220:24 232:22,24 237:10 reviewed 24:25 25:11 33:12 41:14 43:12,15 43:17,20 44:13 48:21 50:8 53:12 60:6 117:7 119:19 132:9 134:3 153:20,24 154:4,5 175:14 187:1,9,10,14,15 187:24,25 188:1 188:4,24,25 189:4 215:20 217:19 231:18 232:13 238:17 reviewing 46:3 47:9 117:25 129:9 228:18 236:11 reviews 39:3 40:2 188:17 192:3 Rice 2:8 right 6:8,12 7:1 7:11 8:5 11:12 12:1,7,11,19 14:7,14 17:6,16 27:1 28:3 29:3 29:24 32:2,9 34:8,14,23 35:2 35:12,19 37:1,16	37:19 40:23 41:16 46:8 47:11 47:18 48:23 49:14 53:15 54:5 55:24 56:13,17 61:25 62:3,22 63:20 64:6,8,9 66:9 68:24 69:7 70:19 71:5,6 72:5,9,16 74:7 74:14 75:3,10,20 75:22 76:7 78:19 79:2 82:19,23 83:4 84:1,8 85:18,21,25 87:6 87:11 89:23 91:21 96:4 97:16 98:7,10,19 101:3 101:5,8,10,10 103:4,13,21,23 104:2,2,21 105:5 105:17,22 107:2 107:7,8 108:7,9 108:11 109:23 110:12,25 111:17 111:22 112:15 113:24 115:8 116:15,18,19 120:22 121:12,25 124:10 125:3 126:5,16,18 127:16 128:9 129:14,15 134:20 135:14 136:11 137:19 138:4,7 139:13,13 143:25 144:16 145:5,12 147:8 149:1 150:12 151:7,16 152:2,11 155:4 156:10 157:7 158:22 161:20 167:19,21,25 172:9 175:9,21 176:15,16 177:9 179:22 180:4 183:11 186:6,10 186:11,22,22 188:15 189:21
--	--	---	---

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 27

195:7 201:6,10 202:16 204:6 205:4 206:14 209:1,1 212:10 215:22 217:1 218:20 219:1 221:3 224:1 226:1,20,24,25 227:12,24 234:1 236:10 239:20,23 right-hand 104:13 ring 155:5 risk 74:20 78:9 Riverview 228:16 228:24 229:8,20 229:21,23 230:7 Road 227:24 228:7 Robert 20:2 role 160:1 161:6 161:9,10,11,12 163:21,24 root 67:6,8 68:12 165:22 204:24 205:16 233:18,25 234:4,7 routine 179:7 RPR 1:18 241:14 242:4,22 run 140:10,11 158:9 171:4,17 running 141:4 170:11 215:7,10 Runyon 162:15 Rusnak 2:2 Russ 9:12 10:18 Ryan 1:18 4:18 241:14 242:4,22 R&D 46:9 161:5,13	203:20 218:6 sampled 108:6 111:23 samples 46:4 47:12 107:8 112:21 119:15 125:19 126:1 128:25 198:14,21 198:22,23,25 200:5,16,16 201:11 204:13 212:15 sampling 99:23 110:4,6,6 112:9 198:3,6,8,13 199:6,13 201:13 202:1,13 212:14 217:20,22 218:1 218:8,13 San 2:6,20 sanction 197:8 sanctioned 207:6 sat 15:12 18:13 72:11 satisfaction 145:9 177:7 satisfied 47:1 48:14 144:23 save 155:20 173:23 saw 25:8 34:4 42:7 118:18,20 188:13 234:11 235:12 saying 17:8 78:24 104:17 134:21 185:23 203:23 215:17 229:5,21 230:3 says 13:6 14:9 28:13 30:2 36:3 37:12 48:18 56:11,20,21 57:1 57:13 59:13,19 59:22 63:21 68:20 71:19 72:18,20,25 74:16,23 75:23 83:6 84:14 85:1	85:9 89:17 104:13 110:24 112:2 121:3,6 122:14 127:19 128:8 143:6 144:7 146:18,24 147:20,24 148:21 149:1,9 150:4,17 150:20,23 151:1 151:16 152:8 168:1 173:6 175:10 176:1 194:25 195:19 202:20 207:8 223:9 225:11 SC 2:9 scan 107:1 155:19 Schering 191:20 193:6 scholarly 177:25 school 13:11 science 79:12,13 156:24 scientific 19:6,9 19:14,17 64:12 64:16 65:6 78:3 108:19 209:15 215:14 216:1,15 scientifically 19:20 scientist 64:23 Scientists 166:22 178:16 scratch 169:15,16 170:5,8 screen 124:23 se 53:5 seal 241:10 second 7:25 55:12 58:7 74:11,16 75:6 76:11 81:21 137:8 146:12 150:11 168:3 174:20 184:2 215:9 seconds 238:11 section 22:1,3,16 22:16,25 23:4 24:23 25:23	26:12,13,25 28:3 29:17 30:7,24 31:22 50:21 51:12,14,19 84:14 104:12 144:11 146:1,23 149:9 167:3,15 235:18 sections 201:12 220:9 secured 110:9 see 20:4 22:20 23:1,4,17 27:1 27:19 35:7,25 41:7 44:12 45:15 49:17 50:1,6,11 53:25 55:21 56:1 56:5 58:7 77:21 90:1,23 92:18 111:20 118:16 120:18 122:17 124:15 126:3 128:5,11,20 129:16 130:13 133:8 135:1 137:6,10,13,14 141:7 145:4 148:22 158:6 174:20 175:11,12 175:19,20 176:6 180:5 184:6,18 185:2 190:5,11 191:19 194:6 195:5 205:12 214:10 217:1 219:14,18 220:16 220:18 227:19 233:11,23 235:11 239:8 seeing 41:24 42:14 55:7 116:24 118:6 137:17 seek 102:14 seen 10:7,20 22:11 24:21,23 25:7 29:22 30:1 41:19 42:1,12,19 43:25 44:9 47:19
--	---	--	--

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 28

47:23,25 48:6,10	set 17:4 18:18	74:19 78:16	slow 23:22
53:12 55:4,17	30:4 56:19,21,22	215:20	small 76:12
58:20,23 59:2,6	102:1 106:8	side 10:5 104:13	158:20 160:19
71:13,17 72:18	124:17,21 171:9	163:10,17 164:2	Society 166:20,22
72:24 73:7,11	186:25 198:16	164:3,14,23,24	178:20,22
74:4 84:6 89:5	232:16	165:1 169:22,23	soft-pedaled
89:15 96:6,15	seven 173:20	significant 63:3	78:25
106:17,21 111:18	174:13 175:21	77:6 108:2,3,4	solid 160:24
112:15 114:22	176:1,16 177:12	112:4,20,25	162:3 163:11,17
118:21,24 119:3	225:6,7,9	156:15	168:21 169:2,6
119:6,16 123:24	severe 179:13	simple 132:6,8	solve 100:23
124:15 141:14	shakes 37:6	single 53:2	101:1 206:2
146:1 183:18,22	share 211:16	sir 16:25 23:22	Soma 9:12 10:18
186:4 197:7,23	sheer 112:7 116:1	30:12 37:7 50:17	somebody 6:14
209:14 216:25	116:12	51:4 55:16 63:16	53:19 66:7 68:20
218:16 219:9	sheet 133:6	65:15 137:8	101:12 102:9
221:12 226:22	134:18	159:13 170:6,16	113:3 115:3
231:3 239:10	Sheraton 7:21	182:21 184:7	116:14,23 120:23
segment 39:24	shifted 79:12	186:14 191:18	130:22 170:9
selectively	ship 47:13 48:17	199:9 213:19	182:7 208:23
189:12	shipped 83:13	217:9 225:13,21	209:14
Selegiline 161:3	229:17	sit 38:7 96:11	somebody's 19:16
sell 14:11	Shook 2:18 4:6,25	111:1 145:4,8	19:21 114:21
Semigran 154:22	shoot 12:21	156:12 238:13	Somerset 160:17
sent 32:10 198:23	short 26:6 40:12	239:12	160:23
204:20	43:6 79:23 81:17	site 56:9	SOPs 218:8
sentence 28:16	121:15 123:2	sites 21:11,12	sorry 23:23 31:6
29:4 49:23 71:25	140:19 142:23	sitting 206:24	31:12,15 32:8
72:13 76:11	155:25 169:22,23	situation 9:23	37:4 75:7 80:4
84:18 85:1,9	172:15 214:8	66:12 149:12	82:6 88:3,7 95:3
138:25 146:18	236:6	215:23	102:8 104:5
148:6 184:20,22	shortage 77:23	situations 148:21	123:15 126:11
239:22	shotgun 13:5	215:5	143:21 168:23
separate 206:19	show 57:17 93:12	six 129:8 170:7	173:2 182:23
September 173:5	94:5 103:9 109:7	197:4	184:25 187:17
173:10 175:1,2	112:10,12 115:10	size 41:18 42:17	213:1 228:14
sequence 125:10	142:3 157:14	67:8 68:21,24	sort 6:8,24 39:21
serious 77:21	188:7 211:23	70:14 71:11	186:22 197:8
205:1	226:18	73:20 87:22	218:17 221:13
seriously 147:18	showed 52:12	88:16 89:7,18	sound 206:18
seriousness 147:6	97:23	90:3 98:24	sounds 181:7,14
148:2 150:14	showing 42:15	104:17,23 105:10	soup 220:24
served 78:22	58:3 84:5 106:13	111:11 139:2	source 90:15,17
services 125:18	137:4 149:5	165:8,13 219:16	101:12
159:22,24 185:16	216:16	sizes 42:11 43:24	Southern 1:1 4:11
186:1 191:16	shown 45:22 53:15	skeet 12:21	space 18:20 60:16
192:2,6,8	113:10 115:15	skills 102:1	spanning 121:4
session 231:9	195:3 207:22	skimming 130:13	speak 208:7
234:25	shows 57:25 58:24	sloppy 215:17,18	213:12

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 29

speaking 126:6	specifications	197:20,21 202:24	26:22 89:1 131:7
spec 63:9,10	15:17 17:4 28:5	207:7 220:2	135:3 208:1
65:17,24 82:23	31:23 45:23	stages 218:21	statistical 110:6
83:2 93:15 97:7	48:15 50:13	stand 6:6 114:6	status 35:15 36:4
98:10,16 108:22	52:25 59:24	standard 17:23	36:5,11,20 37:15
109:19 110:24	85:21 87:23	134:23 147:11	38:11,15 233:14
131:19,22 132:11	88:17 89:1,7,18	170:21 171:4,10	statute 25:7
133:6,8,14	109:11 119:13	171:22 172:1	28:23
134:18 135:9,25	131:7 134:14,16	239:1,2,7	statutory 24:20
136:10,12,16,23	141:13	standards 18:19	29:8
136:24 137:3	specifics 162:7	74:25 170:11	stay 29:12
138:5 141:3	specs 17:11,12,16	171:7,10,16,19	stenographically
202:20 203:20,22	18:4 19:1 46:21	standpoint 46:3	242:5
204:10,21 208:16	60:12,13 105:21	108:19 159:12	step 20:10 150:13
special 162:21	107:23 108:13	164:4 228:25	206:11 209:4
163:6	111:25 112:5	stand-alone 42:6	steps 46:18
specialty 164:15	130:1 131:9,13	start 70:14 93:18	196:15,18,20
specific 42:6	132:4,5 133:1,4	106:6 158:9	218:24
51:2 58:8 75:15	133:13,16 135:4	166:2 216:22	Stericycle 101:24
82:13 94:13	135:23 136:5,6	227:14 231:19	sticker 44:16
105:23 110:14	136:20 137:10,15	started 66:1	stop 62:5 199:17
122:13 142:6	137:16 138:23	133:21 191:3	239:19
144:19 145:6,19	139:15,16 140:14	197:16	stopped 62:6
181:15 185:11	204:19	starting 34:8	108:22
217:18 218:5,14	speech 61:12,20	170:10	straightforward
220:16 222:13	62:13,14	starts 27:13 65:1	215:3
228:18 235:13	speed 42:18	State 1:19 241:3	strange 95:10
specifically	spend 7:22 8:3,8	241:14 242:2	108:17 181:7,14
11:21,25 15:24	26:10 157:3	stated 72:19	Street 1:9 2:6,19
23:7 55:7 67:15	spilling 166:3	133:5 224:9	strength 28:12
92:22 96:9	spillover 164:25	235:14	42:10 184:16
102:11 122:6	spin-off 147:7	statement 12:17	187:4,23
127:16 144:11	spoke 33:13	48:22 50:11 59:7	stretch 148:18
145:1 161:6	sport 13:20	64:20 68:17 74:1	150:24 222:25
185:8,23 186:19	sports 13:10	77:18 78:25 79:6	226:8
195:25 199:20	spot 218:22	85:16 92:19	strike 68:2 118:8
200:13,20 205:11	spring 32:10	97:16 105:6	118:14 127:2
209:19 211:4	St 156:19	110:2 115:9	striking 61:8
216:15 220:3,22	stability 95:14	129:6 132:10	studied 11:19
228:2 232:5,24	140:4,5,7,10,24	135:5 145:11	206:21
234:8 235:13	172:21 173:22	146:20 148:15	studies 40:21,24
238:9,23	175:22 176:2,3	176:24 180:9	41:12 143:4,7
specification	176:25	215:15 221:13	172:21 176:3,20
28:6,22 31:4,18	stack 151:24	230:18 233:7	study 11:15,23
31:20,24 36:16	152:4,13	statements 77:1	42:9 176:25
50:25 51:3,6,10	staff 58:6,13	222:15	studying 12:9
51:15,16 52:11	205:25	States 1:1 4:10	stuff 26:14 98:12
82:4,11 107:22	staffed 160:11	17:5 22:16,25	102:12 118:19
201:16	stage 93:3 141:1	24:4,5 25:13,22	123:19 124:19

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 30

152:19 193:23 201:8 226:25 227:4 stuff's 114:20 subcontract 102:9 subcontracted 125:18 subcontractor 185:19 subcontractors 155:9 subject 30:10 199:7 223:2 subjected 107:21 126:2 128:19 130:5 140:24 submissions 179:7 submit 47:12 198:14 subscribe 21:1, 3 21:6, 9 177:19 subscription 21:4 21:6 substantial 117:22 sub-potent 92:8 92:15, 20, 24 105:12 148:25 149:4 sub-S 158:5 sue 148:13 sued 6:13 148:8 148:12 152:20 153:3 sufficient 221:18 suggests 103:9 suing 6:13 8:17 suit 152:22 suitability 171:14 suitable 171:16 Suite 1:9 2:19 suits 152:24 summary 126:20 127:24 128:4 223:17 summers 157:3 super 92:15, 20, 23 124:8 148:25	supervised 161:15 supervising 161:12 supervision 161:21 supervisor 162:14 162:15 super-potency 148:23 149:1 super-potent 92:9 104:14, 19, 24 105:9, 12 109:16 149:4 supplied 129:2 155:14 190:9 support 19:12 46:2 79:15 124:5 161:17 supporting 160:21 supports 96:18 supposed 58:10 98:18 171:18 205:9 218:18 supposedly 64:2 sure 8:21 13:25 16:11 17:7 20:5 25:10 32:3, 4, 22 33:2 35:10 43:2 43:16 44:15, 18 48:11 54:17 58:8 59:15, 15 71:12 71:15 73:9, 24 76:5 86:18, 20, 21 86:22 89:9, 20 90:5 96:5 100:7 106:11 110:19 113:6, 13 118:18 118:19 128:3 137:18 139:14 145:21, 22 158:12 170:25 172:12 175:24, 25 176:9 177:2 190:10 191:9 192:12 194:19 204:3 211:13 218:5 220:4, 8, 11 224:23 232:21 234:18 235:22	236:19 239:4 surely 148:2 surprised 108:14 surveillance 109:19 suspect 127:10, 11 172:6 179:24 suspicious 180:13 sustained 182:18 183:13 swear 4:18 5:7 swift 179:13, 14 sworn 5:10, 20 241:8 system 14:11, 12 102:21 107:10 116:9 145:16, 23 166:4 220:25 221:2 systematic 19:9 233:3 systemic 116:8 systems 102:18, 23 159:21 233:3	98:25 99:1 161:8 229:13 tablets 23:20 41:18 51:9 53:17 57:2 58:1, 21, 25 59:3, 8, 13, 20, 25 60:21 63:5, 18 64:14 65:15 66:8 66:8, 15 68:9, 21 70:10, 21 71:1, 10 71:10, 21 72:15 72:20, 25 73:15 75:13 76:13 78:8 87:6, 15, 21 88:16 88:25 92:9, 15, 22 93:1 95:5, 16 96:20 97:6, 9 100:13 101:2 105:9 109:5, 10 110:9, 16 111:11 112:8 113:4 116:13, 18 117:1 120:9 121:9, 11 121:13, 17, 22 122:4, 8, 19 123:9 123:13, 18, 21 124:2, 8, 11 125:11 129:23 132:24 136:19 139:24 142:9 159:1, 7, 10 165:5 165:8, 13, 17, 19 212:9, 14, 23 213:3, 15, 22 216:1, 20, 23, 24 217:13 218:19 219:15 229:14 231:5 234:10 tabs 136:9 tackle 13:18 Taft 227:24 228:7 take 11:15 20:7 20:14 35:21 40:7 46:18 48:1, 19 53:25 59:14 62:9 73:22 86:13 88:6 94:9, 16 110:16 110:22 119:22 147:10 149:16
--	--	---	---

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 31

158:20 169:14	157:14 197:4	Terry 2:5 5:4	188:6 198:4,5,10
172:10 188:20	223:3 231:11	32:7 74:2 106:5	199:2,6,18 201:4
198:14 201:21	239:19	test 11:20 40:3	203:4,9,20
209:4 210:4	tapes 196:24	46:18 67:3 95:12	217:23 218:14,18
211:20 218:7	task 36:15 233:12	95:16 96:13	218:23 219:18,24
222:25 224:22	tasks 164:7	100:22 109:25	220:14,20 221:14
226:7 231:2	taught 13:18	110:17 111:5	222:11
236:2	Teaching 14:16	125:19 141:8,11	tests 107:19,20
taken 1:17 3:12	teams 206:1	141:13,14,21	126:1 128:18
113:3 114:10	technical 201:2	168:13 169:2,10	140:23 197:19
115:4 122:15	technically	170:10,12,21,22	200:8 203:14
147:6 148:1	205:24	171:21,25 202:15	219:7 220:2
takes 195:14	technique 14:18	202:19,21	testy 23:14,15
201:11	techniques 202:13	tested 46:5,5	textbooks 232:10
talk 13:23 32:15	technology 160:11	95:5,13 96:20,23	Thank 148:19
32:19 49:23 50:4	tecum 3:8	97:5,9,14,17	174:5,8 226:9
98:21 127:16	teleconference	98:2 108:5,8	233:6 236:21
152:19 174:19	9:3,5	109:11,18 110:9	237:12
176:13 181:17	telephone 8:14	111:14,23 112:6	theoretical 212:5
211:12,17,25	9:7	112:21 113:2,5	212:24 213:6,10
217:20 219:23	tell 5:10,15 11:8	126:1 127:21	Theoretically
221:16 235:18	14:17 18:10	128:23,25 131:4	229:3
talked 43:10	23:10 24:1 36:10	133:23 140:13	theory 215:14
103:20 105:4,15	36:14 45:10,25	141:15	thereabouts
109:14 170:18	48:3 53:22 62:16	testified 5:12,21	212:10
207:21 209:21	70:12 87:2,10	6:16 7:1 132:4,7	thick 52:11 55:25
210:20	97:5 100:1 107:9	214:3	56:18 57:2,18
talking 15:24	108:11 114:17	testifying 132:12	58:25 60:3 63:23
16:17 29:16	115:17,25 116:1	testimony 5:17,19	66:15 67:7 68:20
30:16 32:20 54:3	116:6 117:11,19	10:18 11:2 12:14	92:21 99:18
68:9 75:19 78:4	129:4 138:24	15:21 17:20 29:1	113:4 120:9
79:11,12 94:23	150:24 185:14	62:23 67:11	213:23
98:22 99:19	190:14 193:4,8	113:16 136:5	thickness 65:10
120:20,21 124:4	193:12 207:4	154:11,22 167:1	65:18,22 71:22
124:10 127:7,15	214:22 218:18	207:15 242:8	123:6 133:11
172:19 173:21	219:20	testing 39:7,13	135:25 136:2,10
176:10 180:20	telling 115:16	39:22 46:12	136:23 139:3,11
205:19 210:9,20	139:10	58:24 59:1 63:6	218:13 219:2
210:22,24 211:2	tells 226:24	93:5,10,15,20	thief 202:1
214:16 216:3	ten 201:11,15	94:19 95:1,25	thin 52:11 58:25
219:1 229:19	203:13 204:13	96:3,6,10,15	65:15 92:21
talks 13:4,22	tendency 102:22	98:22,24 108:24	113:4 121:9,14
56:23 60:7	205:23	112:18 117:15,15	121:15 122:4,19
Tampa 1:9,10 4:7	term 15:1 17:10	119:12 130:22	123:9,13,17,21
4:7	51:5 91:11	140:4,6,8,10	124:1
tape 39:11,25	110:25 148:23	141:9,14 142:19	thing 35:13 36:2
40:7,15 80:1	149:3 171:20	161:9,16,18,22	40:18 83:13
120:5 152:15	terms 8:15 118:5	162:2,8 168:14	89:22 90:19
155:22 156:3	201:24	168:18,21 176:4	94:15 106:19

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 32

112:17 113:8	18:13 62:21,25	172:13,16,21	222:20
198:16 215:25	72:11 108:22	173:22,23 176:3	topic 100:2
223:1 228:17	123:16 238:8	176:20,22,25	156:23 179:17
238:18	thoughts 33:25	177:4 181:5	total 88:18
things 12:4 32:18	34:8	188:13 196:25	170:12 181:19
34:10 40:1 69:4	thousands 94:12	197:2 199:5	214:4 224:14
69:5 70:23 71:7	94:12 115:11	216:8 221:10	totality 238:5
108:13 110:14	threat 224:13	224:10 226:11,13	totally 230:18
114:5 120:7	three 75:8,11	231:11 235:20	Totowa 2:16 128:8
145:15 146:6	80:1 119:21	236:4,7 240:14	233:1 238:10
153:20,24 156:7	125:19,19 140:3	timeline 77:5	tough 38:17
166:2 168:14	140:4 169:8	times 6:22 7:5	tougher 134:23,23
175:3 178:11	176:22 177:8,10	37:25 38:5,9,13	tournaments 12:22
179:9 180:17	191:22 192:7	38:15 39:3 52:12	toxicity 207:24
182:8 189:15	209:17 227:20,22	97:22 112:9	209:17
190:13 212:15	228:13 234:3	144:9 163:23	trade 178:8,9,12
219:16 224:9	239:9	169:5 175:6	train 69:13
227:7	threw 53:19,20	191:15	trained 205:24
think 13:5 19:2	throw 117:22	tinfoil 60:15,20	training 56:24
25:12 38:8 49:8	throwing 216:21	title 14:4 29:16	77:16 162:21
49:11 60:22 61:2	thrown 115:22	158:6	163:7
62:7,9 64:25	thumb 41:23	titled 84:13	transcript 242:7
69:11,12 71:7,9	190:21,23	TLC 165:15	transcripts 10:21
74:6 82:13 84:7	tie 240:7	today 4:2 6:20	11:5
89:3 99:8 104:8	tighter 132:5,11	9:11 11:8 96:11	trap 12:21
112:4,20 114:9	136:3,5 137:15	97:5 118:21	treatises 232:10
114:14,22 115:2	137:23 138:6,8	153:23 154:4	trend 214:12
115:21,22 116:7	139:2	182:7 226:20	trends 90:23
117:21 133:7	time 4:3,15 6:23	232:14 238:4,13	trial 238:6
140:8 155:3	7:8,9,17 14:23	239:13	tried 34:16 65:9
163:23 164:21	15:17 23:15,21	today's 23:11	trouble 222:23
169:13 174:15,15	26:3,7,10 40:9	89:13	true 16:8 40:4
179:9 200:24	40:13 41:14 43:3	toilet 118:4	46:13 91:18 96:1
202:13 211:1,25	43:7 47:5 48:12	told 10:13 18:8	131:19,22 151:11
213:8,9,13,25	56:10,16 66:10	41:24 56:12	242:7
214:8,24 215:19	79:21,24 81:15	70:25 100:12	trust 20:9 54:2
233:9 236:1	81:18 86:13 92:9	106:8 154:4	75:17 114:12
238:8 239:24	94:16 98:5,5	215:25 233:9,9	129:18 151:20
thinking 168:24	101:6 106:21	tolerance 139:4	212:17
third 75:3,22	110:1 118:2	tolerances 139:1	truth 5:10,11,11
104:13 128:23	119:24 120:3	139:3	62:16 129:4
148:6	122:24 130:16	top 24:14 35:13	try 19:12 103:16
third-party	140:16,20 142:6	49:17 86:4 97:13	114:5 188:21
184:13 185:25	142:21,24 143:4	110:25 115:23	198:22 199:17
Thompson 34:21	143:7 144:4	128:9,13 129:15	trying 14:17
thorough 34:17	146:7,8 152:14	137:11 152:8,11	41:25 65:21,24
232:22	155:20,23 156:1	175:10 181:22	70:1,2 73:8
thoroughly 205:15	162:6 165:17	199:2 206:24	100:14 102:4
thought 15:13	166:19 170:10	207:5,17 214:6	130:21 132:9

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 33

134:15 137:18	236:17 237:7	194:9,20 201:5	90:24 171:17
175:24 176:9	238:15 239:14	208:19 230:19	199:10 221:19
177:21 194:13	UDL's 131:3 132:2	234:15,16 239:12	uses 148:22
195:7 209:12	132:4 136:2	239:17	USP 18:4 19:1
214:1	139:1,4,17	understanding	46:20 131:9,10
tubing 139:5	237:22	30:13,19 53:18	132:5 133:16
Tucker 2:13	ugly 108:16	150:6 238:3	136:23
turn 55:14 233:4	126:24	understands	usually 164:18
233:17	uh-huh 18:7 36:25	102:20	199:1 205:25
TV 115:12	37:2,5 44:7	understood 15:9	U.S 175:15
twice 72:21 77:9	45:20 48:2,13	undertake 101:15	V
146:11	49:22 50:10,20	uniformity 67:2	vague 12:3 72:3
two 12:4 15:14	50:23 54:19	67:21 68:1 92:7	235:9
20:24 21:8 27:5	56:14 70:5,9,11	93:3,5,20,22	vaguely 12:2
32:24 38:25	70:13,16 74:12	94:4,7,21 95:4	221:17
40:15 42:22	84:10 90:5 93:25	95:12 105:14	valid 19:20 203:2
44:19 68:11	94:3 95:22	109:17 141:24	validate 169:14
69:15 77:21	103:24 104:1,3	168:18,21 198:3	170:2 228:25
80:17,18 117:1	106:16 107:6,15	199:6,13,18,25	229:1
117:25 121:22	107:18 112:24	200:5,18 201:1	validated 45:18
128:18 129:9	129:22,25 146:13	201:12 203:13,24	47:2 169:1
138:23 150:19	146:15 158:24	204:10,19 205:20	221:19
155:5 157:10	169:12 172:22	207:1,7,10	validating 167:20
170:13 175:2	184:9 190:4	218:24 220:1	validation 40:21
178:10 188:24	201:19 202:5,11	unique 66:12	40:24 41:12,17
193:3 209:17	204:15 206:15	102:1 206:20	42:6,9,16,22
217:18 234:3	213:4,16 223:22	218:9	43:21,23 44:8
TX 2:3	223:25 236:21	United 1:1 4:10	45:10,12,25 46:1
type 38:3,4	237:13	17:5 22:15,25	46:2,7,15 47:5
106:19 131:17	ultimately 33:14	24:4,5 25:13,22	49:2 141:24
types 32:18 122:7	umbrella 236:18	26:22 89:1 131:7	142:4,18 143:8
182:15 206:1	uncorrected 200:7	135:3 208:1	144:3,5,8 168:7
typically 67:7	undergo 168:7	universally 168:6	168:15 170:11,15
179:12 198:12	undergraduate	168:12	170:17 172:20
<hr/>			
U			
UDL 2:22 5:2 60:7	underlying 19:15	unusual 63:8	values 108:20
60:9 116:5	78:13,14	upper 137:22	variance 139:11
117:16 125:17	underneath 215:21	upper-end 141:2	varied 45:15
131:4 132:16	undersigned 241:6	upside 82:18	varies 198:16
133:13,22 134:6	understand 13:2,8	up-front 171:13	various 40:4
134:22,22 135:11	16:11 17:7 19:23	Up-tick 208:3	201:11 218:21
136:10 137:11,15	30:22,23 37:5	up-to-date 155:15	varying 165:8,14
137:21 138:5,9	48:20 53:16	156:6	verified 47:20
139:10,23 140:2	66:20 68:6 70:2	usage 91:6,7,8,9	57:6,11 119:17
140:24 157:20	78:24 83:22 84:3	91:19	verify 41:25
161:23 162:14,16	98:3 110:4	USC 24:6,23 26:11	
162:17,18 230:20	126:11 143:15	use 24:12 28:17	
231:2,4 234:6	148:24 149:3	28:17 31:8 35:6	
	170:25 189:7	46:17 51:22	
		60:15,19 84:16	

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 34

Veritext 4:2, 18	61:17 193:18	watch 41:23	172:14 176:9
version 25:13, 15	240:4	124:23	182:6 191:6
35:6, 22 49:9	Wanda 175:14	Watson 159:15	192:12 193:21
versions 32:24	want 13:25 17:6	way 31:5 32:19	196:25 205:19
video 3:7 14:11	43:15 52:2 61:12	33:10 34:12	224:23 226:12
14:12 122:22	61:13, 22 70:6	35:19 50:3, 19	236:5 239:18
123:3 125:8, 11	73:9 78:20 82:25	72:19 83:11	240:15
125:15 140:15, 17	83:3 86:12 89:25	88:22 98:10, 18	we've 43:10 141:6
236:3	93:24 94:16	98:21 99:17	141:9
videographer 2:24	100:21 139:14	100:16 136:22	whatsoever 207:22
4:1 5:6 26:3, 7	142:16 145:19, 22	138:14 188:9, 18	wholesale 220:23
39:10 40:9, 13	151:20 173:15	200:15 201:3	wider 134:24
42:25 43:3, 7	181:16 184:2	206:6, 8 218:25	136:3 139:16
79:21, 24 81:15	193:18 198:21, 25	221:15 227:5	wife 114:15
81:18 118:10	211:15, 19 226:7	231:9	157:12 158:1
119:21, 24 120:3	228:23 236:2	ways 150:18	181:16
122:24 125:7, 12	wanted 100:12	web 14:9 157:24	wife's 157:13
140:16, 20 142:21	110:1, 3 190:5	website 13:4, 21	William 20:3
142:24 151:25	wants 52:5 198:20	14:1, 5 16:4	Williamson 2:2
152:16 155:21	231:8	25:16 45:1 73:14	winter 32:10
156:1 172:13, 16	warn 73:19 92:13	74:8 77:19 84:9	wise 60:14
194:18 196:23	92:17	90:13, 21 167:3	withdraw 23:16
197:2 223:4	warned 200:3	167:12 220:10	24:9 56:7 75:7
226:11, 13 236:4	207:6	225:22	181:4 207:20
236:7 240:14	warning 39:18	websites 178:7	witness 4:13, 18
VIDEOTAPE 1:14	73:13 79:19	week 10:16 106:10	5:7 6:12, 15 7:6
violation 77:6	80:10 81:8 92:18	weeks 178:10	12:16 15:23
78:16	141:20 143:1, 6	weight 98:24	17:22 20:15
violations 149:14	143:10, 24 144:7	111:11 121:15	23:19, 23 27:12
150:1 226:3	146:19 147:5, 8	214:4 218:13	29:3 31:11, 15
violative 149:12	147:17, 20, 25	219:2, 16	52:8 61:16 63:2
Virginia 1:1 4:12	148:7, 10 149:24	went 33:23 108:12	64:19 67:13 68:6
visit 167:11	150:9 151:7, 9	111:23 118:2	81:20 88:6
visual 75:25 76:8	174:10, 13, 22, 25	145:2 173:24	109:14 113:15, 18
99:4 110:24	180:12 183:19	200:7	113:25 120:22, 24
visually 110:15	184:1 185:11	weren't 109:10	123:5 131:18, 21
121:10 219:14	188:12 195:16, 18	130:2 184:1	132:15, 19 143:1
volume 57:3	197:8 218:10	200:8 211:2	143:13, 16, 21
116:13	219:10 221:13	West 1:1 2:13	152:2 155:10
voluminous 79:19	228:6	4:12	172:10 173:13
voluntarily	warnings 221:24	we'll 52:14	174:2, 5, 8 182:23
149:16	Washington 51:9	189:19 191:12	184:22, 24 193:20
voluntary 71:20	54:3	we're 6:20 26:4, 8	194:2, 19 207:17
149:20 150:1, 10	wasn't 6:11 18:1	32:20 40:10 43:4	211:17 224:25
175:10 182:17	113:5 125:11	72:6 78:4 79:11	227:16 231:13
225:23	182:22 201:6	79:12 94:1 98:22	240:3, 8 241:9
W	207:11 217:4	104:8 119:25	242:8
wait 51:25 61:17	224:17	122:25 125:7, 8	witnesses 154:12
	waste 212:14, 20	142:22 155:23	woman-owned

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 35

157:25	written 26:18	117:25 121:22	124:10,11
word 13:6 14:4	76:18 85:16	163:24 209:17	01:16 124:12,13
18:6 24:12,14	133:4 137:18	214:16 216:8	124:14,15,16,17
26:17 28:6,10,17	138:14 167:19	239:9	124:18,19,20,21
28:18,19 51:15	235:8,14 237:25	yellow 58:8	124:22
51:22 52:19	238:1	yesterday 7:19	01:17 124:23,24
148:23 199:10	wrong 85:11,15	8:2,7 11:8 97:5	124:25 125:1,2,3
wording 28:23	109:6 139:10	119:9 124:18	125:4,5,6,7,8,9
29:7	148:14	188:13	125:10,11
words 31:22 51:2	wrote 9:21,22	yield 212:5,25	01:18 125:12,13
56:12 71:25	32:6,15 167:7	213:6,10 214:12	125:14,15,16,17
83:23 85:18	Wyeth 191:19	214:15	125:18,19,20,21
87:18 92:17	193:4	Yoakum 2:3	125:22,23,24,25
105:20 114:25			01:19 126:1,2,3,4
155:9 197:10			126:5,6,7,8,9,10
215:16 224:4			126:11,12,13,14
239:15			126:15,16,17,18
work 12:9 15:7			126:19
89:9 90:13,21			01:20 126:20,21
98:18 155:8			126:22,23,24,25
164:12,22 168:7			127:1,2,3,4,5,6
168:8 181:6			127:7,8,9,10,11
186:12 191:3			127:12,13,14,15
198:1,2 201:9			127:16,17,18,19
worked 81:24			127:20,21
91:13 160:9,18			01:21 127:22,23
162:24 163:9			127:24,25 128:1
185:19 191:15,19			128:2,3,4,5,6,7
191:23 192:1,15			128:8,9,10,11,12
192:18 217:6			128:13,14,15
working 114:4			01:22 128:16,17
193:7,24,24			128:18,19,20,21
workload 199:3			128:22,23,24,25
world 88:22 151:5			129:1
194:16			01:23 129:2,3,4,5
wouldn't 12:16			129:6,7,8,9,10
53:20 64:19			01:24 129:11,12
65:23 92:11			129:13,14,15,16
95:11 103:6			129:17,18,19,20
113:2 199:10			129:21,22,23
213:23 221:9			01:25 129:24,25
229:16			130:1,2,3,4,5,6
wrap 39:24			130:7,8,9
write 31:5,9,11			01:26 130:10,11
32:24 54:17			130:12
100:8 206:7			01:27 130:13,14
240:6			130:15,16,17,18
writing 87:25			130:19,20,21,22
139:6 160:12			130:23,24,25

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 36

131:7,8,9,10,11 131:12,13 01:28 131:14,15 131:16,17,18,19 131:20,21,22,23 131:24,25 132:1 132:2,3,4,5,6,7 132:8,9,10,11,12 01:29 132:13,14 132:15,16,17,18 132:19,20,21,22 132:23,24,25 133:1,2 01:30 133:3,4,5,6 133:7,8,9,10,11 133:12,13,14,15 133:16 01:31 133:17,18 133:19,20,21,22 133:23,24,25 134:1,2,3,4,5,6 01:32 134:7,8,9 134:10,11,12,13 134:14,15,16,17 134:18,19,20,21 134:22 01:33 134:23,24 134:25 135:1,2,3 135:4,5,6,7,8,9 135:10,11 01:34 135:12,13 135:14,15,16,17 135:18,19,20,21 135:22,23,24,25 01:35 136:1,2,3,4 136:5,6,7,8,9,10 136:11,12,13,14 136:15,16,17,18 136:19,20 01:36 136:21,22 136:23,24,25 137:1,2,3,4,5,6 137:7,8 01:37 137:9,10,11 137:12,13,14,15 137:16,17,18 01:38 137:19,20 137:21,22,23,24 137:25 138:1,2	01:39 138:3,4,5,6 138:7,8,9,10,11 138:12,13,14,15 138:16,17,18,19 138:20,21,22,23 138:24,25 139:1 01:40 139:2,3,4,5 139:6,7,8,9,10 139:11,12,13,14 139:15,16,17,18 139:19 01:41 139:20,21 139:22,23,24 01:42 139:25 140:1,2,3,4,5,6 140:7,8,9,10,11 140:12,13 01:43 140:14 01:44 140:15,16 140:17,18 01:47 140:19 01:48 140:20 01:49 140:21,22 140:23,24,25 141:1,2,3,4,5,6 141:7,8,9,10,11 141:12 01:50 141:13,14 141:15,16,17,18 141:19,20,21,22 141:23,24,25 142:1,2 01:51 142:3,4,5,6 142:7,8,9,10,11 142:12,13,14,15 142:16,17,18 01:52 142:19,20 142:21,22 01:55 142:23,24 01:56 142:25 143:1,2,3,4,5,6 143:7,8,9,10,11 143:12,13,14,15 143:16,17,18,19 143:20,21,22 01:57 143:23,24 143:25 144:1,2,3 144:4,5,6,7,8,9 144:10,11,12,13	144:14,15,16,17 144:18,19,20,21 01:58 144:22,23 144:24,25 145:1 145:2,3 01:59 145:4,5,6,7 145:8,9,10,11,12 145:13,14,15,16 145:17,18,19,20 145:21 02:00 145:22,23 145:24,25 146:1 146:2,3,4,5,6,7 02:01 146:8,9,10 146:11,12,13,14 146:15,16,17,18 146:19,20,21,22 146:23,24,25 147:1,2,3,4,5,6 02:02 147:7,8,9 147:10,11,12,13 147:14,15,16,17 147:18,19,20,21 147:22,23,24,25 148:1 02:03 148:2,3,4,5 148:6,7,8,9,10 148:11,12,13,14 148:15,16,17,18 148:19,20 02:04 148:21,22 148:23,24,25 149:1,2,3,4,5,6 149:7 02:05 149:8,9,10 149:11,12,13,14 149:15,16,17,18 149:19 02:06 149:20,21 149:22,23,24,25 150:1,2,3,4,5,6 150:7,8,9,10,11 02:07 150:12,13 150:14,15,16,17 150:18,19,20,21 150:22,23,24,25 151:1,2,3,4,5,6 151:7,8,9 02:08 151:10,11	151:12,13,14,15 151:16,17,18,19 151:20,21,22,23 151:24,25 152:1 152:2,3,4,5,6,7 152:8 02:09 152:9,10,11 152:12,13,14,15 152:16,17,18,19 152:20,21,22,23 152:24 02:10 152:25 153:1,2,3,4,5,6 153:7,8,9,10,11 153:12,13,14,15 153:16,17,18,19 153:20,21,22,23 02:11 153:24,25 154:1,2,3,4,5,6 154:7,8,9,10,11 154:12,13,14,15 154:16 02:12 154:17,18 154:19,20,21,22 154:23,24,25 155:1,2,3,4,5,6 155:7,8,9 02:13 155:10,11 155:12,13,14,15 155:16,17,18,19 02:14 155:20,21 155:22,23,24 02:18 155:25 156:1,2 02:19 156:3,4,5,6 156:7,8,9,10,11 156:12,13,14,15 156:16,17,18,19 156:20,21,22 02:20 156:23,24 156:25 157:1,2,3 157:4,5,6,7,8,9 157:10,11,12,13 157:14,15,16 02:21 157:17,18 157:19,20,21,22 157:23,24,25 158:1,2,3,4,5,6 158:7,8,9,10
--	--	--	--

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 37

02:22 158:11,12 158:13,14,15,16 158:17,18,19,20 158:21,22,23,24 158:25 159:1,2,3 159:4,5,6,7,8,9 159:10	165:12,13,14,15 165:16,17 02:33 165:18,19 165:20,21,22,23 165:24,25 166:1 166:2,3,4,5,6,7 166:8,9,10,11,12	02:47 172:17,18 172:19,20,21,22 02:48 172:23,24 172:25 173:1,2,3 173:4,5,6,7,8,9 173:10,11,12,13 173:14,15	179:15,16,17,18 179:19,20,21,22 179:23,24,25 180:1,2,3,4,5,6 180:7,8
02:23 159:11,12 159:13,14,15,16	166:13,14,15 02:34 166:16,17	02:49 173:16,17 173:18,19,20,21 173:22,23,24,25 174:1	180:12,13,14,15 180:16,17,18,19 180:20,21,22,23 180:24,25 181:1
02:24 159:17,18 159:19,20,21,22 159:23,24,25 160:1,2,3,4	166:18,19,20,21 166:22,23,24,25 167:1,2,3,4,5,6 167:7,8,9,10,11	02:50 174:2,3,4,5 174:6,7,8,9,10 174:11,12,13,14	03:00 181:2,3,4,5 181:6,7,8,9,10 181:11,12,13,14
02:25 160:5,6,7,8 160:9,10,11,12 160:13,14,15,16 160:17,18,19	167:12,13,14,15 167:16,17 02:35 167:18,19	02:51 174:15,16 174:17,18,19,20 174:21,22,23,24 174:25	03:01 181:15,16 181:17,18,19,20 181:21,22,23,24 181:25 182:1,2,3
02:26 160:20,21 160:22,23,24,25 161:1,2,3,4,5,6 161:7,8,9,10,11	167:24,25 168:1 168:2,3,4,5,6,7 168:8,9,10,11,12 168:13,14,15,16	02:52 175:1,2,3,4 175:5,6,7,8,9,10 175:11,12,13,14	182:4,5,6,7,8,9 182:10,11
02:27 161:14,15 161:16,17,18,19 161:20,21,22,23 161:24,25 162:1	168:16,17 02:36 168:17,18	175:15,16,17,18 175:19,20,21	03:02 182:12,13 182:14,15,16,17 182:18,19,20,21 182:22,23,24,25
162:2,3	168:19,20,21,22 168:23,24,25	02:53 175:22,23 175:24,25 176:1	183:1,2,3,4,5,6 183:7
02:28 162:4,5,6,7 162:8,9,10,11,12 162:13,14,15,16 162:17,18,19,20	169:1,2,3,4,5,6 169:7,8 02:37 169:9,10,11	176:2,3,4,5,6,7 176:8,9,10,11,12 176:13,14,15,16	03:03 183:8,9,10 183:11,12,13,14 183:15,16
02:29 162:21,22 162:23,24,25 163:1,2,3,4,5,6 163:7,8,9,10,11	169:12,13,14,15 169:16,17,18,19 169:20,21,22	02:54 176:20,21 176:22,23,24,25	03:04 183:17,18 183:19,20
163:12,13	02:38 169:23,24	177:1,2,3,4,5,6 177:7	03:05 183:21,22
02:30 163:14,15 163:16,17,18,19 163:20,21,22,23 163:24,25 164:1	169:25 170:1,2,3 170:4,5,6,7,8,9	02:55 177:8,9,10 177:11,12,13,14	183:23,24,25 184:1,2,3,4,5,6
164:2,3,4,5,6,7	170:10,11,12,13 170:14,15,16,17	177:15,16,17,18	184:7,8,9,10,11 184:12,13
02:31 164:8,9,10 164:11,12,13,14 164:15,16,17,18 164:19,20,21,22	170:18,19 02:39 170:20,21	177:19,20,21,22 177:23,24	03:06 184:14,15
164:23	170:22,23,24,25 171:1,2,3,4,5,6	02:56 177:25 178:1,2,3,4,5,6	184:16,17,18,19 184:20,21,22,23
02:32 164:24,25 165:1,2,3,4,5,6	171:7,8,9,10,11 171:12,13,14,15	178:7,8,9,10,11 178:12,13,14,15	184:24,25 185:1
165:7,8,9,10,11	02:40 171:16,17 171:18,19,20,21	178:16,17,18,19 178:20,21,22,23	185:2,3,4,5,6,7
	171:22,23,24,25 172:1,2,3,4,5,6	02:57 178:24,25 179:1,2,3,4,5,6	185:8,9
	172:7,8,9,10,11 172:12,13	179:7,8,9,10,11 179:12	03:07 185:10,11
	02:41 172:14 02:46 172:15,16	02:58 179:13,14	185:12,13,14,15 185:16,17,18,19
			185:20,21,22,23 185:24,25 186:1
			186:2,3,4
			03:08 186:5,6,7,8
			186:9,10

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 38

03:09 186:11,12 186:13,14,15,16 186:17,18,19	03:19 193:9,10,11 193:12,13,14,15 193:16,17,18,19	200:9,10,11,12 200:13,14,15,16 200:17,18,19,20	207:12,13,14,15 207:16,17,18,19 207:20
03:10 186:20,21 186:22,23,24,25 187:1,2	193:20,21,22,23 193:24,25 194:1 194:2,3,4	03:40 200:21,22 200:23,24,25 201:1,2,3,4,5,6	03:49 207:21,22 207:23,24,25 208:1,2,3,4,5,6
03:11 187:3,4,5,6 187:7,8,9,10,11 187:12,13,14,15 187:16,17,18,19 187:20,21	03:20 194:5,6,7,8 194:9,10,11,12 194:13,14,15,16	201:7,8,9,10,11 201:12,13,14,15 201:16	208:7,8,9,10,11 208:12,13
03:12 187:22,23 187:24,25 188:1 188:2,3,4,5,6,7 188:8,9,10	194:21 03:21 194:22,23 194:24,25 195:1	03:41 201:17,18 201:19,20,21,22 201:23,24,25	03:50 208:14,15 208:16,17,18,19 208:20,21,22,23
03:13 188:11,12 188:13,14,15,16 188:17,18,19,20 188:21,22,23,24 188:25 189:1,2,3 189:4	195:2,3,4,5,6,7 195:8,9,10,11,12 195:13,14,15,16 195:17,18,19,20	202:1,2,3,4,5,6 202:7,8,9,10,11 202:12,13,14	208:24,25 209:1 209:2,3,4,5,6,7 209:8,9,10,11
03:14 189:5,6,7,8 189:9,10,11,12 189:13,14,15,16 189:17,18,19,20 189:21,22,23,24 189:25 190:1,2,3	03:22 195:21,22 195:23,24,25 196:1,2,3,4,5,6 196:7,8,9,10,11 196:12,13	03:42 202:15,16 202:17,18,19,20 202:21,22,23,24	03:51 209:12,13 209:14,15,16,17 209:18,19,20,21
03:15 190:4,5,6,7 190:8,9,10,11,12 190:13,14,15,16 190:17,18,19,20 190:21,22,23,24 190:25 191:1,2,3 191:4,5	196:16,17,18,19 196:20,21,22,23 196:24,25 197:1	202:25 203:1,2,3 203:4,5,6,7	209:22,23,24,25 210:1,2,3,4,5,6 210:7,8,9,10,11
03:16 191:6,7,8,9 191:10,11,12,13 191:14,15,16,17 191:18,19,20,21 191:22	03:34 197:2,3,4,5 197:6,7	03:43 203:8,9,10 203:11,12,13,14 203:15,16,17,18	03:52 210:12,13 210:14,15,16,17 210:18,19,20,21
03:17 191:23,24 191:25 192:1,2,3 192:4,5,6,7,8,9 192:10,11,12,13	03:35 197:8,9,10 197:11,12,13,14 197:15,16,17,18	203:19,20,21 03:44 203:22,23 203:24,25 204:1	210:22,23,24,25 211:1,2,3,4,5,6 211:7
03:18 192:14,15 192:16,17,18,19 192:20,21,22,23 192:24,25 193:1 193:2,3,4,5,6,7 193:8	197:21,22,23,24 197:25 198:1,2,3 198:4,5,6,7,8,9 198:10,11,12,13	204:2,3,4,5,6,7 204:8,9,10,11,12 204:13,14,15,16 204:17,18,19,20 204:21	03:53 211:8,9,10 211:11,12,13,14 211:15,16,17,18
03:19 192:14,15 192:16,17,18,19 192:20,21,22,23 192:24,25 193:1 193:2,3,4,5,6,7 193:8	03:36 197:19,20 198:14,15	204:24,25 205:1 205:2,3,4,5,6,7 205:8,9,10,11,12 205:13,14,15,16 205:17	211:19,20,21,22 211:23,24,25 212:1,2,3
03:20 193:1 200:2,3,4	03:37 198:14,15 198:16,17,18,19 198:20,21,22,23 198:24,25 199:1	03:45 204:22,23 204:24,25 205:1 205:2,3,4,5,6,7 205:8,9,10,11,12 205:13,14,15,16 205:17	03:54 212:4,5,6,7 212:8,9,10,11,12 212:13,14,15,16 212:17,18,19,20
03:21 193:8	199:2,3,4,5,6,7 199:8,9	03:46 205:18,19 205:20,21,22,23 205:24,25 206:1	03:55 212:21,22 212:23,24,25 213:1,2,3,4,5,6
	03:38 199:10,11 199:12,13,14,15 199:16,17,18,19 199:20,21,22,23 199:24,25 200:1	206:2,3,4,5,6,7 206:8,9,10,11,12 03:47 206:13,14 206:15,16,17,18	213:7,8,9,10,11 213:12,13,14,15 213:16,17,18
	200:2,3,4	206:23,24,25 207:1,2,3,4,5,6 207:7,8	03:56 213:19,20 213:21,22,23,24 213:25 214:1,2,3
	03:39 200:5,6,7,8	03:48 207:9,10,11	214:4,5,6,7,8,9 214:10,11,12
			03:57 214:13,14 214:15,16,17,18

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 39

214:19,20,21,22	04:07 221:21,22	228:10,11,12,13	235:12,13,14,15
214:23,24,25	221:23,24,25	228:14,15,16,17	235:16,17
215:1,2,3,4,5,6	222:1,2,3,4,5,6	228:18,19,20,21	04:38 235:18,19
03:58 215:7,8,9	222:7,8,9,10,11	228:22,23	235:20,21,22,23
215:10,11,12,13	222:12,13	04:29 228:24,25	235:24,25 236:1
215:14,15,16,17	04:08 222:14,15	229:1,2,3,4,5,6	236:2,3,4,5
215:18,19,20,21	222:16,17,18,19	229:7,8,9,10,11	04:39 236:6,7
215:22,23,24,25	222:20,21,22,23	229:12,13,14,15	04:46 236:8,9,10
216:1	222:24	229:16,17	236:11,12,13,14
03:59 216:2,3,4,5	04:09 222:25	04:30 229:18,19	236:15,16
216:6,7,8,9,10	223:1	229:20,21,22,23	04:47 236:17,18
216:11,12,13,14	04:10 223:2,3,4,5	229:24,25 230:1	236:19,20,21,22
216:15,16,17,18	223:6,7,8,9,10	230:2,3,4,5,6,7	236:23,24,25
216:19,20,21,22	223:11,12,13,14	230:8,9,10,11,12	237:1,2,3,4
216:23,24	223:15,16,17,18	04:31 230:13,14	04:48 237:5
04:56:4	223:19,20,21,22	230:15,16,17,18	04:49 237:6
04:00 216:25	223:23,24,25	230:19,20,21,22	04:50 237:7,8,9
217:1,2,3,4,5,6	224:1,2,3	230:23,24,25	237:10,11,12,13
217:7,8,9,10,11	04:11 224:4,5,6,7	231:1,2,3,4	237:14,15,16,17
217:12,13,14,15	224:8,9,10,11,12	04:32 231:5,6,7,8	237:18,19,20,21
217:16,17,18,19	224:13,14,15,16	231:9,10,11,12	237:22
04:01 217:20,21	224:17,18,19,20	231:13,14,15,16	04:51 237:23,24
217:22,23,24,25	224:21,22	231:17,18,19,20	237:25 238:1,2,3
218:1,2,3,4	04:12 224:23,24	231:21	238:4,5,6,7,8,9
04:02 218:5,6,7,8	224:25 225:1,2,3	04:33 231:22,23	238:10,11,12
218:9,10,11,12	225:4,5,6,7,8,9	231:24,25 232:1	04:52 238:13,14
218:13,14,15,16	225:10,11	232:2,3,4,5,6,7	238:15,16,17,18
218:17,18,19,20	04:13 225:12,13	232:8,9,10,11,12	238:19,20,21,22
04:03 218:21,22	225:14,15,16,17	232:13,14,15,16	238:23,24,25
218:23,24,25	225:18,19,20	232:17,18,19	239:1,2,3,4,5
219:1,2,3,4,5,6	04:14 225:21,22	04:34 232:20,21	04:53 239:6,7,8,9
219:7,8,9,10,11	225:23,24,25	232:22,23,24,25	239:10,11,12,13
219:12,13,14,15	226:1,2,3,4,5,6	233:1,2,3,4,5,6	239:14,15,16,17
219:16,17,18	226:7,8	233:7,8,9,10,11	239:18,19,20,21
04:04 219:19,20	04:15 226:9,10,11	233:12,13,14,15	239:22,23,24,25
219:21,22,23,24	226:12	233:16	04:54 240:1,2,3,4
219:25 220:1,2,3	04:25 226:13,14	04:35 233:17,18	240:5,6,7,8,9,10
220:4,5	04:26 226:15,16	233:19,20,21,22	240:11,12,13,14
04:05 220:6,7,8,9	226:17,18,19,20	233:23,24,25	240:15
220:10,11,12,13	226:21,22,23,24	234:1,2,3,4,5,6	05:12 4:11
220:14,15,16,17	226:25 227:1,2,3	234:7	06:12 4:11 167:25
220:18,19,20,21	227:4,5,6,7,8,9	04:36 234:8,9,10	181:1 189:3
220:22,23,24,25	227:10,11,12	234:11,12,13,14	215:18
221:1,2	04:27 227:13,14	234:15,16,17,18	07:12 4:11 181:1
04:06 221:3,4,5,6	227:15,16,17,18	234:19,20,21,22	189:3 215:18
221:7,8,9,10,11	227:19,20,21,22	234:23,24	08:12 1:20 124:12
221:12,13,14,15	227:23,24,25	04:37 234:25	181:1 189:3
221:16,17,18,19	228:1,2,3,4,5	235:1,2,3,4,5,6	09:08 4:1,2,3,4,5
221:20	04:28 228:6,7,8,9	235:7,8,9,10,11	4:6,7,8,9,10,11

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 40

4:12,13,14,15,16 4:17,18,19 09:09 4:20,21,22 4:23,24,25 5:1,2 5:3,4,5,6,7,8,9 5:10,11,12,13,14 5:15,16,17,18,19 5:20,21,22,23,24 5:25 6:1,2 09:10 6:3,4,5,6,7 6:8,9,10,11,12 6:13,14,15,16,17 6:18,19,20,21,22 6:23,24,25 09:11 7:1,2,3,4,5 7:6,7,8,9,10,11 7:12,13,14,15,16 7:17,18,19,20,21 7:22,23,24 09:12 7:25 8:1,2 8:3,4,5,6,7,8,9 8:10,11,12,13,14 8:15,16,17,18,19 8:20,21,22,23,24 8:25 9:1,2 09:13 9:3,4,5,6,7 9:8,9,10,11,12 9:13,14,15,16,17 9:18,19,20,21,22 09:14 9:23,24,25 10:1,2,3,4,5,6,7 10:8,9,10,11,12 09:15 10:13,14,15 10:16,17,18,19 10:20,21,22,23 10:24,25 11:1 09:16 11:2,3,4,5 11:6,7,8,9,10,11 11:12,13,14,15 11:16,17,18,19 11:20 09:17 11:21,22,23 11:24,25 12:1,2 12:3,4,5,6,7,8,9 09:18 12:10,11,12 12:13,14,15,16 12:17,18,19,20 12:21,22,23,24 12:25 13:1	09:19 13:2,3,4,5 13:6,7,8,9,10,11 13:12,13,14,15 13:16,17,18,19 13:20,21,22,23 13:24,25 09:20 14:1,2,3,4 14:5,6,7,8,9,10 09:21 14:11,12,13 14:14,15,16,17 14:18,19,20,21 14:22,23,24,25 15:1,2 09:22 15:3,4,5,6 15:7,8,9,10,11 09:23 15:12,13,14 15:15,16,17,18 15:19,20,21,22 15:23 09:24 15:24,25 16:1,2,3,4,5,6,7 16:8,9,10,11,12 16:13,14,15,16 16:17,18,19,20 16:21,22,23,24 16:25 17:1,2 09:25 17:3,4,5,6 17:7,8,9,10,11 17:12,13,14,15 17:16 09:26 17:17,18,19 17:20,21,22,23 17:24,25 18:1,2 18:3,4,5,6,7,8,9 18:10,11 09:27 18:12,13,14 18:15,16,17,18 18:19,20,21,22 18:23,24,25 19:1 09:28 19:2,3,4,5 19:6,7,8,9,10,11 19:12,13,14,15 09:29 19:16,17,18 19:19,20,21,22 19:23,24,25 20:1 20:2 09:30 20:3,4,5,6 20:7,8,9,10,11 20:12,13,14	09:32 20:15,16,17 20:18,19,20,21 20:22,23,24,25 21:1,2,3 09:33 21:4,5,6,7 21:8,9,10,11,12 21:13,14,15,16 21:17,18,19 09:34 21:20,21,22 21:23,24,25 22:1 22:2,3,4,5,6,7,8 22:9 09:35 22:10,11,12 22:13,14,15,16 22:17 09:36 22:18,19,20 22:21,22,23,24 22:25 23:1,2,3,4 23:5,6,7,8,9,10 23:11,12,13,14 23:15,16,17,18 09:37 23:19,20,21 23:22,23,24,25 24:1,2,3,4,5,6,7 09:39 24:8,9,10 24:11,12,13,14 24:15 09:40 24:16,17,18 24:19,20,21,22 24:23,24 09:41 24:25 25:1 25:2,3,4,5,6,7,8 25:9,10,11,12,13 09:42 25:14,15,16 25:17,18,19,20 25:21,22,23,24 25:25 26:1,2,3,4 26:5 09:57 26:6,7,8,9 26:10 09:58 26:11,12,13 26:14,15,16,17 26:18,19,20,21 26:22,23,24,25 27:1,2,3,4,5,6,7 27:8 09:59 27:9,10,11 27:12,13,14,15 27:16,17,18,19	27:20,21,22,23 27:24 1 13:11 41:16 43:10 232:17 1(a) 42:8 43:10 1(b) 42:15 43:11 1,300 97:20 99:18 99:23 100:5 120:9 124:8 125:10 1,600 121:11,13 123:9 124:9,11 1,600,000 41:18 1:0 139:12 1.6 42:17 1:12 120:4 1:16 122:25 1:47 140:17 1:51 140:21 1:55 142:21 1:58 142:25 10 174:22,25 175:1 10-2-3 149:9 10-2-4 149:23 10-6 149:7 10-7 149:22 10:00 27:25 28:1 28:2,3,4,5,6,7,8 28:9 10:01 28:10,11,12 28:13,14,15,16 28:17,18,19,20 28:21,22 10:02 28:23,24,25 29:1,2,3,4,5,6,7 29:8,9,10,11,12 29:13 10:03 29:14,15,16 29:17,18,19,20 10:04 29:21,22,23 29:24,25 30:1,2 30:3,4,5,6,7,8 10:05 30:9,10,11 30:12,13,14,15 30:16,17,18,19 30:20,21,22,23
---	---	--	---

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 41

30:24	38:12,13,14,15	45:8,9,10,11,12	52:18,19,20,21
10:06 30:25 31:1	10:17 38:16,17,18	45:13,14,15	52:22,23,24,25
31:2,3,4,5,6,7,8	38:19,20,21,22	10:36 45:16,17,18	53:1,2,3
31:9,10,11,12,13	38:23,24,25 39:1	45:19,20,21,22	10:47 53:4,5,6,7
31:14,15,16,17	39:2,3,4,5,6,7	45:23,24,25 46:1	53:8,9,10,11,12
31:18,19	10:18 39:8,9,10	46:2,3,4,5,6,7,8	53:13,14,15,16
10:07 31:20,21,22	39:11,12,13,14	46:9,10,11,12,13	53:17,18,19,20
31:23,24,25 32:1	39:15,16,17,18	10:37 46:14,15,16	10:48 53:24,25
32:2,3,4,5,6,7,8	39:19,20,21,22	46:17,18,19,20	54:1,2,3,4,5,6,7
32:9	39:23,24,25 40:1	46:21,22,23,24	54:8,9,10,11,12
10:08 32:10,11,12	40:2,3	46:25 47:1,2	54:13,14,15,16
32:13,14,15,16	10:19 40:4,5,6,7	10:38 47:3,4,5,6	54:17,18
32:17,18,19,20	40:8,9,10,11	47:7,8,9,10,11	10:49 54:19,20,21
32:21	10:22 40:12,13,14	47:12,13,14,15	54:22,23,24,25
10:09 32:22,23,24	40:15,16,17,18	47:16,17,18,19	55:1,2,3,4,5,6,7
32:25 33:1,2,3,4	40:19	47:20	10:50 55:8,9,10
33:5,6,7,8,9	10:23 40:14,20,21	10:39 47:21,22,23	55:11,12,13,14
10:10 33:10,11,12	40:22,23,24,25	47:24,25 48:1,2	55:15,16,17,18
33:13,14,15,16	41:1,2,3,4,5,6,7	48:3,4,5,6,7	55:19,20,21,22
33:17,18,19,20	41:8,9,10,11,12	10:40 48:8,9,10	10:51 55:23,24,25
33:21,22,23,24	41:13,14,15,16	48:11,12,13,14	56:1,2,3,4,5,6,7
33:25 34:1,2,3,4	41:17	48:15,16,17,18	56:8,9,10,11,12
34:5	10:24 41:18,19,20	48:19,20,21,22	56:13,14,15,16
10:11 34:6,7,8,9	41:21,22,23,24	48:23,24,25 49:1	56:17,18,19
34:10,11,12,13	41:25 42:1,2,3,4	49:2	10:52 56:20,21,22
34:14,15,16,17	42:5	10:41 49:3,4,5,6	56:23,24,25 57:1
34:18,19,20,21	10:25 42:6,7,8,9	49:7,8,9,10,11	57:2,3,4,5,6,7,8
34:22,23,24,25	42:10,11,12,13	49:12,13,14,15	57:9,10,11,12,13
35:1,2,3,4,5,6	42:14,15,16,17	49:16,17,18,19	57:14,15,16,17
10:12 35:7,8,9,10	42:18	49:20,21,22,23	57:18,19
35:11,12,13,14	10:26 42:19,20,21	49:24	10:53 57:20,21,22
35:15,16,17,18	42:22,23,24,25	10:42 49:25 50:1	57:23,24,25 58:1
35:19,20,21,22	43:1	50:2,3,4,5,6,7,8	58:2
35:23,24,25 36:1	10:27 43:2,3,4,5	50:9,10,11,12,13	10:54 58:3,4
10:13 36:2,3,4,5	10:30 43:6,7,8,9	50:14,15,16,17	10:55 58:5,6,7,8
36:6,7,8,9,10,11	43:10,11,12,13	50:18	58:9,10,11,12,13
36:12	43:14	10:43 50:19,20,21	58:14,15,16,17
10:14 36:13,14,15	10:32 43:15,16,17	50:22,23,24,25	58:18,19,20,21
36:16,17,18,19	43:18,19	51:1,2,3,4	10:56 58:22,23,24
36:20,21,22,23	10:33 43:20,21,22	10:44 51:5	58:25 59:1,2,3,4
36:24,25	43:23,24	10:45 51:6,7,8,9	59:5,6,7
10:15 37:1,2,3,4	10:34 43:25 44:1	51:10,11,12,13	10:57 59:8,9,10
37:5,6,7,8,9,10	44:2,3,4,5,6,7,8	51:14,15,16,17	59:11,12,13
37:11,12,13,14	44:9,10,11,12,13	51:18,19,20,21	10:58 59:14,15,16
37:15,16,17,18	44:14,15,16,17	51:22,23,24,25	59:17,18,19,20
37:19,20,21,22	44:18,19,20,21	52:1,2,3,4	59:21,22,23,24
37:23,24,25 38:1	44:22,23	10:46 52:5,6,7,8	59:25 60:1,2,3,4
10:16 38:2,3,4,5	10:35 44:24,25	52:9,10,11,12,13	10:59 60:5,6,7,8
38:6,7,8,9,10,11	45:1,2,3,4,5,6,7	52:14,15,16,17	

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 42

60:9,10,11,12,13	66:18,19,20,21	11:19 74:11,12,13	11:35 81:17,18,19
60:14,15,16,17	66:22,23,24,25	74:14,15,16,17	81:20,21,22,23
60:18,19,20,21	67:1,2,3,4	74:18,19,20,21	81:24,25 82:1,2
60:22,23,24,25	11:06 67:5,6,7,8	74:22,23,24,25	82:3,4,5,6,7,8,9
61:1,2	67:9,10,11,12,13	75:1,2,3,4,5,6	82:10
100 1:9 4:6 17:3	67:14,15,16,17	11:20 75:7,8,9,10	11:36 82:11,12,13
17:9,13	67:18	75:11,12,13,14	82:14,15,16,17
1020 2:6	11:07 67:19,20,21	75:15,16,17,18	82:18,19,20,21
105 131:12,24,25	67:22,23,24,25	75:19,20,21,22	82:22,23,24,25
135:7,8	68:1,2,3,4,5,6,7	75:23,24,25 76:1	83:1,2,3,4,5,6
106 3:7 226:15,19	68:8,9,10,11,12	76:2	11:37 83:7,8,9,10
107 3:9 45:2,5	68:13,14	11:21 76:3,4,5,6	83:11,12,13,14
153:23 154:3,19	11:08 68:15,16,17	76:7,8,9,10,11	83:15,16,17,18
108 3:10 45:3,5	68:18,19,20,21	76:12,13,14,15	83:19,20,21
153:23 154:3,19	68:22,23,24,25	76:16,17,18,19	11:38 83:22,23,24
109 3:12 240:12	69:1,2,3,4,5,6,7	76:20,21,22,23	83:25 84:1,2,3,4
11:00 61:3,4,5,6	69:8,9,10	76:24,25 77:1	84:5,6
61:7,8,9,10,11	11:09 69:11,12,13	11:22 77:2,3,4,5	11:39 84:7,8,9,10
61:12,13,14,15	69:14,15,16,17	77:6,7,8,9,10,11	84:11,12,13,14
61:16,17,18,19	69:18,19,20,21	77:12,13,14	84:15,16,17,18
61:20,21,22,23	69:22,23,24,25	11:23 77:15,16,17	84:19,20,21,22
61:24,25 62:1,2	70:1,2,3,4,5,6	77:18,19,20,21	84:23,24,25 85:1
62:3,4,5,6,7,8,9	11:10 70:7,8,9,10	77:22,23,24,25	85:2
62:10,11,12,13	70:11,12,13,14	78:1	11:40 85:3,4,5,6
62:14,15,16,17	70:15,16,17,18	11:24 78:2,3,4,5	85:7,8,9,10,11
11:01 62:18,19,20	70:19,20,21,22	78:6,7,8,9,10,11	85:12,13,14,15
62:21,22,23,24	70:23,24,25 71:1	78:12,13,14,15	85:16,17,18,19
62:25 63:1,2,3,4	71:2,3,4,5,6,7,8	78:16,17,18,19	85:20,21,22,23
63:5,6,7,8,9,10	71:9,10,11	78:20,21	85:24,25 86:1
11:02 63:11,12,13	11:11 71:12,13,14	11:25 78:22,23,24	11:41 86:2,3,4,5
63:14,15,16,17	71:15,16,17	78:25 79:1,2,3,4	86:6,7,8,9
63:18,19,20,21	11:12 71:18,19,20	79:5,6,7,8,9,10	11:42 86:10,11,12
63:22,23,24,25	71:21,22,23,24	79:11,12,13,14	86:13,14,15,16
64:1,2,3,4,5,6,7	71:25 72:1,2,3,4	79:15,16,17,18	86:17,18,19,20
64:8,9,10,11,12	72:5,6,7,8,9,10	79:19,20	86:21,22,23,24
64:13	72:11,12,13	11:26 79:21,22	86:25 87:1,2,3
11:03 64:14,15,16	11:13 72:14,15,16	11:31 79:23,24,25	11:43 87:4,5,6,7
64:17,18,19,20	72:17,18,19,20	80:1,2,3	87:8,9,10,11,12
64:21,22,23,24	72:21,22,23,24	11:32 79:25 80:4	87:13,14,15,16
64:25 65:1,2,3,4	72:25 73:1,2,3,4	80:5,6,7,8,9,10	87:17,18,19,20
11:04 65:5,6,7,8	73:5,6,7,8,9,10	80:11,12,13,14	87:21,22
65:9,10,11,12,13	73:11	80:15,16,17,18	11:44 87:23,24,25
65:14,15,16,17	11:14 73:12,13,14	80:19,20,21	88:1,2,3,4,5,6,7
65:18,19,20,21	73:15,16,17,18	11:33 80:22,23,24	88:8,9,10,11,12
65:22,23,24,25	73:19,20,21	80:25 81:1,2,3,4	88:13,14,15,16
66:1,2,3,4	11:15 73:22,23,24	81:5,6,7,8,9,10	88:17,18,19,20
11:05 66:5,6,7,8	11:18 73:25 74:1	81:11,12,16	88:21,22,23,24
66:9,10,11,12,13	74:2,3,4,5,6,7,8	11:34 81:13,14,15	88:25
66:14,15,16,17	74:9,10	81:16	11:45 89:1,2,3,4

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 43

89:5,6,7,8,9,10	96:18,19,20,21	103:4	110:8,9,10,11,12
89:11,12,13	96:22,23,24,25	12:08 103:5,6,7,8	110:13,14,15,16
11:46 89:14,15,16	97:1,2,3,4,5,6,7	103:9,10,11,12	110:17,18,19,20
89:17,18,19,20	97:8,9,10,11,12	103:13,14,15,16	110:21,22,23,24
89:21,22,23,24	97:13,14,15,16	103:17,18,19	12:19 110:25
89:25 90:1,2,3,4	97:17,18	12:09 103:20,21	111:1,2,3,4,5,6
90:5	1150 2:13	103:22,23,24,25	111:7,8,9,10,11
11:50 90:6,7,8,9	11687 126:3,12,13	104:1,2,3,4,5,6	111:12,13,14,15
90:10,11,12,13	11718 128:7	104:7,8,9,10,11	111:16,17,18,19
90:14,15,16,17	11719 126:22	104:12	111:20,21,22,23
90:18	128:15	12:10 104:13,14	12:20 111:24,25
11:51 90:19,20,21	11748 128:22	104:15,16,17,18	112:1,2,3,4,5,6
90:22,23,24,25	1237 :24,25 38:10	104:19,20,21,22	112:7,8,9,10,11
91:1,2,3,4,5,6,7	117:24	12:11 104:23,24	112:12,13,14,15
91:8	12:00 97:19,20,21	104:25 105:1,2,3	112:16,17,18,19
11:52 91:9,10,11	97:22,23,24,25	105:4,5,6,7,8,9	112:20,21,22,23
91:12,13,14,15	98:1,2,3,4,5,6,7	105:10,11,12,13	112:24,25
91:16,17,18,19	98:8,9,10,11,12	105:14,15,16,17	12:21 113:1,2,3,4
91:20,21,22,23	98:13,14,15,16	12:12 105:18,19	113:5,6,7,8,9,10
91:24,25 92:1,2	98:17,18,19,20	105:20,21,22,23	113:11,12,13,14
92:3,4,5	98:21	105:24,25 106:1	113:15
11:53 92:6,7,8,9	12:01 98:22,23,24	106:2,3,4,5	12:22 113:16,17
92:10,11,12,13	98:25 99:1,2,3,4	12:13 106:6,7,8,9	113:18,19,20,21
92:14,15,16,17	99:5,6,7,8,9,10	106:10,11,12,13	113:22,23,24,25
92:18,19,20,21	99:11,12,13,14	106:14,15,16,17	114:1,2,3,4,5,6
92:22,23	99:15,16,17	106:18,19,20,21	114:7,8,9,10,11
11:54 92:24,25	12:02 99:18,19,20	106:22,23	12:23 114:12,13
93:1,2,3,4,5,6,7	99:21,22,23,24	12:14 106:24,25	114:14,15,16,17
93:8,9,10,11,12	99:25	107:1,2,3,4,5,6	114:18,19,20,21
93:13,14,15	12:03 100:1,2,3,4	107:7,8,9,10,11	114:22,23,24,25
11:55 93:16,17,18	100:5,6,7,8	107:12	115:1,2,3,4,5,6
93:19,20,21,22	12:04 100:9,10,11	12:15 107:13,14	115:7,8,9,10,11
93:23,24,25 94:1	100:12,13,14,15	107:15,16,17,18	115:12,13
94:2,3,4,5,6,7,8	100:16,17,18,19	107:19,20,21,22	12:24 115:14,15
11:56 94:9,10,11	100:20,21,22,23	107:23,24,25	115:16,17,18,19
94:12,13,14,15	12:05 100:24,25	108:1,2,3,4,5	115:20,21,22,23
94:16,17,18,19	101:1,2,3,4,5,6	12:16 108:6,7,8,9	115:24,25 116:1
94:20,21,22,23	101:7,8,9,10,11	108:10,11,12,13	116:2,3,4
94:24,25	101:12,13,14,15	108:14,15,16,17	12:25 116:5,6,7,8
11:57 95:1,2,3,4	101:16,17,18,19	108:18,19,20,21	116:9,10,11,12
95:5,6,7,8,9,10	101:20,21,22,23	108:22,23,24,25	116:13,14,15,16
95:11,12,13,14	12:06 101:24,25	109:1,2,3,4,5,6	116:17,18,19
95:15,16,17,18	102:1,2,3,4,5,6	12:17 109:7,8,9	12:26 116:20,21
95:19,20,21,22	102:7,8,9,10,11	109:10,11,12,13	116:22,23,24,25
95:23,24,25	102:12,13,14,15	109:14,15,16,17	117:1,2,3,4,5,6
11:58 96:1,2,3,4	102:16,17,18	109:18,19,20,21	117:7,8,9,10,11
96:5,6,7,8,9,10	12:07 102:19,20	109:22,23,24,25	117:12,13
96:11,12,13,14	102:21,22,23,24	110:1,2,3	12:27 117:14,15
11:59 96:15,16,17	102:25 103:1,2,3	12:18 110:4,5,6,7	117:16,17,18,19

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 44

117:20,21,22,23	2:17 155:23	2010 10:4	139:13
117:24,25 118:1	2:22 156:2	2011 1:10 4:3	3.29 138:5,13,17
118:2	2:43 172:13	241:10 242:17	139:12
12:28 118:3,4,5,6	2:50 172:17	2014 241:15	3.7 138:3,13,17
118:7,8,9,10,11	2055:15 75:13	21 16:17,24 22:15	139:12
118:12,13,14,15	77:4 97:19	22:25 23:9 24:3	3/5/08 132:20
118:16,17,18,19	129:23 130:3	24:5,23 25:22	3:26 196:25
118:20,21,22,23	132:23 134:9	26:11,12 29:17	3:37 197:3
118:24,25 119:1	135:20 233:18	30:1 50:4,12	30 119:3
119:2,3	200 107:14 110:9	238:23	31 119:6 176:1
12:29 119:4,5,6,7	110:16	21-plus 232:13	310.500 24:3
119:8,9,10,11,12	2000 67:18 183:12	210 16:17,24	32 119:11
119:13,14,15,16	2000s 142:9	29:17,18 30:1	33 119:11 236:20
119:17,18	2001 121:4 122:20	238:24	236:22
12:30 119:19,20	123:10,14,22	210.1(b) 30:2,24	333 2:19
119:21,22,23,24	2002 122:20	31:3,17	33602 1:10
119:25 120:1	123:14,15,22,24	211 16:18,24	34 119:11
12:31 119:25	183:12	29:18 30:1,4	35 124:14
125 41:18 42:10	2003 53:24 54:2,6	238:24	351 22:16,25 23:8
87:12 125:22	217:4	216) 592-5000 2:15	23:9 24:4,6,23
212:8	2004 54:2,12,18	22:51:6 62:8	25:23 26:12,13
13 37:24,25 38:10	55:14 57:19	183:17 185:7	36 66:14 71:16
124:10 152:16	116:16,21 117:1	226 3:7 30:5	3611(a) 56:3
216:8	217:11	23 186:4,6	38 74:2,7
14 139:13	2005 94:8,20	231 3:5	39 84:5
15 236:20,22	119:18 141:12	24 106:13 107:4	4
152 95:20,24	142:7 214:20	107:20	4 47:19 53:24
96:13	218:11	24th 186:7	76:11 148:22
168 4:10	2006 142:17	240 3:12	217:4
17 174:17	174:17,23 175:1	25 1:10 4:3 43:24	4-2 146:14
171 172:24 175:8	207:24	111:18 174:2	4-3 148:20
18 236:25	2007 75:12 86:16	175:7,9 223:4	4.2 43:24
18th 227:3,15	107:5,14 135:11	225:12	4.8 42:10 212:9
1867209 186:20	135:17 143:2,24	250 125:21,21	212:13 213:17,21
19 67:18 237:2	172:24 173:6,10	137:20 138:2	213:23
1968 1:3	175:2 183:20	26 112:15 152:5	4:17 226:11
1990 123:6,18	186:7 188:12	263 3:11	4:28 226:14
124:3 223:11	207:24 215:2	27 118:16	4:41 236:4
1992 117:24	226:3	28 2:9 118:21,22	4:49 236:8
1994 161:25	2008 75:12 86:3	175:1 241:15	4:57 240:15,17
1995 48:4,21	104:13,23 116:17	2883 184:4	40 175:7,9 176:1
161:25 214:25	117:2 129:14,20	29 118:24 121:4	41 143:21,21
223:21	132:18 134:6	2900 1:9	174:3 237:4
2	152:6 207:24	29464 2:9	415) 544-1900 2:20
2 43:22	215:2 216:7	3	42 143:21,22
2(b) 27:6,7,8	218:11 224:14	344:2,6	174:7
2.7 138:3,11	225:2,12,13	3rd 241:10 242:16	43 237:4
139:12	226:3	3.15 138:5,10,21	4310 2:3
	2009 74:9 159:15		

David Bliesner, Ph.D.

Videotaped

January 25, 2011

Page 45

438 172:23	136:15	83 139:22 140:14
44115 2:14	59 58:3,11 237:8	843) 216-9383 2:10
45 3:9,10	<hr/>	<hr/>
46 236:25 237:5	6	9
47 237:5	6 35:4,10,11	9 23:19
478969 137:9	55:14,21 94:8,20	9th 172:24 173:5
483 73:13 79:19	119:18 141:12	173:5 183:20
81:8 90:18 92:18	142:7 158:23	9:08 1:11 4:4
100:3 121:3	214:20	9:43 26:4
122:2 123:23	60 237:9 238:11	9:58 26:7
150:7,19 151:8	600 2:19	90 131:12,24,25
151:13,22 152:5	61 225:16,19,20	135:7,8
175:13,16 180:11	63 145:25 225:11	90s 142:9
197:7 206:8	225:15	92 32:20 33:8
218:10 221:12	64 149:5	35:7,9 49:19
228:5	69 129:1 130:8	104:8,8
483s 39:18 80:7	<hr/>	925 2:14
99:25 141:19	7	93 155:13
150:24 151:5,10	7 94:8,20 104:7	93401 2:6
151:16 173:11	119:18 141:12	94 33:4,8 35:7,20
195:16,18 200:11	142:7,17 173:16	49:14
207:2,10 221:24	214:20 222:24	94014-2828 2:20
484 39:7,13 97:10	223:7	95 160:18 215:17
106:14 107:8,10	70 132:16	216:6
107:12 111:8,18	70078(a)(1)	97 160:18
112:17 118:19	107:17	97.4 131:25
119:9 124:18	70924 75:13	98 135:6
127:15	71 134:2	988415 241:15
484s 106:7,22	713) 223-3330 2:4	990 228:15
119:12 133:21	72 135:10	
141:9 154:3	73 137:5	
484-related	75 29:20 30:24	
111:20	32:2	
49 237:2,6	7655 129:21	
<hr/>	7656 131:1	
5	7671 132:23	
5 3:4 44:4,9	7688 134:9	
47:25 48:1 55:10	77006-5818 2:3	
158:23 175:1	78A 22:10 24:19	
5th 173:10	24:22 25:21	
501 30:8	26:22	
505285 175:8	78(a) 32:7	
51 158:12,19	<hr/>	
52 114:15	8	
54 237:2,5	8 86:16 94:8,20	
56 237:5	119:18 141:12	
57 237:6	142:7,17 194:23	
58 237:6	214:21 227:15,18	
5815 135:19	805) 541-0300 2:7	